As filed with the Securities and Exchange
Commission on June 7 , 2018
Registration
No.
333-221384
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Post-Effective
Amendment No. 1 to
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Integrity
Applications, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
3841
|
|
98-0668934
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
|
(Primary
Standard Industrial
Classification
Code Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
Integrity
Applications, Inc.
19
Ha’Yahalomim St.
PO
Box 12143
Ashdod
L3 7760049, Israel
972
(8) 675-7878
(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
John
Graham
Chief
Executive Officer
Integrity
Applications, Inc.
19
Ha’Yahalomim St.
PO
Box 12143
Ashdod
L3 7760049, Israel
972
(8) 675-7878
972
(8) 675-7850 (facsimile)
(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies
to
:
Mitchell
L. Lampert
Robinson
& Cole LLP
1055 Washington
Boulevard
Stamford, CT 06901
Direct 203.462.7559 | Fax 203.462.7599
Approximate
date of commencement of proposed sale to the public:
From time to time after the effective date of this registration statement.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933 check the following box: [X]
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
[ ]
Large accelerated filer
|
[ ]
Accelerated filer
|
[ ]
Non-accelerated filer (Do not check if a smaller reporting company)
|
[X]
Smaller reporting company
[ ]
Emerging growth company
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
CALCULATION
OF REGISTRATION FEE
Title
of Each Class
of Securities to be Registered
|
|
Amount
to be
Registered
(1)
|
|
|
Proposed
Maximum
Offering
Price
Per
Share (2)
|
|
|
Proposed
Maximum
Aggregate
Offering
Price (2)
|
|
|
Amount
of
Registration
Fee
(3)
|
|
Common Stock, par value
$.001 per share, issuable upon the conversion of shares of the registrant’s Series C 5.5% Convertible Preferred Stock
|
|
|
2,667,540
|
|
|
$
|
4.50
|
|
|
$
|
12,003,930.00
|
|
|
$
|
1,494.49
|
|
Common Stock, $0.001 par value per share,
issuable upon exercise of Series C-1 Warrants and Series C-2 Warrants to purchase shares of common stock
|
|
|
5,335,080
|
|
|
$
|
4.50
|
|
|
$
|
24,007,860.00
|
|
|
$
|
2,998.98
|
|
Common Stock, $0.001 par value per share,
issued as stock dividends on the registrant’s Series C 5.5% Convertible Preferred Stock (4)
|
|
|
180,502
|
|
|
$
|
4.50
|
|
|
$
|
812,259.00
|
|
|
$
|
101.13
|
|
Common Stock, $0.001 par value per share,
issuable as stock dividends on the registrant’s Series C 5.5% Convertible Preferred Stock (5)
|
|
|
553,076
|
|
|
$
|
4.50
|
|
|
$
|
2,488,842.00
|
|
|
$
|
309.87
|
|
Total
|
|
|
8,736,198
|
|
|
|
|
|
|
$
|
39,312,891.00
|
|
|
$
|
4,894.47
|
|
(1)
|
Pursuant
to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also
registers such additional shares of common stock as may become issuable to prevent dilution as a result of stock splits, stock
dividends or similar transactions.
|
(2)
|
The
selling stockholders will be offering their shares at prevailing market prices or at privately negotiated prices. For illustration
purpose, the Offering Prices herein are based on the closing bid price of $4.50 per share of the Registrant’s common
stock, par value $0.001 per share (“Common Stock”), on the OTCQB on November 1, 2017.
|
(3)
|
Calculated
under Section 6(b) of the Securities Act as the aggregate offering price multiplied by 0.0001245.
|
(4)
|
Represents
shares of Common Stock issued as stock dividends on the Series C Preferred Stock through June 30, 2017.
|
(5)
|
Represents
shares of Common Stock which have been recorded by the Company and will be issued as stock dividends on the Series C Preferred
Stock. Also refer to Note 1 above regarding additional shares of common stock issuable as stock dividends that are deemed
registered under this Registration Statement.
|
(6)
|
The
registration fee for these securities was paid when the Company filed the Registration Statement on Form S-1 on November 7,
2017 and is transferred and carried forward to this amendment pursuant to Rule 429 under the Securities Act.
|
The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until
the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section 8(a) of the Securities Act, or until the Registration Statement shall become effective on
such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY
NOTE
Integrity
Applications, Inc. (the “Company,” “we,” or “us”) filed a Registration Statement on Form S-1
with the Securities and Exchange Commission (“SEC”) on November 7, 2017, which was amended on December 8, 2017 and
December 21, 2017 (the “Registration Statement”). The Registration Statement was declared effective on December 26,
2017.
The
Company is submitting this Post-Effective Amendment No. 1 (“Amendment”) to its Registration Statement solely for the
purpose of providing information from its Quarterly Report on Form 10-Q for the period ended March 31, 2018 and Annual Report
on Form 10-K for the year ended December 31, 2017 filed with the SEC on May 15, 2018 and March 30, 2018, respectively, and incorporating
by reference the Current Reports on Form 8-K filed since December 21, 2017 to the date of this Amendment.
The
contents of the Registration Statement as previously filed which are not modified and revised by this Amendment are hereby incorporated
by reference.
The
information in this prospectus is not complete and may be changed. The selling stockholders may not sell these securities until
the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to
sell these securities and it is not soliciting offers to buy these securities in any state where the offer or sale is not permitted.
Subject to Completion, dated June 7 ,
2018
8,736,198
Shares of Common Stock
This
prospectus relates to the resale by the selling stockholders named herein of up to an aggregate of 8,736,198 shares of common
stock, par value $0.001 per share (“Common Stock”), of Integrity Applications, Inc. (the “Company” or
“Integrity”), consisting of 2,667,540 shares issuable upon conversion of our Series C Preferred Stock, 5,335,080 shares
issuable upon the exercise of the Series C Warrants, 180,502 shares issued as stock dividends on the Series C Preferred Stock
and 553,076 shares issuable as stock dividends on the Series C Preferred Stock.
The
shares of Common Stock described in this prospectus may be offered for sale from time to time by the selling stockholders named
herein. The selling stockholders may offer and sell the shares in a variety of transactions as described under the heading “
Plan
of Distribution
” beginning on page 89 , including transactions on any stock exchange, market or facility on which
our Common Stock may be traded, in privately negotiated transactions or otherwise at market prices prevailing at the time of sale,
at prices related to such market prices or at negotiated prices. We have no basis for estimating either the number of shares of
our Common Stock that will ultimately be sold by the selling stockholders or the prices at which such shares will be sold.
All
of the shares of Common Stock are being sold by the selling stockholders named in this prospectus. We will not receive any of
the proceeds from the sale of the shares of Common Stock being sold by the selling stockholders. We are bearing all of the expenses
in connection with the registration of the shares of Common Stock, but all selling and other expenses incurred by the selling
stockholders, including commissions and discounts, if any, attributable to the sale or disposition of the shares will be borne
by them.
Our
Common Stock is quoted on the OTCQB under the symbol “IGAP”.
You
should read this prospectus, the applicable prospectus supplement, if any, and other offering materials carefully before you invest
in the Company’s Common Stock.
There
is no relationship between Integrity Applications, Inc., the registrant under the registration statement of which this prospectus
is a part, and Integrity Applications, Incorporated, the engineering and software services company based in Chantilly, Virginia.
An
investment in our Common Stock involves substantial risks. See “
Risk Factors
” beginning on page 4 of this prospectus.
Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is June 7,
2018.
TABLE
OF CONTENTS
Prospectus
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus includes forward-looking statements. These forward-looking statements include statements about our expectations, beliefs
or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects.
All statements other than statements of historical fact included in this prospectus, including statements regarding our future
activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory
approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business
strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations,
plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements.
The words “believe,” “expect,” “intend,” “anticipate,” “estimate,”
“plan,” “may,” “will,” “could,” “would,” “should” and
other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking
statements made in this prospectus are based on certain historical trends, current conditions and expected future developments
as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date
on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made
in this prospectus are qualified by these cautionary statements and there can be no assurance that the actual results anticipated
by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or
our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of
risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could
adversely affect our business, include the risks identified in this prospectus under the caption “
Risk Factors
,”
beginning on page 4. We undertake no obligation to publicly update or revise any forward-looking statements to reflect events
or circumstances that may arise after the date of this prospectus unless required by law.
SUMMARY
This
summary highlights information contained elsewhere in this prospectus. This summary is not complete and does not contain all of
the information that you should consider before deciding to invest in our Common Stock. You should read this entire prospectus,
including the section entitled “Risk Factors,” and our financial statements and the notes included in the Annual Report
on Form 10-K for year ended December 31, 2017and Quarterly Report on Form 10-Q for the period ended March 31, 2018, incorporated
herein by reference, before deciding to invest in our Common Stock. Unless the context otherwise requires, the terms “the
Company”, “Integrity”, “we”, “our”, “ours” and “us”, refer to
A.D. Integrity Applications, Ltd., an Israeli corporation (“Integrity Israel”), for all periods prior to July 15,
2010 and to Integrity Israel and Integrity Applications, Inc., a Delaware corporation (“Integrity U.S.”), on a combined
basis, for all periods from and including July 15, 2010.
Our
Company
Overview
Integrity
Applications, Inc., incorporated in Delaware in May 2010, is a medical device company focused on the design, development and commercialization
of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. On July 15, 2010, we completed a
reverse triangular merger with Integrity Applications, Ltd., an Israeli corporation (“Integrity Israel”), and Integrity
Acquisition Corp. Ltd., an Israeli corporation and a wholly owned subsidiary of ours, pursuant to which Integrity Acquisition
Corp. Ltd. merged with and into Integrity Israel and all of the stockholders and option holders of Integrity Israel became entitled
to receive shares and options in us in exchange for their shares and options in Integrity Israel (the “Reorganization”).
Following the Reorganization, the former equity holders of Integrity Israel were entitled to the same proportional ownership in
us as they had in Integrity Israel prior to the Reorganization. As a result of the Reorganization, Integrity Israel became a wholly
owned subsidiary of ours. We operate primarily through Integrity Israel.
Integrity
Israel was founded in 2001 with a mission to develop, produce and market non-invasive blood glucose monitors for home use by diabetics.
We have developed a non-invasive glucose monitor, the GlucoTrack® model DF-F glucose monitoring device, which is designed
to help people with diabetes and pre-diabetics obtain blood glucose level readings without the pain, inconvenience, cost and difficulty
of conventional (invasive) spot finger stick devices. The GlucoTrack® model DF-F utilizes a patented combination of ultrasound,
electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that
is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood or
interstitial fluid.
In
June 2013, we received the initial Conformité Européene (CE) Mark (indicating the conformity of the Company’s
product with health, safety, and environmental protection standards for products sold within the European Economic Area) approval
for the GlucoTrack® model DF-F non-invasive glucose monitoring device from DEKRA Certification B.V., our European notified
body (the “Notified Body”), which is an entity that has been accredited by a member state of the European Union (“EU”)
to assess whether a product to be placed on the market meets certain preordained standards. This original approval required that
the device be re-calibrated every 30 days, with each such re- calibration taking between 2.5 and 3 hours to complete. In March
2014, we received CE Mark approval for six months’ calibration validity of the same device. This approval eliminates the
need for monthly re-calibrations and enables the calibration process to be conducted only when the sensor is replaced,
once every 6 months. We believe that this is a significant feature of the GlucoTrack® model DF-F. Receipt of the CE Mark allows
us to market and sell the GlucoTrack® model DF-F glucose monitoring device in EU member countries that have adopted the European
Medical Device Directive (the “MDD”) without being subject to additional national regulations with regard to demonstration
of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure uniform regulation
throughout the EU. Accordingly, member countries may apply and enforce the MDD’s terms differently, and certain EU member
countries may request or require performance and/or safety data additional to the MDD’s requirements from time to time,
on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement with the
EU. This would include some countries in South East Asia as well as Latin America opening new potential markets for Integrity
on a global basis.
On
August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack® model DF-F which simplify
and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These
improvements are intended to reduce the backlog created as purchasers of the device await calibration. In addition, we received
approval from the Notified Body on the updated intended use for the device, which expands the intended user population to include
not only Type 2 diabetics, but also persons suffering from pre-diabetes conditions as well, which we believe represents a material
expansion of the potential market for the device. In December 2015, we received approval from the Notified Body for further improvements
to the GlucoTrack® model DF-F that increase the accuracy and efficacy of the device. On February 19, 2016, we received an
extension of our ISO 13485:2003 certificate and Annex II certification from the EU. The ISO 13485:2003 certification signifies
that we have met the standards required for company-wide implementation of device quality management system(s). The scope of the
certification is design, development, manufacture and service of non-invasive glucose monitoring systems for home use. Annex II
certification also addresses quality control systems. The certification allows us to self-certify certain modifications and changes
and simplifies some of the reporting to and review by the relevant Notified Body. This can shorten the CE-mark review process
of future GlucoTrack® model DF-F enhancements or revisions, including software updates and other improvements of the device
that do not affect the intended use and/or safety performance. Without an Annex II certification, each new device enhancement
or modified version would be subject to the full EU CE-mark review process. The ISO 13485:2003 and Annex II certifications enable
us to potentially improve the time to market for product sales on new, enhanced or modified GlucoTrack® model DF-F devices.
In
addition to the improvements to the GlucoTrack® model DF-F described above, we have also continued to work on additional improvements
to the device and the development of new devices and, subject to our raising sufficient funds to do so, intend to continue these
efforts in 2018. Specifically, we developed wireless communication module (WLM) with embedded Bluetooth Low-Energy (BLE) and Wi-Fi
technologies, which we expect will enable transmission of measurement data captured by the GlucoTrack® model DF-F to a cloud-based
server. We also started to design the next generation of GlucoTrack®.
Re-Structuring
During
2017, the Company has undergone a significant transformation due to the changes in senior management. The Company has reviewed
and reworked its corporate strategy as well as the operational plan to bring more focus and reduce expense. The areas most impacted
have been the Company’s commercial operations and research & development. This has resulted in significant organizational
changes to right-size the Company to reflect its priorities and reduce costs. The Company has reduced headcount across the whole
organization from approximately 45 to 27 full-time employees. Positions have been eliminated in management, commercial operations
group and research & development group, which in turn has resulted in a significant reduction in operational costs.
Our
Product
Our
non-invasive blood glucose monitor, the GlucoTrack® model DF-F, utilizes a patented combination of ultrasound, electromagnetic
and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto
one’s earlobe and connected to a handheld control and display unit.
We
believe that the GlucoTrack® model DF-F addresses the unmet need for more frequent monitoring of blood glucose among people
with diabetes by overcoming two of the most significant challenges facing the market:
|
●
|
pain,
as the GlucoTrack® model DF-F is a truly non-invasive device; and
|
|
●
|
cost,
as, despite the relatively high upfront cost of purchasing a GlucoTrack® model DF-F, we anticipate that the total cost
of purchasing a device and purchasing replacement ear clips every six months (anticipated to be the only recurring cost, other
than calibration costs, which are expected to be minimal) over the useful life of the device will be significantly lower than
the cost of purchasing single use glucose sticks over that same period.
|
Corporate
Information
Our
principal offices are located at 19 Ha’Yahalomim St., Ashdod, Israel 7760049 and our telephone number is 972-8-675-7878.
Our website address is http://www.integrity-app.com; the reference to such website address does not constitute incorporation by
reference of the information contained on the website and such information should not be considered part of this prospectus.
The
Offering
Common
Stock Offered by Selling Stockholders:
|
8,736,198
shares, consisting of 2,667,540 shares issuable upon conversion of our Series C Preferred Stock, 5,335,080 shares issuable
upon the exercise of the Series C Warrants, 180,502 shares issued as stock dividends on the Series C Preferred Stock and 553,076
shares issuable as stock dividends on the Series C Preferred Stock.
|
Common
Stock Outstanding Before the Offering:
|
7,586,715
shares as of June 7 , 2018, excluding:
|
|
●
|
83,556
shares issuable upon the conversion of our Series A 5% Convertible Preferred Stock;
|
|
●
|
3,340,252
shares issuable upon the conversion of our Series B Preferred Stock;
|
|
●
|
2,667,540
shares issuable upon the conversion of our Series C Preferred Stock;
|
|
●
|
14,915,037
shares issuable upon the exercise of warrants, including 12,630,773 warrants issued to investors in our past offerings and
2,284,264 warrants issued to our consultants and placement agent;
|
|
●
|
856,411
shares issuable as stock dividends on the Series B Preferred Stock;
|
|
●
|
887, 1618
shares issuable as stock dividends on the Series C Preferred Stock; and
|
|
●
|
6,058,955
shares issuable upon the exercise of outstanding stock options.
|
Trading
market:
|
Our
Common Stock is quoted on the OTCQB under the symbol “IGAP”. There is currently limited trading volume for our
Common Stock and there is no guarantee that any sustained trading market will develop in the future.
|
Use
of proceeds:
|
We
will not receive any of the proceeds from the sale or other disposition of the shares of Common Stock offered hereby. We would,
however, receive proceeds upon the exercise of the warrants held by the selling stockholders which, if such warrants are exercised
in full, would be approximately $24 million. Proceeds, if any, received from the exercise of such warrants will be used for
working capital and general corporate purposes. No assurances can be given that any of such warrants will be exercised.
|
Risk
factors:
|
We
are subject to a number of risks that you should be aware of before you decide to purchase our Common Stock. These risks are
discussed more fully in the section captioned “
Risk Factors
,” beginning on page 4 of this prospectus.
|
RISK
FACTORS
An
investment in our Common Stock involves a high degree of risk. Before making an investment decision, you should carefully consider
the following risk factors. If any of these risks actually occur, our business, financial condition and results of operations
could be materially harmed. In addition, risks and uncertainties not presently known to us or that we currently deem immaterial
may also materially harm our business, financial condition and results of operations. If this were to happen, the value of our
Common Stock could decline significantly and you could lose all or part of your investment.
We
will need to secure additional financing in 2018 in order to continue to finance our operations. If we are unable to secure additional
financing on acceptable terms, or at all, we may be forced to curtail or cease our operations.
Our cash on hand was
approximately $14,500 as of June 7 , 2018. Based on our current cash burn rate, strategy and operating plan, we believe
that our cash and cash equivalents will enable us to operate for a period of less than one month from the date of this Prospectus.
In order to fund our anticipated liquidity needs beyond such period (or possibly earlier if our current cash burn rate, strategy
or operating plan change in a way that accelerates or increases our liquidity needs), we will need to raise additional capital.
Until
we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance
future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. We do not
know whether additional funding will be available on acceptable terms, or at all. If we are unable to secure additional financing
in the near term, we may be forced to: curtail or abandon our existing business plans; limit or terminate our applications for
the regulatory approvals or clearances, as the case may be, in the countries in which we intend to market the GlucoTrack®
model DF-F; reduce our headcount; default on our debt obligations; file for bankruptcy; seek to sell some or all of our assets;
and/or cease our operations. If we are forced to take any of these steps, any investment in our securities may be worthless. To
the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution,
and debt financing, if available, may involve restrictive covenants. In addition to the dilution normally attendant to an equity
offering, holders of our shares of Common Stock may experience additional dilution as a result of the anti-dilution and most favored
nation provisions of our Preferred Stock and Warrants.
We
have a history of operating losses, and there is no assurance that we will generate material revenues or become profitable in
the near future.
We
are a medical device company with a limited operating history. We are not profitable and have incurred losses since our inception.
To date we have not generated material revenue from the sale of products and we do not anticipate that we will report operating
income in the near future. Our initial product, the GlucoTrack® model DF-F, has not been approved for marketing in the United
States and may not be sold or marketed without the FDA clearance or approval in the United States. While our GlucoTrack® model
DF-F received CE Mark approval in 2013, there is no assurance that we will be able to generate any material revenues from sales
of such model in the EU or any other jurisdictions. We continue to incur research and development and selling, marketing and general
and administrative expenses related to our operations, development and commercialization of our first product. Our operating losses
for the three months ended March 31, 2018 and 2017 were approximately $1.9 million and $2.6 million, respectively, and we had
an accumulated deficit of approximately $49.7 million as of March 31, 2018. We expect to continue to incur losses for the foreseeable
future, and these losses will likely increase as we prepare for and begin to commercialize the GlucoTrack® model DF-F. If
we are not successful in manufacturing and distributing the GlucoTrack® model DF-F, or if the GlucoTrack® model DF-F does
not achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able
to sustain profitability in subsequent periods.
Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
Our
independent registered public accounting firm noted in its report accompanying our financial statements for the fiscal year ended
December 31, 2017 that we had suffered significant accumulated deficit and had negative operating cash flows and that the development
and commercialization of our product is expected to require substantial expenditures. We have not yet generated any material revenues
from our operations to fund our activities and are therefore dependent upon external sources for financing our operations.
There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. As a result, our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we cannot successfully
continue as a going concern, our stockholders may lose their entire investment in our Common Stock.
The
agreements governing our outstanding Preferred Stock contain various covenants that limit our ability to take certain actions
and our failure to comply with any of the covenants would have a material adverse effect on our business, financial condition
and results of operations.
The
agreements governing our outstanding Preferred Stock contain a number of significant covenants that, among other things, limit
our ability to incur indebtedness or liens, and repay, repurchase, pay dividends on or otherwise make distributions in respect
of any shares of Common Stock or other securities junior to the Preferred Stock. Unless we receive a consent or a waiver from
the holders of our Preferred Stock, these covenants may restrict our ability to take certain actions that we would have otherwise
taken in the absence of these covenants and which may be in the best interests of the Company and our stockholders. There can
be no assurance that we will be able to receive a consent or waiver on acceptable terms, if at all. If we fail to comply with
these covenants, we will be in default of the agreements governing our outstanding Preferred Stock, which would have a material
adverse effect on our business, financial condition and results of operations.
We
cannot guarantee we would have sufficient surplus to pay the quarterly dividends to the holders of our Preferred Stock.
Pursuant
to the Certificates of Designations of our Preferred Stock, the holders of Series A Preferred Stock, Series B Preferred Stock
and Series C Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value
per share of the Preferred Stock, which was initially $1,000 per share. Dividends on the Series A Preferred Stock, Series B Preferred
Stock and Series C Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year, and
on each conversion date (with respect to the shares of Preferred Stock being converted). Under Delaware law, we can only pay dividends,
whether in cash or common stock, either out of “surplus,” which is defined as total assets at fair market value minus
total liabilities, minus statutory capital, or out of current or the immediately preceding year’s earnings. During the third
and fourth quarters of 2017 and the first quarter of 2018, we did not have sufficient earnings to achieve a “surplus”.
Due to the statutory limitation, we were unable to distribute quarterly dividends to the holders of our Preferred Stock for the
quarters ended September 30, 2017, December 31, 2017 and March 31, 2018. The Company will incur a late fee of 9% per annum, payable
in cash, on dividends that are not paid within three trading days of the applicable dividend payment date.
We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock
in the foreseeable future.
We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock
in the foreseeable future. Any cash that might be available for payment of dividends will be used to expand our business. Payments
of any cash dividends in the future will depend on our financial condition, results of operation and capital requirements, as
well as other factors deemed relevant to our Board of Directors. Furthermore, pursuant to the certificate of designations, preferences
and rights governing the Series C Preferred Stock, as long as any shares of Series C Preferred Stock are outstanding, without
the written consent of the holders of a majority in stated value of the then outstanding Series C Preferred Stock, we will not
be permitted to, among other things, pay dividends on or otherwise make distributions in respect of any shares of our Common Stock
or other securities junior to the Series C Preferred Stock.
We
may be required to redeem our Preferred Stock upon the occurrence of certain events, which would have a material adverse effect
on our financial condition and results of operations.
We
may become obligated to redeem the Preferred Stock in cash upon the occurrence of certain triggering events, including, among
others, a material breach by us of certain contractual obligations to the holders of the Preferred Stock, the occurrence of a
change in control of the Company, the occurrence of certain insolvency events relating to the Company, or the failure of the Common
Stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges or a regulated
quotation service. In addition, upon the occurrence of certain triggering events, each holder of Preferred Stock will have the
option to require us to redeem such holder’s shares of Preferred Stock for a redemption price payable in shares of Common
Stock or receive an increased dividend rate of 9% on all of such holder’s outstanding Preferred Stock. Any obligation to
redeem the Preferred Stock would require a large expenditure of cash by us, which would have a material adverse effect on our
financial condition and results of operations.
Economic
crises and market instability may materially and adversely affect the demand for our products, as well as our ability to obtain
credit or secure funds through sales of our stock, which may materially and adversely affect our business, financial condition
and ability to fund our operations.
Economic
crises may reduce the demand for new and innovative medical devices, resulting in delayed market acceptance of our products, if
and when they are approved. Such a delay could have a material adverse impact on our business, expected cash flows, results of
operations and financial condition. Additionally, we have funded our operations to date primarily through private sales of securities,
including Common Stock and other securities convertible into or exercisable for shares of our Common Stock. Economic turmoil and
instability in the world’s equity and credit markets and in the unstable world may materially adversely affect our ability
to sell additional securities and/or borrow cash. There can be no assurance that we will be able to raise additional working capital
on acceptable terms or at all, and any failure to do so may materially adversely affect our ability to continue operations.
Healthcare
reforms, changes in healthcare policies, including recently enacted legislation reforming the U.S. healthcare system, and changes
to third-party reimbursements for diabetes-related products may affect demand for our products and have a material adverse effect
on our financial condition and results of operations.
The
United States government has in the past considered and may in the future consider healthcare policies and proposals intended
to curb rising healthcare costs, including those that could significantly affect reimbursement for healthcare products such as
the GlucoTrack® model DF-F. These policies have included, and may in the future include: basing reimbursement policies and
rates on clinical outcomes, the comparative effectiveness and costs of different treatment technologies and modalities; imposing
price controls and taxes on medical device providers; and other measures.
In
March 2010, President Obama signed into law both the Patient Protection and Affordable Care Act (the “Affordable Care Act”)
and the reconciliation law known as Health Care and Education Reconciliation Act (the “Reconciliation Act”, and, with
the Affordable Care Act, the “2010 Health Care Reform Legislation”). The 2010 Health Care Reform Legislation signed
into law was and is considered by some to be the most dramatic change to the country’s healthcare system in decades. The
principal aim of the law currently enacted is to expand health insurance coverage to approximately 32 million Americans who are
currently uninsured. The law’s most far- reaching changes did not take effect until 2014, including a requirement that most
Americans carry health insurance. The consequences of these significant coverage expansions on the sale of our products are still
unknown and speculative at this point.
The
enacted legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The
most relevant of these provisions are those that impose fees or taxes on certain health-related industries, including medical
device manufacturers like us. The legislation imposed an annual excise tax (or sales tax) on medical devices like ours, beginning
with calendar year 2013. The taxes are allocated based on our proportionate share of the prior-year’s aggregate domestic
gross receipts from medical device sales.
We
expect that the Trump administration and U.S. Congress will seek to modify, repeal, or otherwise invalidate all or certain provisions
of, the Affordable Care Act. Since taking office, President Trump has continued to support the repeal of all or portions of the
Affordable Care Act. In January 2017, the House and Senate passed a budget resolution that authorizes congressional committees
to draft legislation to repeal all or portions of the Affordable Care Act and permits such legislation to pass with a majority
vote in the Senate. President Trump also issued an executive order in which he stated that it is his administration’s policy
to seek the prompt repeal of the Affordable Care Act and directed executive departments and federal agencies to waive, defer,
grant exemptions from, or delay the implementation of the provisions of the Affordable Care Act to the maximum extent permitted
by law. In October 2017, President Trump signed a second executive order allowing for the use of association health plans and
short-term health insurance, which may provide fewer health benefits than the plans sold through the Affordable Care Act exchanges.
At the same time, the Administration announced that it will discontinue the payment of cost-sharing reduction payments to insurance
companies until Congress approves the appropriation of funds for such cost-sharing reduction payments. The loss of the CSR payments
is expected to increase premiums on certain policies issued by qualified health plans under the Affordable Care Act. Moreover,
with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by President Trump on December 22, 2017, U.S. Congress repealed
the “individual mandate,” which requires most Americans to carry a minimal level of health insurance. The repeal of
this provision will become effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate
will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Further, each chamber
of the U.S. Congress has put forth multiple bills designed to repeal or repeal and replace portions of the Affordable Care Act.
Although none of these measures has been enacted by Congress to date, U.S. Congress may consider other legislation to repeal and
replace elements of the Affordable Care Act. There is still uncertainty with respect to the impact President Trump’s administration
and the U.S. Congress may have, if any, and any changes will likely take time to unfold, and could have an impact on coverage
and reimbursement for healthcare items and services covered by plans that were authorized by the Affordable Care Act.
In
addition to the 2010 Health Care Reform Legislation and possible repeal of such discussed above, various healthcare reform proposals
have also emerged at the state level. Future significant changes in the healthcare systems in the United States or elsewhere could
also have a negative impact on the demand for the GlucoTrack® model DF-F or other GlucoTrack® products, if approved for
sale, or our future products, if any. These include changes that may lower reimbursement rates for such products from what we
might otherwise have obtained and changes that may be proposed or implemented by the current administration or Congress.
We
cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, or the effect any future
legislation or regulation will have on us. In addition to the taxes imposed by the 2010 Health Care Reform Legislation, any further
expansion in government’s role in the U.S. healthcare industry may lower reimbursements for our products, reduce medical
procedure volumes and materially adversely affect our business, financial condition and results of operations.
In
the EU, although there have not been any recent amendments to the relevant regulatory legislation, there are ongoing discussions
regarding amending the current regulatory framework for medical devices. Moreover, because the European Medical Device Directive
(the “MDD”) requires only minimum harmonization in the EU, member countries may alter their enforcement of the directives
or amend their national regulatory rules. We cannot predict what healthcare initiatives, if any, will be implemented by the EU
or EU member countries, or the effect any future legislation or regulation will have on us.
The
GlucoTrack® model DF-F may not be approved for sale in the United States or other (non-CE Mark)
jurisdictions.
We
will likely be required to undertake significant clinical trials to demonstrate to the FDA that the GlucoTrack® model DF-F
is either safe and effective for its intended use or is substantially equivalent in terms of safety and effectiveness to an existing,
lawfully marketed non-Section 515 premarket approval (PMA) device (refer to “
Management Discussion and Analysis - Government
Regulatory
”). We may also be required to undertake clinical trials by non-U.S. regulatory agencies in non-CE Mark jurisdictions.
Clinical trials are expensive and uncertain processes that may take years to complete. Failure can occur at any point in the process
and early positive results do not ensure that the entire clinical trial will be successful. Product candidates in clinical trials
may fail to show desired efficacy and safety traits despite early promising results. A number of companies in the medical device
industry have suffered significant setbacks in advanced clinical trials, even after their product candidates demonstrated promising
results at earlier points.
Positive
results from the limited pre-clinical trials and safety and performance clinical trial that we have conducted should not be relied
upon as evidence that later-stage or large-scale clinical trials will succeed. These trials involved limited patient populations
and there is no assurance that the experimental protocol or protocols, as the case may be, used in these informal trials will
be methodologically similar to ones submitted to the FDA or any other regulatory body for its approval. Because of the sample
size, possible variation in methodology, differences in exclusion/inclusion criteria, or differences in endpoints, the results
of these pre-clinical trials may not be indicative of future results. We will likely be required to demonstrate through well-controlled
clinical trials that the GlucoTrack® model DF-F or future product candidates, if any, are safe and effective for their intended
uses. In the event that the FDA deems GlucoTrack® model DF-F to be a Class II device, which we do not believe is likely at
this point, then we would be required to demonstrate that it is substantially equivalent in terms of safety and effectiveness
to a device lawfully marketed either through a premarket notification or prior to May 28, 1976.
Additionally,
although we have received our CE Mark approval for the GlucoTrack® model DF-F non-invasive glucose monitoring device, EU member
countries may request or require additional performance and/or safety data from time to time, on a case-by-case basis. We have
also received final approval from South Korea to commence sales of the GlucoTrack® model DF-F in South Korea.
Further,
the GlucoTrack® model DF-F or our future product candidates, if any, may not be cleared or approved, as the case may be, even
if the clinical data are satisfactory and support, in our view, its or their clearance or approval. The FDA or other non-U.S.
regulatory authorities may disagree with our trial design or interpretation of the clinical data. In addition, any of these regulatory
authorities may change requirements for the clearance or approval of a product candidate even after reviewing and providing comment
on a protocol for a pivotal clinical trial that has the potential to result in FDA approval. In addition, any of these regulatory
authorities may also clear or approve a product candidate for fewer or more limited uses than we request or may grant clearance
or approval contingent on the performance of costly post-marketing clinical trials. In addition, the FDA or other non-regulatory
authorities may not approve the labeling claims necessary or desirable for the successful commercialization of the GlucoTrack®
model DF-F or our future product candidates, if any.
We
are highly dependent on the success of our initial product candidate, the GlucoTrack® model DF-F, and cannot give any assurance
that it will receive regulatory approval or clearance or be successfully commercialized.
We
are highly dependent on the success of our initial product candidate, the GlucoTrack® model DF-F. We cannot give any assurance
that the FDA will permit us to clinically test the device, nor can we give any assurance that the clinical trials will be successful
or that the GlucoTrack® model DF-F will receive regulatory clearance or approval or be successfully commercialized, for a
number of reasons, including, without limitation, the potential introduction by our competitors of more clinically-effective or
cost-effective alternatives, failure in our sales and marketing efforts, or the failure to obtain positive coverage determinations
or reimbursement. Any failure to obtain approval to conduct clinical trials, favorable clinical data, clearance or approval of
or to successfully commercialize the GlucoTrack® model DF-F would have a material adverse effect on our business.
If
our competitors develop and market products that are more effective, safer or less expensive than GlucoTrack® model DF-F or
our future product candidates, if any, our commercial opportunities will be adversely affected.
The
life sciences industry is highly competitive and we face significant competition from many medical device companies that are researching
and marketing products designed to address the needs of persons suffering from diabetes. We are currently developing medical devices
that will compete with other medical devices that currently exist or are being developed. Products that we may develop in the
future are also likely to face competition from other medical devices and therapies. Some of our competitors have significantly
greater financial, manufacturing, marketing and product development resources than we do. Large medical device companies, in particular,
have extensive experience in clinical testing and in obtaining regulatory clearances or approvals for medical devices. These companies
also have significantly greater research and marketing capabilities than us. Some of the medical device companies that we expect
to compete with include Roche Diesetronic, a division of Roche Diagnostics; LifeScan, Inc., a division of Johnson & Johnson;
the MediSense and TheraSense divisions of Abbott Laboratories; Ascensia, a spin off from the Bayer Corporation; Echo Therapeutics,
Inc.; Grove Instruments; and Medtronic, Inc. In addition, many other universities and private and public research institutions
are or may become active in research involving blood glucose measurement devices.
We
believe that our ability to successfully compete will depend on, among other things:
|
●
|
our
ability to have partners manufacture and sell commercial quantities of any approved products to the market;
|
|
●
|
acceptance
of product candidates by physicians and other health care providers;
|
|
●
|
the
results of our clinical trials;
|
|
●
|
our
ability to recruit and enroll patients for our clinical trials;
|
|
●
|
the
efficacy, safety, performance and reliability of our product candidates;
|
|
●
|
the
speed at which we develop product candidates;
|
|
●
|
our
ability to obtain prompt and favorable review by institutional review boards (“IRB”) (refer to “
Management
Discussion and Analysis - Government Regulatory
”) and approval at each of our clinical sites;
|
|
●
|
our
ability to commercialize and market any of our product candidates that may receive regulatory clearance or approval;
|
|
●
|
our
ability to design and successfully execute appropriate clinical trials;
|
|
●
|
the
timing and scope of regulatory clearances or approvals;
|
|
●
|
appropriate
coverage and adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and
|
|
●
|
our
ability to protect intellectual property rights related to our products.
|
If
our competitors market products that are more effective, safer, easier to use or less expensive than GlucoTrack® model DF-F
or our future product candidates, if any, or that reach the market sooner than GlucoTrack® model DF-F or our future product
candidates, if any, we may not achieve commercial success. In addition, the medical device industry is characterized by rapid
technological change. It may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at
the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by
our competitors may render our technologies or product candidates obsolete or less competitive.
Our
product development activities could be delayed or stopped.
We
do not know whether our future clinical trials will begin on time, or at all, and whether ongoing and/or future clinical trials
will be completed on schedule, or at all.
The
commencement of future clinical trials could be substantially delayed or prevented by several factors, including:
|
●
|
the
failure to obtain sufficient funding to pay for all necessary clinical trials;
|
|
●
|
limited
number of, and competition for, suitable patients that meet the protocol’s inclusion criteria and do not meet any of
the exclusion criteria;
|
|
●
|
limited
number of, and competition for, suitable sites to conduct the clinical trials, and delay or failure to obtain FDA approval,
if necessary, to commence a clinical trial;
|
|
●
|
delay
or failure to obtain sufficient supplies of the product candidate for clinical trials;
|
|
●
|
requirements
to provide the medical device required in clinical trials at cost, which may require significant expenditures that we are
unable or unwilling to make;
|
|
●
|
delay
or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites
or investigators; and
|
|
●
|
delay
or failure to obtain IRB approval or renewal of such approval to conduct a clinical trial at a prospective or accruing site,
respectively.
|
The
completion of clinical trials in connection with our application for FDA approval could also be substantially delayed or prevented
by several factors, including:
|
●
|
slower
than expected rates of patient recruitment and enrollment;
|
|
●
|
failure
of patients to complete the clinical trial;
|
|
●
|
unforeseen
safety issues;
|
|
●
|
lack
of efficacy evidenced during clinical trials;
|
|
●
|
termination
of clinical trials by one or more clinical trial sites;
|
|
●
|
inability
or unwillingness of patients or medical investigators to follow clinical trial protocols; and
|
|
●
|
inability
to monitor patients adequately during or after treatment.
|
Our
clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB for any given site,
or us. Any failure or significant delay in completing clinical trials for GlucoTrack® or future product candidates, if any,
could materially harm our financial results and the commercial prospects for our product candidates.
The
regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization
of GlucoTrack® model DF-F or our future product candidates, if any.
The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of medical devices are subject to extensive
regulation by the FDA and other non-U.S. regulatory authorities, which regulations differ from country to country. We are not
permitted to market our product candidates in the United States until we receive a clearance letter under the 510(k)-premarket
notification process or approval of a Section 515 PMA, from the FDA, depending on the nature of the device. We have not submitted
an application or premarket notification for or received marketing clearance or approval for any of our product candidates. Obtaining
approval of any PMA can be a lengthy, expensive and uncertain process. While the FDA normally reviews, and clears a premarket
notification in three months, there is no guarantee that our products will qualify for this more expeditious regulatory process,
which is reserved for Class I and II devices, nor is there any assurance that, even if a device is reviewed under the 510(k)-premarket
notification process, the FDA will review it expeditiously or determine that the device is substantially equivalent to a lawfully
marketed non-PMA device. If the FDA fails to make this finding, then we cannot market the device. In lieu of acting on a premarket
notification, the FDA may seek additional information or additional data which would further delay our ability to market the product.
In addition, failure to comply with FDA, non-U.S. regulatory authorities or other applicable U.S. and non-U.S. regulatory requirements
may, either before or after product clearance or approval, if any, subject us to administrative or judicially imposed sanctions,
including:
|
●
|
restrictions
on the products, manufacturers or manufacturing process;
|
|
●
|
adverse
inspectional observations (Form 483), warning letters or non-warning letters incorporating inspectional observations, i.e.,
so- called “untitled letter”;
|
|
●
|
civil
and criminal penalties;
|
|
●
|
injunctions;
|
|
●
|
suspension
or withdrawal of regulatory clearances or approvals;
|
|
●
|
product
seizures, detentions or import bans;
|
|
●
|
voluntary
or mandatory product recalls and publicity requirements;
|
|
●
|
total
or partial suspension of production;
|
|
●
|
imposition
of restrictions on operations, including costly new manufacturing requirements; and
|
|
●
|
refusal
to clear or approve pending applications or premarket notifications.
|
Regulatory
approval of a PMA or PMA supplement or clearance pursuant to a 510(k)-premarket notification is not guaranteed, and the approval
or clearance process, as the case may be, is expensive and may, especially in the case of the PMA, take several years. The FDA
also has substantial discretion in the medical device clearance or approval processes. Despite the time and expense exerted, failure
can occur at any stage and we could encounter problems that cause us to abandon clinical trials or to repeat or perform additional
pre-clinical studies and clinical trials. The number of pre-clinical studies and clinical trials that will be required for FDA
clearance or approval varies depending on the medical device candidate, the disease or condition that the medical device candidate
is designed to address, and the regulations applicable to any particular medical device candidate. The FDA can delay, limit or
deny clearance or approval of a medical device candidate for many reasons, including:
|
●
|
a
medical device candidate may not be deemed safe or effective, in the case of a PMA;
|
|
●
|
a
medical device candidate may not be deemed to be substantially equivalent to a lawfully marketed non-PMA device in the case
of a 510(k)-premarket notification;
|
|
●
|
FDA
officials may not find the data from the clinical trials sufficient;
|
|
●
|
the
FDA might not approve our third-party manufacturer’s processes or facilities; or
|
|
●
|
the
FDA may change its clearance or approval policies or adopt new regulations.
|
Further,
while we have received CE Mark approval for the GlucoTrack® model DF-F, the MDD requires only minimum harmonization. In practice,
uniform regulation throughout the EU is not ensured. Rather, member countries may apply and enforce the MDD’s terms differently,
and certain EU member countries may request or require performance and/or safety data additional to the MDD’s requirements
from time to time, on a case-by-case basis. Therefore, we cannot predict whether we will be able to successfully commercialize
the GlucoTrack® model DF-F or our future product candidates, if any, in the EU.
Failure
to recruit and enroll patients for clinical trials may cause the development of our product candidates to be delayed.
We
may encounter delays if we are unable to recruit and enroll and retain enough patients to complete clinical trials. Patient enrollment
depends on many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to
clinical sites and the eligibility criteria for the trial. Delays in patient enrollment are not unusual. Any such delays in planned
patient enrollment may result in increased costs, which could harm our ability to develop products.
The
terms of clearances or approvals and ongoing regulation of our products may limit how we manufacture and market our product candidates,
which could materially impair our ability to generate anticipated revenues.
Once
regulatory clearance or approval for a product candidate has been granted, the cleared or approved product and its manufacturer
are subject to continual review. Any cleared or approved product may only be promoted for its indicated uses. In addition, if
the FDA or other non-U.S. regulatory authorities clear or approve GlucoTrack® model DF-F or our future product candidates,
if any, the labeling, packaging, adverse event reporting, storage, advertising and promotion for the product will be subject to
extensive regulatory requirements. We, and the manufacturers of our products, if other than us, also will be required to comply
with the FDA’s Quality System Regulation, which includes requirements relating to quality control and quality assurance,
as well as the corresponding maintenance of records and documentation. Moreover, device manufacturers are required to report adverse
events by filing Medical Device Reports with the FDA, which are publicly available. Further, regulatory agencies must approve
our manufacturing facilities before they can be used to manufacture products, and these facilities are subject to ongoing regulatory
inspection. If we fail to comply with the regulatory requirements of the FDA and other non-U.S. regulatory authorities, or if
previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we could be subject to
administrative or judicially imposed sanctions, including:
|
●
|
restrictions
on the products, manufacturers or manufacturing process;
|
|
●
|
adverse
inspectional observations (Form 483), warning letters, or non-warning letters incorporating inspectional observations;
|
|
●
|
civil
or criminal penalties or fines;
|
|
●
|
injunctions;
|
|
●
|
product
seizures, detentions or import bans;
|
|
●
|
voluntary
or mandatory product recalls and publicity requirements;
|
|
●
|
suspension
or withdrawal of regulatory clearances or approvals;
|
|
●
|
total
or partial suspension of production;
|
|
●
|
imposition
of restrictions on operations, including costly new manufacturing requirements; and
|
|
●
|
refusal
to clear or approve pending applications or premarket notifications.
|
In
addition, the FDA and other non-U.S. regulatory authorities, including the EU and each of the EU member countries individually,
may change their policies and additional regulations may be enacted that could prevent or delay regulatory clearance or approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance,
we will likely not be permitted to market future product candidates and may not achieve or sustain profitability.
Even
if we receive regulatory clearance or approval to market the GlucoTrack® model DF-F or our future product candidates, if any,
the market may not be receptive to our products.
Even
if GlucoTrack® model DF-F or our future product candidates, if any, obtain regulatory clearance or approval, resulting products
may not gain market acceptance among physicians, patients, health care payors or the medical community. We believe that the degree
of market acceptance will depend on a number of factors, including:
|
●
|
timing
of market introduction of competitive products;
|
|
●
|
safety
and efficacy of our product;
|
|
●
|
prevalence
and severity of any side effects;
|
|
●
|
potential
advantages or disadvantages over alternative treatments;
|
|
●
|
strength
of marketing and distribution support;
|
|
●
|
price
of our product candidates, both in absolute terms and relative to alternative treatments; and
|
|
●
|
availability
of coverage and reimbursement from government and other third-party payors.
|
If
the GlucoTrack® model DF-F or our future product candidates, if any, fail to achieve market acceptance, we may not be able
to generate significant revenue or achieve or sustain profitability.
The
coverage and reimbursement status of newly cleared or approved medical devices is uncertain, and failure to obtain adequate coverage
and adequate reimbursement could limit our ability to market GlucoTrack® model DF-F or future product candidates, if any,
and may inhibit our ability to generate revenue from GlucoTrack® model DF-F or our future product candidates, if any, that
may be cleared or approved.
There
is significant uncertainty related to the third-party coverage and reimbursement of newly cleared or approved medical devices.
The commercial success of GlucoTrack® model DF-F or our future product candidates, if any, in both domestic and international
markets will depend in part on the availability of coverage and adequate reimbursement from third-party payors, including government
payors, such as the Medicare and Medicaid programs, managed care organizations and other third-party payors. Government and other
third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement
for new products and, as a result, they may not cover or provide adequate payment for GlucoTrack® model DF-F or our future
product candidates, if any. These payors may conclude that our products are not as safe or effective as existing devices or that
the overall cost of using one of our devices exceeds the overall cost of the competing device, and third-party payors may not
approve GlucoTrack® model DF-F or our future product candidates, if any, for coverage and adequate reimbursement. Furthermore,
deficit reduction and austerity measures in the United States and abroad may put further pressure on governments to limit coverage
of, and reimbursement for, our products. The failure to obtain coverage and adequate reimbursement for GlucoTrack® model DF-F
or our future product candidates, if any, or health care cost containment initiatives that limit or restrict reimbursement for
such products may reduce any future product revenue.
We
may not obtain insurance coverage to adequately cover all significant risk exposures.
We
will be exposed to liabilities that are unique to the products we provide. We currently maintain premises insurance and there
can be no assurance that we will acquire or maintain insurance for certain risks, that the amount of our insurance coverage will
be adequate to cover all claims or liabilities, or that we will not be forced to bear substantial costs resulting from risks and
uncertainties of business. It is also not possible to obtain insurance to protect against all operational risks and liabilities.
The failure to obtain adequate insurance coverage on terms favorable to us, or at all, could have a material adverse effect on
our business, financial condition and results of operations.
If
product liability lawsuits are brought against us, we may incur substantial liabilities.
We
face a potential risk of product liability as a result of any of the products that we offer for sale. For example, we may be sued
if any product we sell allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing
or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to
warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur
substantial liabilities. Even successful defense would require significant financial and management resources. Regardless of the
merits or eventual outcome, liability claims may result in:
|
●
|
decreased
demand for products that we may offer for sale;
|
|
●
|
injury
to our reputation;
|
|
●
|
costs
to defend the related litigation;
|
|
●
|
a
diversion of management’s time and our resources;
|
|
●
|
substantial
monetary awards to trial participants or patients;
|
|
●
|
product
recalls, withdrawals or labeling, marketing or promotional restrictions; and
|
|
●
|
a
decline in our stock price.
|
Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. We currently maintain product liability
insurance up to $3,000,000 per claim and in the aggregate. Although we have product liability coverage, we may have to pay amounts
awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance,
and we may not have, or be able to obtain, sufficient capital to pay such amounts.
If
we fail to attract and retain key management and scientific personnel, we may be unable to successfully develop or commercialize
the GlucoTrack® model DF-F or our future product candidates, if any.
We
will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to
successfully pursue our research, development and commercialization efforts for GlucoTrack® model DF-F or our future product
candidates, if any. Our success depends on our continued ability to attract, retain and motivate highly qualified management and
pre-clinical and clinical personnel. The loss of the services of any of our senior management could delay or prevent the development
or commercialization of GlucoTrack® model DF-F or our future product candidates, if any. At present, we do not have key man
insurance policies with respect to any of our employees. We will need to hire additional personnel as we continue to expand our
research and development activities and build a sales and marketing function. Although we currently have employment agreements
with each of Messrs. Graham, Malka, Sassoun and Podwalski, those agreements provide that they may be terminated by Mr. Graham,
Malka and Sassoun as applicable, upon 90 days written notice to us, respectively.
We
may not be able to attract or retain qualified management and scientific personnel in the future due to the intense competition
for qualified personnel among medical device and other businesses. If we are not able to attract and retain the necessary personnel
to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our research
and development objectives, our ability to raise additional capital and our ability to implement our business strategy. In particular,
if we lose any members of our senior management team, we may not be able to find suitable replacements in a timely fashion or
at all and our business may be harmed as a result.
As
we continue to evolve from a company primarily involved in development to a company also involved in commercialization, we may
encounter difficulties in managing our growth and expanding our operations successfully.
As
the GlucoTrack® model DF-F has received a CE Mark, we have begun to expand our manufacturing, marketing and sales capabilities
by contracting with third parties to provide these capabilities. We anticipate that, as our operations expand, we will need to
manage additional relationships with such third parties. Maintaining these relationships and managing our future growth will impose
significant added responsibilities on members of our management. We must be able to manage our development efforts effectively;
manage our clinical trials effectively; hire, train and integrate additional management, development, administrative and sales
and marketing personnel; improve managerial, development, operational and finance systems; and expand our facilities, all of which
may impose a strain on our administrative and operational infrastructure.
We
rely on third parties to manufacture and supply our product.
We
do not own or operate manufacturing facilities for clinical or commercial production of the GlucoTrack® model DF-F, other
than a prototype lab. We have no experience in medical device manufacturing and lack the resources and the capability to
manufacture the GlucoTrack® model DF-F on a commercial scale. We currently manufacture the GlucoTrack® model DF-F with
a third-party manufacturer in Israel. In July 2014, we entered into a manufacturing agreement with Wistron. Wistron is in the
process of preparing a production line for the GlucoTrack® model DF-F. Wistron has produced a small pilot batch and is in
the process of producing a second pilot batch of the GlucoTrack® model DF-F device. Following the receipt of an official clearance
from the Taiwanese authorities on January 11, 2017 and the successful completion of a GMP (Good Manufacturing Practice) audit
by the local regulatory authorities in July 2017, the production line for the GlucoTrack® model DF-F is now operational. We
intend to utilize the services of both Wistron and the Israeli third-party manufacturer to produce the GlucoTrack® model DF-F.
If
our manufacturing partners are unable to produce our products in the amounts, timing or pricing that we require, we may not be
able to establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the quantities
or pricing we require. We expect to depend on third-party contract manufacturers for the foreseeable future.
The
GlucoTrack® model DF-F does, and our future product candidates, if any, likely will require precise, high quality manufacturing.
Any of our contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and other non-U.S. regulatory
authorities to ensure strict compliance with quality system regulations, including current good manufacturing practices and other
applicable government regulations and corresponding standards. If our contract manufacturers fail to achieve and maintain high
manufacturing standards in compliance with quality system regulations, we may experience manufacturing errors resulting in patient
injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery,
delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that could
seriously harm our business.
Any
performance failure on the part of our contract manufacturers could delay clinical development or regulatory clearance or approval
of our product candidates or commercialization of our future product candidates, depriving us of potential product revenue and
resulting in additional losses. In addition, our dependence on a third-party for manufacturing may adversely affect our future
profit margins. Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers
is limited and the FDA must approve any replacement manufacturer before it can begin manufacturing our product candidates. Such
approval would require additional non-clinical testing and compliance inspections. It may be difficult or impossible for us to
identify and engage a replacement manufacturer on acceptable terms in a timely manner, or at all.
We
are dependent on third-party distributors to market and sell our products.
We
have limited internal marketing, sales or distribution capabilities and currently we do not intend to develop extensive internal
marketing, sales or distribution capabilities in the future. Rather, we intend to utilize third-party distributors to market our
products and have entered into exclusive distribution agreements with respect to certain territories. There is no assurance
that third party distributors will achieve acceptable levels of sales or that, if any of our existing arrangements expire or terminate,
we will be able to replace any distributors on terms advantageous to us, or at all. Further, there is no assurance that we will
be able to expand our distribution network by adding additional distributors. If third party distributors cease to promote our
products, or if we are unable to make acceptable arrangements with distributors or sales personnel in other markets, our business
prospects, operating results or financial condition could be materially adversely affected.
After
months of protracted negotiations with our China distributor, we finally reached an impasse on several critical issues and decided
that it would be in the best interests of the Company to terminate the existing agreements with such distributor due to various
breaches of the distributor. On May 14, 2018, the Company sent notices to the distributor regarding the Company’s intention
to terminate the agreement unless the breaches are cured within 30 days. On June 6, 2018, the Company received a response
from the distributor denying all the allegations of breaches. The distributor plays a critical role in assisting the Company
to obtain regulatory approval by the China Food and Drug Administration (“CFDA”) for the GlucoTrack® model DF-F.
If the breaches are not cured within the given timeframe and the relationship is terminated, the registration of GlucoTrack®
in China will be delayed significantly while we seek new partnering options; and as a result of the breaches of the distributor
and the termination of such relationship, the Company may likely be unable to re-submit the file to the CFDA for the
current product for a period of up to five years. While the Company is of the opinion that such termination will have little adverse effect on
its future business opportunities in China, as it believes that it should be able to file applications with the CFDA for
its next generation products through another distributor in China, there can be no assurance that the Company will be successful
in this endeavor. If we were unable to partner with another distributor in China on terms mutually agreed upon by us and receive CFDA clearance
to sell its future products in China, we would not have the ability to distribute our products in China and accordingly our
business potential could be materially adversely affected.
Independent
clinical investigators and contract research organizations that we engage to conduct our clinical trials may not be diligent,
careful or timely.
We
will depend on independent clinical investigators to conduct our clinical trials. Contract research organizations may also assist
us in the collection and analysis of data. These investigators and contract research organizations will not be our employees and
we will not be able to control, other than by contract, the amount of resources, including time, that they devote to products
that we develop. If independent investigators fail to devote sufficient resources to the clinical trials, or if their performance
is substandard, it will delay the approval or clearance and commercialization of any products that we develop. Further, the FDA
requires that we comply with standards, commonly referred to as good clinical practice, for conducting, recording and reporting
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial subjects are protected. If our independent clinical investigators and contract research organizations fail to comply
with good clinical practice, the results of our clinical trials could be called into question and the clinical development of
our product candidates could be delayed. Failure of clinical investigators or contract research organizations to meet their obligations
to us or comply with federal regulations could adversely affect the clinical development of our product candidates and harm our
business.
If
we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.
Our
success depends, among other things, on our ability to protect proprietary methods and technologies that we develop under the
patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully
using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us
to commercialize proposed products. For this and other reasons, we may be unable to secure desired patent rights, thereby losing
desired exclusivity. Although we do not believe that we need any licenses for the GlucoTrack® model DF-F, we may need to obtain
licenses in the future for other products or in certain circumstances, such as if one of our patents were declared invalid in
the future. If such licenses are not available to us on acceptable terms, we will not be able to market the affected products
or conduct the desired activities, unless we successfully challenge the validity, enforceability or infringement of the third-party
patent or otherwise circumvent the third-party patent.
Our
strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. The process of obtaining patent
protection is expensive and time-consuming. Despite our efforts to protect our proprietary rights, unauthorized parties may be
able to obtain and use information that we regard as proprietary.
The
issuance of a patent does not guarantee that it is valid or enforceable. Any patents we have obtained, or which we may obtain
in the future, may be challenged, invalidated, unenforceable or circumvented. Moreover, the United States Patent and Trademark
Office (the “USPTO”) may commence interference proceedings involving our patents or patent applications. Any challenge
to, finding of unenforceability or invalidation or circumvention of our patents or patent applications would be costly, would
require significant time and attention of our management and could have a material adverse effect on our business. In addition,
court decisions may introduce uncertainty in the enforceability or scope of patents owned by medical device companies.
Our
pending patent applications may not result in issued patents. The patent position of medical device companies, including us, is
generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts
use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy
regarding the subject matter and scope of claims granted or allowable in medical device patents. Accordingly, we do not know the
degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to
us or to others. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign
countries may not protect our rights to the same extent as the laws of the United States. Therefore, the enforceability or scope
of our patents in the United States or in foreign countries cannot be predicted with certainty, and, as a result, any patents
that we own may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection
for our pending patent applications or those we may file in the future.
We
cannot assure you that any patents that will issue, that may issue or that may be licensed to us will be enforceable or valid
or will not expire prior to the commercialization of our product candidates, thus allowing others to more effectively compete
with us. Therefore, any patents that we own may not adequately protect our product candidates or our future products.
If
we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products
could be adversely affected.
In
addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential
and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we will seek to enter
into confidentiality and non-disclosure agreements with our employees, consultants and collaborators upon the commencement of
their relationships with us. These agreements generally require that all confidential information developed by the individual
or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and
not disclosed to third parties. Our agreements with employees also generally provide and will generally provide that any inventions
conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain
these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. In
the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained,
may not provide meaningful protection, particularly for trade secrets or other confidential information. To the extent that our
employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise
between us and those third parties as to the rights in related inventions.
Adequate
remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of trade
secrets would impair our competitive position and may materially harm our business, financial condition and results of operations.
Some
jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could be extended to include some of
our product candidates, which may limit potential revenue opportunities.
Many
countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In addition, most countries limit the enforceability of patents against government agencies or
government contractors. In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement,
which could materially diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly
popular in developing countries, either through direct legislation or international initiatives. Such compulsory licenses could
be extended to include some of our product candidates, which may limit our potential revenue opportunities.
Our
commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights
of third parties.
Other
entities may have or obtain patents or proprietary rights that could limit our ability to manufacture, use, sell, offer for sale
or import products or impair our competitive position. In addition, to the extent that a third party develops new technology that
covers our products, we may be required to obtain licenses to that technology, which licenses may not be available on commercially
reasonable terms, if at all. If licenses are not available on acceptable terms, we will not be able to market the affected products
or conduct the desired activities unless we successfully challenge the validity, enforceability or infringement of the third-party
patent or circumvent the third-party patent, which would be costly and would require significant time and attention of our management.
Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products
using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial
condition and results of operations.
If
we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial
costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts.
Third
parties may sue us for infringing their patent rights. Likewise, we may need to resort to litigation to enforce a patent issued
or licensed to us or to determine the scope and validity of proprietary rights of others. In addition, a third party may claim
that we have improperly obtained or used our confidential or proprietary information. The cost to us of any litigation or other
proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would
divert management’s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more
effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation
of any litigation could limit our ability to continue our operations.
If
any parties successfully claim that our creation or use of proprietary technologies infringes upon their intellectual property
rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on
such parties’ patent rights. In addition to any damages we might have to pay, a court could require us to stop the infringing
activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms,
if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same
technology. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively
market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly
prevent us from generating revenue sufficient to sustain operations.
Failure
to obtain additional regulatory approvals outside the United States will prevent or limit us from marketing our product candidates
abroad.
We
intend to market our product candidates in non-U.S. markets. In order to market product candidates in the EU and many other non-U.S.
jurisdictions, we must obtain separate regulatory approvals. In December 2012, we submitted our technical file to the Notified
Body in connection with our application to obtain CE Mark approval for the GlucoTrack® model DF-F non-invasive glucose monitoring
device. On June 6 , 2013, we received CE Mark approval for the GlucoTrack® model DF-F non-invasive glucose monitoring
device from the Notified Body. Receipt of the CE Mark allows us to market and sell the GlucoTrack® model DF-F glucose monitoring
device in EU member countries that have adopted the MDD without being subject to additional national regulations with regard to
demonstration of performance and safety. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition Agreement
with the EU. However, member countries may apply and enforce the MDD’s terms differently, and certain EU member countries
may request or require that we provide performance and/or safety data additional to the MDD’s requirements from time to
time, on a case-by-case basis, in order to be cleared to market and sale the GlucoTrack® model DF-F in such countries.
It is currently uncertain
whether the agreement with our distributor in China will be terminated following our notice of intention to terminate the agreement
due to various breaches of the distributor and the response from the distributor denying the allegations of breaches . If
the breaches are not cured within the given timeframe and the relationship is terminated, the registration of GlucoTrack®
in China will be delayed significantly while we seek new partnering options ; and as a result of the breaches of the distributor
and the termination of such relationship, the Company may likely be unable to re-submit the file to the CFDA for the
current product for a period of up to five years . While the Company is of the opinion that such termination will have little
adverse effect on its future business opportunities in China, as it believes that it should be able to file applications
with the CFDA for its next generation products through another distributor in China, there can be no assurance that
the Company will be successful in this endeavor. If we were unable to partner with another distributor in China on terms
mutually agreed upon by us and receive CFDA clearance to sell its future products in China, we would not have the
ability to distribute our products in China and accordingly our business potential could be materially adversely affected.
Receipt
of FDA approval does not ensure approval by regulatory authorities in countries, and approval by one or more non-U.S. regulatory
authorities (including receipt of the CE Mark) does not ensure approval by regulatory authorities in other countries or by the
FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance.
We may not obtain additional non-U.S. regulatory approvals on a timely basis, if at all. We may not be able to file for additional
non-U.S. regulatory approvals and may not receive necessary approvals to commercialize our product candidates in any market.
Non-U.S.
governments often impose strict price controls, which may adversely affect our future profitability
.
We
intend to seek approval to market GlucoTrack® model DF-F and our future product candidates, if any, in both the U.S. and in
non-U.S. jurisdictions. If we obtain approval in one or more non-U.S. jurisdictions, we will be subject to rules and regulations
in those jurisdictions relating to our products. In some countries, particularly countries of the EU, each of which has developed
its own rules and regulations, pricing may be subject to governmental control under certain circumstances. In these countries,
pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a medical
device candidate. Each of the EU member states has its own unique legal system and thus it is difficult to predict the particular
requirements to which we may be subject. To obtain reimbursement or pricing approval in some countries, we may be required to
conduct a clinical trial that compares the cost-effectiveness of our product to other available products. If reimbursement of
our product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be
unable to achieve or sustain profitability.
Our
business may become subject to economic, political, regulatory and other risks associated with international operations, which
could harm our business.
Our
business is subject to risks associated with conducting business internationally. Accordingly, our future results could be harmed
by a variety of factors, including:
|
●
|
difficulties
in compliance with non-U.S. laws and regulations;
|
|
●
|
changes
in non-U.S. regulations and customs;
|
|
●
|
changes
in non-U.S. currency exchange rates and currency controls;
|
|
●
|
changes
in a specific country’s or region’s political or economic environment;
|
|
●
|
trade
protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
|
|
●
|
negative
consequences from changes in tax laws; and
|
|
●
|
difficulties
associated with staffing and managing foreign operations, including differing labor relations.
|
Conditions
in Israel may harm our ability to produce and sell our products and may adversely affect our business.
Our
principal executive offices and research and development facilities, as well as some of our suppliers, are located in Israel.
Political, economic and military conditions in Israel directly affect our operations. Specifically, we could be materially adversely
affected by:
|
●
|
any
major hostilities involving Israel;
|
|
●
|
a
full or partial mobilization of the reserve forces of the Israeli army;
|
|
●
|
the
interruption or curtailment of trade between Israel and its present trading partners; and
|
|
●
|
a
significant downturn in the economic or financial conditions in Israel.
|
Since
the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighbors.
A state of hostility, varying in degree and intensity, has led to security and economic problems for Israel. Despite the progress
towards peace between Israel and its neighbors, the future of these peace efforts remains uncertain. Since October 2000, there
has been a substantial deterioration in the relationship between Israel and the Palestinian Authority and a significant increase
in violence, civil unrest and hostility, including armed clashes between the State of Israel and Palestinian militants, and acts
of terror have been committed inside Israel and against Israeli targets in the West Bank and Gaza Strip. During the summer of
2006 and the fall of 2012, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and
political party. In December 2008, January 2009, November 2012 and July 2014, there were escalations in violence between Israel,
on the one hand, and Hamas, the Palestinian Authority and/or other groups, on the other hand, as well as extensive hostilities
along Israel’s border with the Gaza Strip, which resulted in missiles being fired from the Gaza Strip into Southern and
central Israel, including near Tel Aviv and at areas surrounding Jerusalem. These conflicts involved missile strikes against civilian
targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively
affected business conditions in Israel. Our offices are located in Ashkelon, Israel, which is within the range of the missiles
and rockets that have been fired at Israeli cities and towns from Gaza sporadically since 2006, with escalations in violence (such
as the recent escalation in July 2014) during which there were a substantially larger number of rocket and missile attacks aimed
at Israel. Since December 2010, there has been a wave of protests and civil resistance demonstrations in several countries in
the Middle East and North Africa, including Egypt and Syria, which share a border with Israel. The demonstrations and acts of
civil resistance in Egypt led to the resignation of the former Egyptian president Hosni Mubarak and to extensive revisions in
the Egyptian governmental structure. The demonstrations and acts of civil resistance in Syria have led to an extended period of
violence and political instability in Syria. It is not clear how this revolutionary wave, also known as the Arab Spring, will
develop and how it will affect the political and security situation in the Middle East. It is also not clear how it will affect
Israel and its relationship with its neighbors. Presently, there is great international concern in connection with Iran’s
efforts to develop and enrich uranium which could lead to the development of nuclear weapons. Iran’s successful enrichment
of uranium could significantly alter the geopolitical landscape in the Middle East, including the threat of international war,
which could significantly impact business conditions in Israel. Any on-going or future violence between Israel and the Palestinians,
armed conflicts, terrorist activities, tension along the Israeli borders or with other countries in the region, including Iran,
or political instability in the region could disrupt international trading activities in Israel and may materially and negatively
affect our business and results of operations and could make it more difficult for us to raise capital. Parties with whom we do
business may decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements
when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel
may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform
their commitments under those agreements pursuant to force majeure provisions in such agreements.
In
addition, Israel’s economy has been subject to numerous destabilizing factors, including a period of rampant inflation in
the early to middle 1980s, low foreign exchange reserves, fluctuations in world commodity prices, military conflicts and civil
unrest. Furthermore, several countries restrict business with Israel and Israeli companies, which may limit our ability to make
sales in those countries. These restrictions, continuing or escalating hostilities in the region or curtailment of trade between
Israel and its present trading partners may have an adverse effect on our operating results and financial condition, including
our ability to develop, manufacture and market our products.
Our
operations could be disrupted as a result of the obligations of key personnel to perform Israeli military service.
Some
of our employees in Israel are obligated to perform up to 40 days, depending on rank and position, of military reserve duty annually
and are subject to being called for active duty under emergency circumstances. Moreover, in light of escalating hostilities and
threats of armed conflict in the Middle East since October 2000, our executive officers and employees may be called for active
military duty for an unlimited period of time. Increased military activity could also result in a reduction of prospective qualified
employees available to work for us to increase our business or replace employees on active military duty. Our operations could
be disrupted by the absence for a significant period of our executive officers or key employees as a result of military service.
Any disruption in our operations could adversely affect our ability to develop and market products.
It
may be difficult to enforce a United States judgment against us or our officers and directors to the extent they are located in
Israel based upon asserted United States securities law claims.
Two
of our executive officers and one of our directors are non-residents of the United States and a substantial portion of our assets
and the assets of these persons will be located outside of the United States. Therefore, it may be difficult for an investor,
or any other person or entity, to enforce a United States court judgment, including a judgment based upon the civil liability
provisions of the Securities Act, and the Exchange Act of 1934, as amended (the “Exchange Act”), in original actions
instituted in an Israeli court against any of these persons. Furthermore, service of process upon these persons may be difficult
to obtain within the United States.
We
may not be able to enforce covenants not-to-compete under current Israeli law, which might result in added competition for our
products.
We
have non-competition agreements or provisions with all of our employees and executive officers, all of which are governed by Israeli
law. These agreements or provisions prohibit our employees from competing with us or working for our competitors, generally during,
and for up to nine months after termination of, their employment with us. However, Israeli courts are reluctant to enforce non-compete
undertakings of former employees and tend, if at all, to enforce those provisions for only relatively brief periods of time or
in restricted geographical areas. In addition, Israeli courts typically require the presence of additional circumstances, such
as a demonstration of an employer’s legitimate interest which was damaged; breach of fiduciary duties, loyalty and acting
not in good faith; a payment of a special consideration for employee’s non-compete obligation; material concern for disclosing
employer’s trade secrets; or a demonstration that an employee has unique value to the employer specific to that employer’s
business, before enforcing a non-competition undertaking against such employee.
The
funding that we received through the Office of the Chief Scientist (the “OCS”) for research and development activities
restricts our ability to manufacture products or to transfer technology outside of Israel.
On
March 4, 2004, the OCS agreed to provide us with a grant of 420,000 New Israeli Shekels (“NIS”), or approximately
$93,300 at an exchange rate of 4.502 NIS/dollar (the exchange rate in effect on such date), for our plan to develop a non-invasive
blood glucose monitor (the “development plan”). This grant constituted 60% of our research and development budget
for the development plan at that time. Due to our acceptance of this grant, we are subject to the provisions of the Israeli Law
for the Encouragement of Industrial Research and Development, 1984 (the “R&D Law”). Among other things, the R&D
Law restricts our ability to sell or transfer rights in technology or know-how developed with OCS funding or transfer any Means
of Control (as defined in the R&D Law) of us to non-Israeli entities. The Industrial Research and Development Committee at
the OCS (the “research committee”) may, under special circumstances, approve the transfer outside of Israel of rights
in technology or know-how developed with OCS funding subject to certain conditions, including the condition that certain payments
be made to the OCS. Additionally, we may not manufacture products developed with OCS funding outside of Israel without the approval
of the research committee. The restrictions regarding the sale or transfer of technology or manufacturing rights out of Israel
could have a material adverse effect on our ability to enter into strategic alliances or enter into merger or acquisition transactions
in the future that provide for the sale or transfer of our technology or manufacturing rights.
If
we are successful in bringing the GlucoTrack® model DF-F to market, we will be required to use a portion of our net sales
to repay certain
loans and to pay
royalties to the OCS, which will have a negative impact on our profitability.
Integrity
Israel is required to pay royalties to the OCS on the proceeds from the sale of our systems resulting from research and development
projects for which the OCS provided a grant. During the first three years of sales, we will be required to pay royalties of 3%
of the sales of such products. In the fourth, fifth and sixth years of sales, we will be required to pay royalties of 4% of such
sales and from the seventh year on we will be required to pay royalties of 5% of such sales, in all cases, up to 100% of the amount
of grants received by us from the OCS plus interest at the London Interbank Offered Rate (“LIBOR”). We do not have
any other future performance obligations related to the OCS grants. As of March 31, 208, the contingent liabilities with respect
to OCS grants subject to repayment under these royalty agreements equaled $34,717, not including interest. To the extent that
we are required to pay royalties to the OCS, such payments will increase our expenses for the year(s) in which such payment(s)
are accrued, and, as a result, will reduce our profits (or increase our losses, as applicable) for such periods. Payments made
to the OCS in lieu of royalties and repayment of the loans described above will reduce our free cash-flow and our cash balance
for the year(s) in which such payment(s) are made.
Messrs.
Avner Gal and Zvi Cohen collectively loaned us NIS 176,000 ($50,085 based on the exchange rate of 3.514 NIS/dollar as of March
31, 2018) in May 2002 pursuant to an oral agreement (the “Gal/Cohen Loan”). Messrs. Nir Tarlovsky, Yitzhak Fisher
and Asher Kugler loaned us NIS 336,300 ($95,703 based on the same exchange rate) on March 16, 2004 (the “Tarlovsky/Fisher/Kugler
Loan”). These loans are not required to be repaid until the first year in which we realize profits in our statement of operations.
At such time, the loans are to be repaid on a quarterly basis in an amount equal to 10% of our total sales after deduction of
VAT in the relevant quarter, beginning the quarter following the first year in which we realize profits in our annual statement
of operations. The total amount to be repaid by us to each lender shall be an amount equal to the aggregate principal amount loaned
by such lender to us, plus an amount equal to the product of the amount of each payment made by us in respect of such loan multiplied
by the percentage difference between the Israeli Consumer Price Index on the date on which the loan was made and the Israeli Consumer
Price Index on the date of such payment. However, notwithstanding the abovementioned mechanism, we will not be required to repay
the loans during any time when such repayment would cause a deficit in our working capital. Our Board of Directors is entitled
to modify the repayment terms of these loans, so long as such modification does not discriminate against any particular lender,
and provided that all payments must be allocated among the lenders on a pro-rata basis.
We
are subject to certain employee severance obligations, which may result in an increase in our expenditures.
Under
Israeli law, employers are required to make severance payments to dismissed employees and employees leaving employment in certain
other circumstances, on the basis of the latest monthly salary for each year of service. This obligation results in an increase
in our expenses, including accrued expenses. Integrity Israel currently makes monthly deposits to insurance policies and severance
pay funds in order to provide for this liability.
The
Company’s and its Israeli subsidiary’s agreements with all of their Israeli employees are in accordance with Section
14 of the Israeli Severance Pay Law -1963 (“Section 14”). Payments in accordance with Section 14 release the Company
from any other future severance payments in respect of those employees. Deposits under Section 14 are not recorded as an asset
in the Company’s balance sheet.
There
is a limited trading market for our common stock, which may make it difficult for our stockholders to sell their shares.
Although
our stock is quoted on the OTCQB, few trades in our stock have taken place, to-date, and an active trading market in our securities
may not develop, or if developed, may not be sustained. If no active market is ever developed for our Common Stock, it will be
difficult for you to sell any shares you purchase in our Company at the time you wish to sell them or at a price that you consider
reasonable or at all. In such a case, you may find that you are unable to achieve any benefit from your investment or liquidate
your shares without considerable delay, if at all. In the absence of an active public trading market, an investor may be unable
to liquidate an investment in our Common Stock. As a result, investors: (i) may be precluded from transferring their shares of
Common Stock; (ii) may have to hold their shares of Common Stock for an indefinite period of time; and (iii) must be able to bear
the complete economic risk of losing their investment in us. In the event a market should develop for the Common Stock, there
can be no assurance that the market price will equal or exceed the price paid for such share by any of our stockholders.
There
may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud
may materially harm our company.
Proper
systems of internal controls over financial accounting and disclosure are critical to the operation of a public company. If we
are unable to effectively establish such systems, this would leave us without the ability to reliably assimilate and compile financial
information about our company and significantly impair our ability to prevent error and detect fraud, all of which would have
a negative impact on our company from many perspectives.
Moreover,
we do not expect that disclosure controls or internal control over financial reporting will prevent all error and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints
and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Failure of our control systems to prevent error or fraud could materially adversely impact us.
The
market price of our Common Stock may fluctuate significantly
.
The
market price of the Common Stock may fluctuate significantly in response to numerous factors, some of which are beyond our control,
such as:
|
●
|
the
announcement of new products or product enhancements by us or our competitors;
|
|
●
|
developments
concerning intellectual property rights and regulatory approvals;
|
|
●
|
variations
in our and our competitors’ results of operations;
|
|
●
|
changes
in earnings estimates or recommendations by securities analysts, if the Common Stock is covered by analysts;
|
|
●
|
developments
in the medical device industry;
|
|
●
|
the
results of product liability or intellectual property lawsuits;
|
|
●
|
future
issuances of Common Stock or other securities;
|
|
●
|
exercise
of warrants and/or sale of underlying Common Stock;
|
|
●
|
the
addition or departure of key personnel;
|
|
●
|
announcements
by us or our competitors of acquisitions, investments or strategic alliances; and
|
|
●
|
general
market conditions and other factors, including factors unrelated to our operating performance.
|
Further,
in recent years, the stock market in general, and the market for medical device companies in particular, have experienced extreme
price and volume fluctuations. Continued or renewed market fluctuations could result in extreme volatility in the price of our
Common Stock, which could cause a decline in the value of the Common Stock. Price volatility of our Common Stock might be significant
if the trading volume of the Common Stock is low, which often occurs with respect to newly traded securities on the OTCQB.
Future
sales of Common Stock could reduce our stock price
.
As of June 7 ,
2018, we had 7,586,715 shares of common stock outstanding. In addition, the shares of Preferred Stock, warrants and employees’
stock options outstanding on such date were convertible into, or exercisable for, an aggregate of 21,072,476 shares of Common
Stock. This Registration Statement on Form S-1 registering the resale of an aggregate of 8,736,198 shares of Common Stock underlying
the Series C Units and related warrants and the placement agent warrants issued in respect thereof. In addition, the shares of
Common Stock sold by us in a previous private placement consummated in the period from December 16, 2010 through July 29, 2011
may be eligible for resale without registration in accordance with one or more exceptions under the Securities Act. Sales by stockholders
of substantial amounts of shares of Common Stock (pursuant to this Registration Statement or pursuant to an exemption from registration),
the issuance of new shares of Common Stock (or securities convertible into or exercisable for shares of our Common Stock) by us
or the perception that these sales may occur in the future, could materially and adversely affect the market price of the Common
Stock.
Because
our Common Stock is a “penny stock,” it may be more difficult for investors to sell shares of the Common Stock, and
the market price of the Common Stock may be adversely affected.
Our
Common Stock is currently a penny stock because, among other things, our stock price is below $5.00 per share, it is not listed
on a national securities exchange or approved for quotation on the Nasdaq Stock Market or any other national securities exchange
or it has not met certain net tangible asset or average revenue requirements. Broker-dealers who sell penny stocks must provide
purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. This document provides information
about penny stocks and the nature and level of risks involved in investing in the penny-stock market. A broker must also give
a purchaser, orally or in writing, bid and offer quotations and information regarding broker and salesperson compensation, make
a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser’s written
agreement to the purchase. Broker-dealers must also provide customers that hold penny stock in their accounts with such broker-dealer
a monthly statement containing price and market information relating to the penny stock. If a penny stock is sold to an investor
in violation of the penny stock rules, the investor may be able to cancel its purchase and get its money back.
The
penny stock rules make it difficult for investors to sell their shares of Common Stock. Because of the rules and restrictions
applicable to a penny stock, there is less trading in penny stocks and the market price of the Common Stock may be adversely affected.
Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell
their shares of Common Stock publicly at times and prices that they feel are appropriate.
Compliance
with changing regulations concerning corporate governance and public disclosure may result in additional expenses.
There
have been changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley
Act of 2002, new regulations promulgated by the SEC and rules promulgated by the national securities exchanges. These new or changed
laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and, as
a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which
could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure
and governance practices. As a result, our efforts to comply with evolving laws, regulations and standards are likely to continue
to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating
activities to compliance activities. Our directors, Chief Executive Officer and Chief Financial Officer could face an increased
risk of personal liability in connection with the performance of their duties. As a result, we may have difficulty attracting
and retaining qualified directors and executive officers, which could harm our business. If our efforts to comply with new or
changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we could be subject
to liability under applicable laws or our reputation may be harmed.
Because
a certain portion of our expenses is incurred in currencies other than the NIS, our results of operations may be harmed by currency
fluctuations and inflation.
The
functional currency of Integrity Israel is the NIS, and we pay a substantial portion of our expenses in NIS. However, we expect
a portion of our future revenues to be denominated in U.S. dollars or in Euros. As a result, we will be exposed to the currency
fluctuation risks relating to the recording of our revenues in NIS. For example, if the NIS strengthens against either the U.S.
dollar or the Euro, our reported expenses in NIS may be higher than anticipated. The Israeli rate of inflation has not offset
or compounded the effects caused by fluctuations between the NIS and the U.S. dollar or the Euro. To date, we have not engaged
in hedging transactions. Although the Israeli rate of inflation has not had a material adverse effect on our financial condition
to date, we may, in the future, decide to enter into currency hedging transactions to decrease the risk of financial exposure
from fluctuations in the exchange rates of the currencies mentioned above in relation to the NIS. These measures, however, may
not adequately protect us from material adverse effects.
The
adoption of the “Conflict Minerals” regulations may adversely affect the manufacturing of our current and future products.
Recent
regulatory requirements regarding the use of “conflict minerals” could affect the sourcing and availability of the
raw materials used by our third-party manufacturers. We may be subject to costs associated with the new regulations, including
for the diligence pertaining to the presence of any conflict minerals used in our products and the cost of remediation and other
changes to products, processes, or sources of supply as a consequence of such verification activities. The impact of the regulations
may result in a limited pool of suppliers who provide conflict free minerals, and we cannot assure that we will be able to obtain
products in sufficient quantities or at competitive prices. We may face reputational challenges with our customers and other stakeholders
if we are unable to sufficiently verify the origins for the metals used in the products we sell. As a result, we may not be able
to obtain the materials necessary to manufacture our products, which could force us to cease production or search for alternative
supply sources, possibly at a higher cost. Such disruptions may have a material adverse effect on our business, financial condition,
results of operations and cash flows.
USE
OF PROCEEDS
We
will not receive any of the proceeds from the sale or other disposition of the shares of Common Stock offered hereby. We would,
however, receive proceeds upon the exercise of the warrants held by the selling stockholders which, if such warrants are exercised
in full, would be approximately $24 million. Proceeds, if any, received from the exercise of such warrants will be used for working
capital and general corporate purposes. No assurances can be given that any of such warrants will be exercised.
DIVIDEND
POLICY
We
have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any dividends on our Common Stock
in the foreseeable future. Any cash that might be available for payment of dividends will be used to expand our business. Payments
of any cash dividends in the future will depend on our financial condition, results of operation and capital requirements, as
well as other factors deemed relevant to our Board of Directors. Furthermore, pursuant to the certificate of designations, preferences
and rights governing the Series C Preferred Stock (the “Series C Certificate of Designations”), as long as any shares
of Series C Preferred Stock are outstanding, without the written consent of the holders of a majority in stated value of the then
outstanding Series C Preferred Stock, we will not be permitted to, among other things, pay dividends on or otherwise make distributions
in respect of any shares of our Common Stock or other securities junior to the Series C Preferred Stock.
Pursuant
to the Series A Certificate of Designations, the holders of Series A Preferred Stock are entitled to receive cumulative dividends
at a rate of 5% per annum, based on the stated value per share of Series A Preferred Stock, which was initially $1,000 per share.
Dividends on the Series A Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year,
and on each conversion date (with respect to the shares of Series A Preferred Stock being converted). For the year ended December
31, 2017, we paid an amount of $5,731 in cash dividends to holders of Series A Preferred Stock.
Pursuant
to the Series B Certificate of Designations, the holders of Series B Preferred Stock are entitled to receive cumulative dividends
at a rate of 5.5% per annum, based on the stated value per share of Series B Preferred Stock, which was initially $1,000 per share.
Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year,
and on each conversion date (with respect to the shares of Series B Preferred Stock being converted). For the year ending December
31, 2017, we distributed a total of 359,505 shares of Common Stock at an estimated fair value of $854,647 as stock dividends to
holders of Series B Preferred Stock.
Pursuant
to the Series C Certificate of Designations, the holders of Series C Preferred Stock are entitled to receive cumulative dividends
at a rate of 5.5% per annum, based on the stated value per share of Series C Preferred Stock, which was initially $1,000 per share.
Dividends on the Series C Preferred Stock are payable quarterly on March 31, June 30, September 30 and December 31 of each year,
beginning on June 30, 2016, and on each conversion date (with respect to the shares of Preferred Stock being converted). For so
long as required under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock
or Series B Preferred Stock, dividends will be payable only in shares of Common Stock. Thereafter, dividends on the Series C Preferred
Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied, shares of Common Stock
or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower of (a) the then current
conversion price of the Series C Preferred Stock or (b) the average of the volume weighted average price for the Common Stock
on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend payment date. The
Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three trading days of the
applicable dividend payment date. For the year ended December 31, 2017, we distributed a total of 237,169 shares of Common Stock
at an estimated fair value of $566,033 as stock dividends to holders of Series C Preferred Stock.
Under
Delaware law, we can only pay dividends, whether in cash or common stock, either out of “surplus” (which is defined
as total assets at fair market value minus total liabilities, minus statutory capital) or out of current or the immediately preceding
year’s earnings. During the third and fourth quarters of 2017 and the first quarter of 2018, we did not have sufficient
earnings to achieve a “surplus”; therefore, we were unable to distribute quarterly dividends to the holders of Series
A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock for these periods.
DETERMINATION
OF OFFERING PRICE
The
selling stockholders may sell their shares of our Common Stock at prevailing market prices or privately negotiated prices.
CAPITALIZATION
You
should read this table together with the section entitled “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” and our financial statements and the related notes incorporated by reference into this prospectus.
The table below sets forth our capitalization on an unaudited basis as of March 31, 2018 and December 31, 2017:
|
|
As
of
March 31, 2018
|
|
|
As
of
December 31, 2017
|
|
|
|
(US
dollars)
(except
share data)
|
|
|
(US
dollars)
(except
share data)
|
|
Cash and cash equivalents
|
|
|
314,387
|
|
|
|
53,782
|
|
Accounts receivable, net
|
|
|
147,378
|
|
|
|
121,782
|
|
Inventories
|
|
|
934,239
|
|
|
|
957,349
|
|
Other current
assets
|
|
|
87,907
|
|
|
|
94,137
|
|
Property and Equipment, Net
|
|
|
198,839
|
|
|
|
216,746
|
|
Long-Term Restricted Cash
|
|
|
39,033
|
|
|
|
39,562
|
|
Funds in Respect
of Employee Rights Upon Retirement
|
|
|
183,088
|
|
|
|
185,570
|
|
Total assets
|
|
|
1,904,871
|
|
|
|
1,668,928
|
|
Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
2,468,230
|
|
|
|
2,419,988
|
|
Other current
liabilities
|
|
|
1,123,436
|
|
|
|
1,265,954
|
|
Long-Term Loans from Stockholders
|
|
|
179,423
|
|
|
|
182,767
|
|
Liability for Employee Rights Upon Retirement
|
|
|
183,088
|
|
|
|
185,570
|
|
Warrants with
down-round protection
|
|
|
815,899
|
|
|
|
768,249
|
|
Total liabilities
|
|
|
4,770,076
|
|
|
|
4,822,528
|
|
|
|
|
|
|
|
|
|
|
Temporary Equity
|
|
|
13,421,333
|
|
|
|
13,421,333
|
|
Stockholders’ Deficit
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
7,532
|
|
|
|
6,824
|
|
Additional paid in capital
|
|
|
33,312,949
|
|
|
|
30,676,180
|
|
Accumulated other comprehensive income
|
|
|
117,979
|
|
|
|
110,675
|
|
Accumulated deficit
|
|
|
(49,724,998
|
)
|
|
|
(47,368,612
|
)
|
Total stockholders’
deficit
|
|
|
(16,286,538
|
)
|
|
|
(16,574,933
|
)
|
Total liabilities,
temporary equity and stockholders’ deficit
|
|
|
1,904,871
|
|
|
|
1,668,928
|
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary
Note Regarding Forward-Looking Statements
This
Registration Statement contains forward-looking statements. These forward-looking statements include statements about our expectations,
beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies
and prospects. All statements other than statements of historical fact included in this Registration Statement, including statements
regarding our future activities, events or developments, including such things as future revenues, capital raising and financing,
product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures
(including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals,
expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and
other such matters, are forward-looking statements. The words “believe,” “expect,” “anticipate,”
“intend,” “estimate,” “plan,” “may,” “will,” “could,”
“would,” “should” and other similar words and phrases, are intended to identify forward-looking statements.
The forward-looking statements made in this Registration Statement are based on certain historical trends, current conditions
and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate
only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking
statements made in this Registration Statement are qualified by these cautionary statements and there can be no assurance that
the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences
to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is
subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the
occurrence of which could adversely affect our business, include the risks identified under the caption “Risk Factors”
included herein. The following discussion should be read in conjunction with the condensed consolidated financial statements and
the notes thereto included in the Quarterly Report on Form 10-Q for the period ended March 31, 2018 and our Annual Report on Form
10-K for the year ended December 31, 2017.
Overview
We
are a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices
for use by people with diabetes and pre-diabetics. We operate primarily through Integrity Israel, our wholly-owned subsidiary.
Integrity Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose monitors for home use
by diabetics. We have developed a non-invasive blood glucose monitor, the GlucoTrack® model DF-F glucose monitoring device,
which is designed to help people with diabetes and pre-diabetics obtain blood glucose level readings without the pain, inconvenience,
cost and difficulty of conventional (invasive) spot finger stick devices. The GlucoTrack® model DF-F utilizes a patented combination
of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small
sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing
blood or interstitial fluid.
On
June 6 , 2013, we received initial CE Mark approval for the GlucoTrack® model DF-F non-invasive glucose monitoring device
from DEKRA Certification B.V., our European notified body (the “Notified Body”). In March 2014, we received CE Mark
approval for six months’ calibration validity of the same device. Receipt of the CE Mark allows us to market and sell the
GlucoTrack® model DF-F glucose monitoring device in European Union (“EU”) member countries that have adopted the
European Medical Device Directive (the “MDD”) without being subject to additional national regulations with regard
to demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not
ensure uniform regulation throughout the EU. Accordingly, member countries may apply and enforce the MDD’s terms differently,
and certain EU member countries may request or require performance and/or safety data additional to the MDD’s requirements
from time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual Recognition
Agreement with the EU.
On
August 31, 2015, we received approval from the Notified Body for improvements to the GlucoTrack® model DF-F which simplify
and shorten (from approximately 2.5 hours to approximately half an hour) the initial calibration process for the device. These
improvements are intended to reduce the potential backlog that may be created as purchasers of the device await calibration. In
addition, we received approval from the Notified Body on the updated intended use for the device, which expands the intended user
population to include not only Type 2 diabetics, but persons suffering from pre-diabetes conditions as well, which we believe
represents a material expansion of the potential market for the device. In December 2015, we received approval from the Notified
Body for further improvements to the GlucoTrack® model DF-F that increase the accuracy and efficacy of the device. On February
19, 2016, we received an extension of our ISO 13485:2003 certificate and Annex II certification from the EU. The ISO 13485:2003
certification signifies that we have met the standards required for company-wide implementation of device quality management system(s).
The scope of the certification is design, development, manufacture and service of non-invasive glucose monitoring systems for
home use. Annex II also addresses quality control systems. The certification allows us to self-certify certain modifications and
changes and simplifies some of the reporting to and review by the relevant Notified Body. This can shorten CE-mark review process
of future GlucoTrack® model DF-F enhancements or revisions. Without an Annex II certification, each new device enhancement
or modified version would be subject to the full EU CE-mark review process. The ISO 13485:2003 and Annex II certifications enable
us to potentially improve the time to market for product sales on new, enhanced or modified GlucoTrack® model DF-F devices.
In
addition to the improvements to the GlucoTrack® model DF-F described above, we have also continued to work on additional improvements
to the device and the development of new devices and, subject to our raising sufficient funds to do so, intend to continue these
efforts in 2018. Specifically, we developed wireless communication module (WLM) with embedded Bluetooth Low-Energy (BLE) and Wi-Fi
technologies, which we expect will enable transmission of measurement data captured by the GlucoTrack® model DF-F to a cloud-based
server. We also started to design the next generation of GlucoTrack®.
Re-Structuring
During
2017, the Company has undergone a significant transformation due to the changes in senior management. The Company has reviewed
and reworked its corporate strategy as well as the operational plan to bring more focus and reduce expense. The areas most impacted
have been the Company’s commercial operations and research & development. This has resulted in significant organizational
changes to right-size the Company to reflect its priorities and reduce costs. The Company has reduced headcount across the whole
organization from approximately 45 to 27 full-time employees. Positions have been eliminated in management, commercial operations
group and research & development group, which in turn has resulted in a significant reduction in operational costs.
Going
Concern
We
have not yet generated material revenues from our operations and, as of March 31, 2018, the Company has incurred accumulated
deficit
of $49,724,998, stockholder’s deficit of $16,286,538 and negative
operating cash flows. We currently have no material
sources of recurring revenue and therefor are dependent upon external sources for financing our operations. There can be no assurance
that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered
public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
Critical
Accounting Policies
This
Management’s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.
GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates
about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses and
the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors
that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, management
reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly
and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual
results could differ from our assumptions and estimates, and such differences could be material. As applicable to the consolidated
financial statements included elsewhere in this report, the most significant estimates and assumptions relate to (i) the fair
value estimate of the Warrants with down-round protection, (ii) the allocation of the proceeds and the related issuance costs
of the Series D Units, (iii) the going concern assumptions, (iv) measurement of stock-based compensation, and (v)
determination of net realizable value of inventory.
Our
significant accounting policies are discussed in Note 2, Summary of Significant Accounting Policies, of the Notes to Consolidated
Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2017 and Quarterly Report on Form
10-Q for the period ended March 31, 2018. Our management believes that, as for the financial statements for the periods included
in this report, the going concern assessment is a critical accounting policy. However, due to the early stage of operations of
the Company, there are no other accounting policies that are considered to be critical accounting policies by management.
Going
Concern Uncertainty
The
development and commercialization of our product will require substantial expenditures. We have not yet generated any material
revenues and have incurred substantial accumulated deficit and negative operating cash flows. We currently have no sources of
recurring revenue and are therefore dependent upon external sources for financing our operations. There can be no assurance that
we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered public
accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty.
Recently
Issued Accounting Pronouncements
1.
Accounting Standard Update 2014-09, “Revenue from Contracts with Customers”
Commencing
January 1, 2018, the Company adopted Accounting Standard Update 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU
2014-09”).
ASU
2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes
most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose
sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount,
timing and uncertainty of revenue and cash flows arising from contracts with customers.
An
entity should apply the amendments in ASU 2014-09 using one of the following two methods: 1. Retrospectively to each prior reporting
period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of
initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method,
it also should provide certain additional disclosures.
During
2016, the FASB issued several Accounting Standard Updates (“ASUs”) that focus on certain implementation issues of
the new revenue recognition guidance including Narrow-Scope Improvements, Practical Expedients and technical corrections.
Since
the company did not report significant revenues, the adoption of ASU 2014-09 did not have a significant impact on its consolidated
financial statements.
2.
Accounting Standard Update (ASU) No. 2017-11, “
Earnings Per Share”
In
July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480);
Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)
Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain
Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”).
Among
others, Part I of ASU 2017-11 simplifies the accounting for certain financial instruments with down round features, which is a
provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise
price based on the price of future equity offerings. Current accounting guidance creates cost and complexity for organizations
that issue financial instruments with down round features by requiring, on an ongoing basis, fair value measurement of the entire
instrument or conversion option.
ASU
2017-11 require companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock,
for purposes of determining liability or equity classification. Companies that provide earnings per share (EPS) data will adjust
their basic EPS calculation for the effect of the feature when triggered (i.e., when the exercise price of the related equity-linked
financial instrument is adjusted downward because of the down round feature) and will also recognize the effect of the trigger
within equity.
ASU
2017-11 also addresses navigational concerns within the FASB Accounting Standards Codification related to an indefinite deferral
available to private companies.
The
provisions of the new ASU related to down rounds are effective for public business entities for fiscal years, and interim periods
within those fiscal years, beginning after December 15, 2018 (fiscal 2019 for the Company). Early adoption is permitted for all
entities.
The
Company is evaluating the impact of ASU 2017-11 on its financial statements. Although this process has not been completed, managements
believes that its provisions might impact the accounting of the financial instruments issued by the Company that include down-round
protection.
Results
of Operations
The
following discussion of our operating results explains material changes in our results of operations for the three-month period
ended March 31, 2018 compared with the same period ended March 31, 2017, and the years ended December 31, 2017, 2016 and 2015.
The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this Registration
Statement.
Three
Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017
Revenues
During
the three-month period ended March 31, 2018, we had revenues of $28,209 from orders for our GlucoTrack® model DF-F glucose
monitoring device and PECs that are replaced every six months, as compared with $96,237 for the prior-year period. During the
first quarter of 2017 we received an initial order from a customer in Hong Kong.
We
recognize revenues from sales of the GlucoTrack® model DF-F and PECs when control is transferred to the customer and collectability
is probable.
Research
and development expenses
Research
and development expenses were $592,697 for the three-month period ended March 31, 2018, as compared to $581,539 for the prior-year
period. There was no material change in research and development expenses between the two periods.
Research
and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation
expenses, materials, travel expenses, clinical trials and other expenses. Subject to the receipt of additional funds to finance
our operations (of which there can be no assurance), we expect research and development expenses to increase during the remainder
of 2018 and beyond, primarily due to hiring additional personnel and developing our product line, as well as improvement of the
GlucoTrack® model DF-F; however, we may adjust or allocate the level of our research and development expenses based on available
financial resources and based on our commercial needs including the FDA registration process, specific requirements from customers,
development of new GlucoTrack® models and others.
Selling
and marketing expenses
Selling
and marketing expenses were $308,637 for the three-month period ended March 31, 2018, as compared to $236,939 for the prior-year
period. The increase is attributable the hiring of a new Chief Commercialization Officer during the second quarter of 2017.
Selling
and marketing expenses consist primarily of salaries, travel expenses and other related expenses. Subject to the receipt of additional
funds to finance our operations (of which there can be no assurance), we expect selling and marketing expenses to increase during
the remainder of 2018 and beyond as we continue our focus on marketing and sales of the GlucoTrack® model DF-F; however, we
may adjust or allocate the level of our marketing based on available financial resources and based on our commercial needs including
the FDA registration process, specific requirements from customers, development of new GlucoTrack® models and others.
General
and administrative expenses
General
and administrative expenses were $1,036,684 for the three-month period ended March 31, 2018, as compared to $1,877,359 for the
prior-year period. The decrease is primarily attributable to severance paid to our former Chairman and CEO and former CFO of approximately
$162,000 during the first quarter of 2017. In addition, the decrease is attributable to a one time signing bonus of $412,500 including
employer payroll taxes and stock-based compensation in the amount of approximately $303,000 paid to our new Chairman and CEO,
recruiting fees of $295,000 and the related professional fees associated with the changes in management, which occurred during
the first quarter of 2017.
General
and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for
executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative
costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional
fees for legal and accounting services. Subject to the receipt of additional funds to finance our operations (of which there can
be no assurance), we expect general and administrative expenses to increase during the remainder of 2018 and beyond.
Financing
income, net
Financing
income, net was $62,015 for the three-month period ended March 31, 2018, as compared to $69,275 for the prior-year period. The
change is primarily attributable to changes in fair market value adjustments relating to our Warrants with down-round protection.
In accordance with U.S. GAAP, we mark the warrants to market on a quarterly basis based on the fair value estimate derived by
using a binomial pricing model, with the changes in fair value recognized as finance expense or income, as applicable, in our
consolidated statement of operations. The decrease in the estimated fair value of our Warrants with down-round protection during
the three-month period ended March 31, 2018 and 2017 amounted to $77,947 and $84,099, respectively, resulting primarily from the
decrease in the expected term of Warrants and the changes in the estimated expected volatility.
Net
Loss
Net
loss was $1,847,794 for the three-month period ended March 31, 2018, as compared to $2,530,325 for the prior-year period. The
decrease in net loss is attributable primarily to the decrease in our general and administrative expenses, as described above.
Year
Ended December 31, 2017 Compared to Year Ended December 31, 2016
Revenues
During
the year ended December 31, 2017, we had revenues of $589,462 from orders for our GlucoTrack® model DF-F glucose monitoring
device and personal ear-clip (“PEC”) that are replaced every six months, as compared with $611,689 for the prior-year
period. The decrease in revenues is not material.
Research
and development expenses
Research
and development expenses were $3,207,466 for the year ended December 31, 2017, as compared to $2,881,817 for the prior-year period.
The increase is attributable primarily to an allowance recorded for slow moving inventory in the amount of $756,134 during 2017
and offset by our efforts to obtain regulatory approval for the GlucoTrack® model DF-F in China which occurred during 2016.
Research
and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation
expenses, materials, travel expenses, clinical trials and other expenses. Subject to the receipt of additional funds to finance
our operations (of which there can be no assurance), we expect research and development expenses to increase in 2018 and beyond,
primarily due to hiring additional personnel and developing our product line, as well as improvement of the GlucoTrack® model
DF-F; however, we may adjust or allocate the level of our research and development expenses based on available financial resources
and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of
new GlucoTrack® models and others.
Selling
and marketing expenses
Selling
and marketing expenses were $1,525,168 for the year ended December 31, 2017, as compared to $1,127,915 for the prior-year period.
The increase is primarily attributable to the hiring of our Chief Commercialization Officer during June 2017 and the related signing
bonus and stock-based compensation associated with his employment. In addition, we incurred higher travel costs for our business
development team during 2017.
Selling
and marketing expenses consist primarily of professional services, salaries, travel expenses and other related expenses. Subject
to the receipt of additional funds to finance our operations (of which there can be no assurance), we expect selling and marketing
expenses to increase in 2018 and beyond as we continue our focus on marketing and sales of the GlucoTrack® model DF-F.
General
and administrative expenses
General
and administrative expenses were $6,432,679 for the year ended December 31, 2017, as compared to $2,257,799 for the prior-year
period. The increase is attributable to severance paid to our former Chairman and CEO of approximately $162,000 as well as stock-based
compensation in the amount of $262,000. In addition, the increase is attributable to a one time signing bonus of $412,500 including
employer payroll taxes and stock-based compensation in the amount of approximately $1,591,000 paid to our new Chairman and CEO,
recruiting fees of $195,000 and the related professional fees associated with the changes in management. The Company also incurred
approximately $327,000 related to stock-based compensation and fees paid to our Board members and $193,000 to key executives.
We also incurred higher legal fees related to the filing of an S-1 in November of 2017 to register the Series C units and additional
fees related to the AGI agreement described above.
General
and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for
executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative
costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional
fees for legal and accounting services.
Financing
(Income) expenses, net
Financing
income, net was $247,045 for the year ended December 31, 2017, as compared to financing income, net of $246,105 for the prior-year
period. The change was not material. In accordance with U.S. GAAP, we mark the Series A Warrants and the Placement Agent Warrants
to market on a quarterly basis based on the fair value estimate derived by using a binomial pricing model, with the changes in
fair value recognized as finance expense or income, as applicable, in our consolidated statement of operations.
Net
Income (Loss)
Net
loss was $(10,328,806) for the year ended December 31, 2017, as compared to a net loss of $(5,409,737) for the prior-year period.
The increase in net loss is attributable primarily to the increase in our research and development, selling and marketing and
general and administrative expenses, as described above.
Year
Ended December 31, 2016 Compared to Year Ended December 31, 2015
During
the year ended December 31, 2016, we had revenues of $611,689 from orders for our GlucoTrack® model DF-F glucose monitoring
device and personal ear-clip (“PEC”) that are replaced every six months, as compared with $143,167 for the prior-year
period. The increase in revenues resulted from increased orders from customers. We did not have any revenue from orders for our
GlucoTrack® model DF-F and PEC in the six-month period ended December 31, 2015, as we were working on improvements to the
GlucoTrack® model DF-F for which we received approval from the Notified Body on August 31, 2015 and December 2015. We also
received final approval in October 2016 from South Korea and recorded $100,000 in revenues as the initial order from our South
Korean distributor during the fourth quarter of 2016.
Research
and development expenses
Research
and development expenses were $2,881,817 for the year ended December 31, 2016, as compared to $2,268,345 for the prior-year period.
The increase is attributable primarily to higher salary costs and related expenses resulting from increased head-count and higher
expenses relating primarily to our efforts to obtain regulatory approval for the GlucoTrack® model DF-F in China.
Research
and development expenses consist primarily of salaries and other personnel-related expenses, including stock-based compensation
expenses, materials, travel expenses, clinical trials and other expenses.
Selling
and marketing expenses
Selling
and marketing expenses were $1,127,915 for the year ended December 31, 2016, as compared to $1,127,434 for the prior-year period.
There was no material change between the years. However, during 2016 we hired additional business development employees to increase
our focus on marketing our products. The increase was offset by the reduction in professional fees relating to a consulting project
performed by a third party during 2015.
Selling
and marketing expenses consist primarily of professional services, salaries, travel expenses and other related expenses
General
and administrative expenses
General
and administrative expenses were $2,257,799 for the year ended December 31, 2016, as compared to $1,402,741 for the prior-year
period. The increase is attributable primarily to higher salaries and related expenses relating to the hiring of our
former
Chief
Operating Officer on January 1, 2016, stock-based compensation and Board member fees to our Board members. The increase
is also attributable to the one-time charge in the amount of $211,077 representing the incremental fair market value adjustments
in respect of modified warrants issued to AGI (See Note 9C to our financial statements).
General
and administrative expenses consist primarily of professional services, salaries, travel expenses and other related expenses for
executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative
costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional
fees for legal and accounting services.
Financing
(Income) expenses, net
Financing
(income) expenses, net was $ (246,105) for the year ended December 31, 2016, as compared to financing expenses, net of $1,186,819
for the prior-year period. The change is primarily attributable to the non-cash loss on partial extinguishment of Series A Preferred
Stock and Series A Warrants (see Note 9C to our Consolidated Financial Statements) during the year ended December 31, 2015 and
the decrease in the fair value estimate to our Warrants with down-round protection that were issued to investors. In accordance
with U.S. GAAP, we mark the Series A Warrants and the Placement Agent Warrants to market on a quarterly basis based on the fair
value estimate derived by using a binomial pricing model, with the changes in fair value recognized as finance expense or income,
as applicable, in our consolidated statement of operations.
Net
Income (Loss)
Net
loss was $(5,409,737) for the year ended December 31, 2016, as compared to a net loss of $(5,842,172) for the prior-year period.
The decrease in net loss is attributable primarily to the change in financing (income) expenses, net and increase in revenues
offset partially by the increase in operating expenses, as described above.
Liquidity
and Capital Resources
Three
Months Ended March 31, 2018 Compared to Three Months Ended March 31, 2017
As
of March 31, 2018, cash on hand was approximately $314,000. During the first quarter of 2018, we received aggregate net proceeds
of approximately $1.7 million (net of related cash expenses), from the issuance and sale in a private placement transaction of
435,556 Series D Units. While we expect to generate additional cash from sales, we do not anticipate that our income from operations
will be sufficient to sustain our operations in the next 12 months. Based on our current cash burn rate, strategy and operating
plan, we believe that our cash and cash equivalents will enable us to operate for a period of less than one month from the date
of this report. In order to fund our anticipated liquidity needs beyond such period (or possibly earlier if our current cash burn
rate, strategy or operating plan change in a way that accelerates or increases our liquidity needs), we will need to raise additional
capital.
We
have a credit line with Bank HaPoalim of NIS 150,000 (approximately $42,686 based on the exchange rate of 3.514 NIS/dollar as
of March 31, 2018). Borrowings under the line of credit are secured by our funds on deposit with the bank at the time of borrowing,
which generally must be sufficient to cover the principal amount of the borrowings in full.
Messrs.
Avner Gal and Zvi Cohen collectively loaned Integrity Israel NIS 176,000 ($50,085 based on the same exchange rate) on May 15,
2002 pursuant to a board approval. Messrs. Nir Tarlovsky, Yitzhak Fisher and Asher Kugler loaned Integrity Israel NIS 336,300
($95,703 based on the same exchange rate) on March 16, 2004. These loans are not required to be repaid until the first year in
which we realize profits in our annual statement of operations (accounting profit). At such time, the loans are to be repaid on
a quarterly basis in an amount equal to 10% of our total sales in the relevant quarter, beginning on the quarter following the
first year in which we realize profits in our annual statement of operations. The total amount to be repaid by us to each lender
shall be an amount equal to the aggregate principal amount loaned by such lender to us, plus an amount equal to the product of
the amount of each payment made by us in respect of such loan multiplied by the percentage difference between the Israeli Consumer
Price Index on the date on which the loan was made and the Israeli Consumer Price Index on the date of such payment. However,
notwithstanding the above-mentioned mechanism, we will not be required to repay the loans during any time when such repayment
would cause a deficit in our working capital. Our Board of Directors is entitled to modify the repayment terms of these loans,
so long as such modification does not discriminate against any particular lender, and provided that all payments must be allocated
among the lenders on a pro-rata basis.
Integrity
Israel is required to pay royalties to the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of the State
of Israel at a rate ranging between 3-5% of the proceeds from the sale of the Company’s products arising from the development
plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of March 31, 2018, the contingent liability
with respect to royalty payment on future sales equaled approximately $34,717, excluding interest.
Net
Cash Used in Operating Activities
Net
cash used in operating activities was $1,426,868 and $1,146,113 for the three-month periods ended March 31, 2018 and 2017, respectively.
Net cash used in operating activities primarily reflects the net loss for those periods of $1,847,794 and $2,530,325, respectively,
increased by non-cash changes in fair value of Warrants with down-round protection of $77,947 and $84,099, respectively and partially
offset by the increase of $187,302 related to stock-based compensation as described above in general and administrative expenses.
Net cash used in operating activities was also partially offset by changes in operating assets and liabilities in the amounts
of $283,276 and $873,678, respectively. The decrease in operating assets and liabilities during the three-month period ended March
31, 2018 resulted primarily from decrease in our current liabilities as a result of deferral of the payment of the one-time signing
bonus to our new Chairman and CEO which was paid during the second quarter of 2017.
Net
Cash Used in Investing Activities
Net
cash used in investing activities was $931 and $1,477 for the three-month periods ended March 31, 2018, and 2017, respectively,
and was used to purchase equipment (such as computers, R&D and office equipment).
Net
Cash Provided by Financing Activities
Net
cash provided by financing activities was $1,697,700 and $2,599,071 for the three-month period ended March 31, 2018 and 2017,
respectively. Cash provided by financing activities for the three-month period ended March 31, 2018 reflected net capital raised
from the issuance of Series D Units. Cash used in financing activities for the three-month period ended March 31, 2017 reflected
net capital raised from the issuance of Series C Units.
Year
Ended December 31, 2017 Compared to Year Ended December 31, 2016
As
of December 31, 2017, and December 31, 2016, cash on hand was approximately $54,000 and $149,000 , respectively.
While we expect to generate additional cash from sales, we do not anticipate that our income from operations will be sufficient
to sustain our operations in the next 12 months. Based on our current cash burn rate, strategy and operating plan, we believe
that our cash and cash equivalents will enable us to operate for a period of less than one month from the date of this report.
In order to fund our anticipated liquidity needs beyond such period (or possibly earlier if our current cash burn rate, strategy
or operating plan change in a way that accelerates or increases our liquidity needs), we will need to raise additional capital.
As
of December 31, 2017, we had an unutilized credit line of approximately $43,265 (NIS 150,000 based on the exchange rate of 3.467
NIS/dollar as of December 31, 2017) with our Israeli bank. Borrowings under the line of credit are secured by our funds on deposit
with the bank at the time of borrowing, which generally must be sufficient to cover the principal amount of the borrowings in
full.
Messrs.
Avner Gal and Zvi Cohen collectively loaned us NIS 176,000 ($50,764 based on the exchange rate of 3.467 NIS/dollar as of December
31, 2017) in May 2002 pursuant to an oral agreement. Messrs. Nir Tarlovsky, Yitzhak Fisher and Asher Kugler loaned us NIS 336,300
($97,000based on the same exchange rate) on March 16, 2004. These loans are not required to be repaid until the first year in
which we realize profits in our statement of operations. At such time, the loans are to be repaid on a quarterly basis in an amount
equal to 10% of our total sales after deduction of VAT in the relevant quarter, beginning on the quarter following the first year
in which we realize profits in our annual statement of operations. The total amount to be repaid by us to each lender shall be
an amount equal to the aggregate principal amount loaned by such lender to us, plus an amount equal to the product of the amount
of each payment made by us in respect of such loan multiplied by the percentage difference between the Israeli Consumer Price
Index on the date on which the loan was made and the Israeli Consumer Price Index on the date of such payment. However, notwithstanding
the above-mentioned mechanism, we will not be required to repay the loans during any time when such repayment would cause a deficit
in our working capital. The Israeli Consumer Price Index was 177.6386, and 178.5793, respectively, as of the dates of the Gal/Cohen
Loan and the Tarlovsky/Fisher/Kugler Loan. As of December 31, 2017, the Israeli Consumer Price Index, was 221.3468. Our Board
is entitled to modify the repayment terms of these loans, so long as such modification does not discriminate against any particular
lender, and provided that all payments must be allocated among the lenders on a pro-rata basis.
We
are required to pay royalties to the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor of the State of
Israel at a rate ranging between 3-5% of the proceeds from the sale of the Company’s products arising from the development
plan up to an amount equal to $93,300, plus interest at LIBOR from the date of grant. As of December 31, 2017, the contingent
liability with respect to royalty payment on future sales equaled to approximately $36,083, excluding interest.
Net
Cash Used in Operating Activities
Net
cash used in operating activities was $5,895,119 and $5,311,830 for the years ended December 31, 2017 and 2016, respectively.
Net cash used in operating activities primarily reflects the net loss for those periods of $10,328,806 and $5,409,737, respectively.
Net cash used in operating activities was partially offset by the one-time charges in the amount of $211,077 representing the
incremental fair market value adjustments in respect of modified warrants issued to AGI during the year ended December 31, 2016
and partially offset by the decrease of $2,672,174 related to stock-based compensation as described above in general and administrative
expenses. Net increase in operating assets and liabilities during the year ended December 31, 2017 increased our net cash used
in operating activities for the year ended December 31, 2017 by $1,958,043, which resulted primarily from deferral of payments
to suppliers in the amount of $620,978 and the write down of inventory in the amount of 756,134 for slow moving items.
Net
Cash Used in Investing Activities
Net
cash used in investing activities was $19,467 and $76,455 for the years ended December 31, 2017 and 2016, respectively. During
the years ended December 31, 2017 and 2016, cash used in investment activities consisted of equipment purchases (such as computers,
research and development and office equipment) in the amount of $19,467 and $76,455, respectively.
Net
Cash Provided by Financing Activities
Net
cash provided by financing activities was $5,750,736 and $4,936,556 for the years ended December 31, 2017 and 2016, respectively.
Cash provided by financing activities for the year ended December 31, 2017 reflected net capital raised from the issuance of Series
C Units and Series D Units in the amounts of $5,379,217 and $377,250, respectively. Cash provided by financing activities for
the year ended December 31, 2016 reflected net capital raised from the issuance of Series C Units in the amounts of $4,950,085,
offset partially by dividends paid to the holders of our Preferred Stock in the amounts of $13,529.
Year
Ended December 31, 2016 Compared to Year Ended December 31, 2015
Net
Cash Used in Operating Activities
Net
cash used in operating activities was $5,311,830 and $4,565,224 for the years ended December 31, 2016 and 2015, respectively.
Net cash used in operating activities primarily reflects the net loss for those periods of $5,409,737 and $5,842,172, respectively.
Net cash used in operating activities was partially offset by the one-time charges in the amount of $211,077 representing the
incremental fair market value adjustments in respect of modified warrants issued to AGI during the year ended December 31, 2016
and loss on extinguishment of Series A Preferred Stock and Series A Warrants during the year ended December 31, 2015 in the amount
of $1,284,354. Net changes in operating assets and liabilities during the year ended December 31, 2016 increased our net cash
used in operating activities for the year ended December 31, 2016 by $47,254, which resulted primarily from deferral of payments
to suppliers in the amount of $526,560, offset partially by build-up of inventory in the amount of $590,616 in anticipation of
future orders by our distributors.
Net
Cash Used in Investing Activities
Net
cash used in investing activities was $76,455 and $203,167 for the years ended December 31, 2016 and 2015, respectively. During
the years ended December 31, 2016 and 2015, cash used in investment activities consisted of equipment purchases (such as computers,
research and development and office equipment) in the amount of $76,455 and $143,736, respectively, cash used to fund deposits
in respect of employees rights upon retirement in the amount of $0 and $24,279, respectively, and cash used in investments in
certificates of deposit, which are used to secure Integrity Israel’s obligations in respect of its headquarters lease in
the amount of $0 and $35,152, respectively.
Net
Cash Provided by (Used in) Financing Activities
Net
cash provided by (used in) financing activities was $4,936,556 and $(460,863) for the years ended December 31, 2016 and 2015,
respectively. Cash provided by financing activities for the year ended December 31, 2016 reflected net capital raised from the
issuance of Series C Units in the amounts of $4,950,085, offset partially by dividends paid to the holders of our Preferred Stock
in the amounts of $13,529. Cash used in financing activities for the year ended December 31, 2015, primarily reflected the repayment
of a stockholder loan in the amount of $439,939 and cash dividends paid to the holders of our Series A Preferred Stock in the
amounts of $57,061, offset partially by proceeds from exercise of stock options by our employees in the amount of $36,137.
Off-Balance
Sheet Arrangements
As
of March 31, 2018, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
BUSINESS
Our
mission is to develop, produce and market non-invasive glucose monitors for home use by diabetics. We have developed a non-invasive
blood glucose monitor, the GlucoTrack® model DF-F glucose monitoring device, which is designed to help people with diabetes
and individuals with pre-diabetics obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of
conventional (invasive) spot finger stick devices. The GlucoTrack® model DF-F utilizes a patented combination of ultrasound,
electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that
is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood or
interstitial fluid.
In
June 2013, we received the initial Conformité Européene (CE) Mark (indicating the conformity of the Company’s
product with health, safety, and environmental protection standards for products sold within the European Economic Area) approval
for the GlucoTrack® model DF-F non-invasive glucose monitoring device from DEKRA Certification B.V., our European notified
body (the “Notified Body”), which is an entity that has been accredited by a member state of the European Union (“EU”)
to assess whether a product to be placed on the market meets certain preordained standards. This original approval required
that the device be re-calibrated every 30 days, with each such re- calibration taking between 2.5 and 3 hours to complete.
In March 2014, we received CE Mark approval for six months’ calibration validity of the same device. This approval
eliminates the need for monthly re-calibrations and enables the calibration process to be conducted only when the sensor
is replaced, once every 6 months. We believe that this is a significant feature of the GlucoTrack® model DF-F.
On
August 31, 2015, we received a further approval from the Notified Body for improvements to the GlucoTrack® model DF-F to simplify
and shorten the initial calibration process for the device (from approximately 2.5 hours to approximately half an hour).
All these improvements enhance the competitiveness of the device and its commercial viability. In addition, we received
approval from the Notified Body on the updated intended use for the device, which expands the intended user population to include
not only Type 2 diabetics, but also people suffering from pre-diabetes conditions, which we believe represents a material expansion
of the potential market for the device. In December 2015, we received approval from the Notified Body for further improvements
to the GlucoTrack® model DF-F that increase the accuracy and efficacy of the device. As a result of these incremental,
but important, enhancements to the performance of the device, we believe that the product is ready for commercial launch in specific
market segments.
Receipt
of the CE Mark allows us to market and sell the GlucoTrack® model DF-F glucose monitoring device in EU member countries that
have adopted the European Medical Device Directive (the “MDD”) without being subject to additional national regulations
with regard to demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice
it does not ensure uniform regulation throughout the EU. Accordingly, member countries may apply and enforce the MDD’s terms
differently, and certain EU member countries may request or require performance and/or safety data in addition to the MDD’s
requirements from time to time, on a case-by-case basis. The CE Mark also permits the sale in countries that have an MDD Mutual
Recognition Agreement with the EU. This would include some countries in South East Asia as well as Latin America opening new potential
markets for Integrity on a global basis.
Safety
and quality are non-negotiables in the medical devices industry. Regulatory requirements are increasingly stringent throughout
every step of a product’s life cycle, including service and delivery. It is becoming more and more common that organizations
in the industry are expected to demonstrate their quality management processes and ensure best practice in everything they do.
ISO 13485 is an internationally agreed standard that sets out the requirements for a quality management system specific
to the medical devices industry. On February 19, 2016, we received an extension of our ISO 13485:2003 certificate and Annex II
certification from the EU. The ISO 13485:2003 certification signifies that we have met the standards required for company-wide
implementation of device quality management system(s). The scope of the certification is design, development, manufacture
and service of non-invasive glucose monitoring systems for home use. Annex II also addresses quality control systems.
The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to and review
by the relevant Notified Body. This can shorten the CE-mark review process of future GlucoTrack® model DF-F enhancements
or revisions, including software updates and other improvements of the device that do not affect the intended use and/or safety
performance. The ISO 13485:2003 and Annex II certifications enable us to potentially reduce the time to market for product
sales on new, enhanced or modified GlucoTrack® model DF-F devices.
The
GlucoTrack® model DF-F has not yet been approved for commercial sale in the United States. On August 10, 2015, we submitted
pre-submission documents to the U.S. Food and Drug Administration (the “FDA”) in connection with our
proposed future application for FDA approval of our U.S. clinical trial protocol. The pre-submission documentation was submitted
to the FDA in order to obtain the FDA’s guidance regarding the U.S. regulatory pathway for the GlucoTrack® model DF-F,
the proper approach to refining the trial protocol and preparing the pre-marketing application. On October 19, 2015, we
met with the FDA to discuss the pre-submission documents, including the approach to and details of the clinical trial protocol
for the GlucoTrack® model DF-F. On May 10, 2016, we submitted a pre-submission supplement (including clinical trial
protocol) to the FDA which reflects the feedback received from the FDA at our October 2015 meeting. On July 18, 2016, we
completed a teleconference with the FDA to further discuss our pre-submission supplement. At the end of this discussion,
we received verbal confirmation from the FDA that clinical trials of the GlucoTrack® model DF-F constitute non-significant
risk device studies, which allows the trials to proceed without an Investigational Device Exemption (IDE) application. Such
trials are assessed by the FDA and not considered to present a potential for serious risk to the health, safety or the welfare
of subjects. We expect that the regulatory pathway would be that of a
de novo
510k, requiring a clinical trial design
based on feedback from the agency. Our initiation of clinical trials in the USA is subject to raising adequate financing to fund
the clinical program through completion. If we are unable to raise additional capital of at least $10 million, we do not expect
to commence such clinical trials.
Clinical
trials conducted recently in Germany by Pfutzner Science & Health Institute, GmbH, headed by Prof. Dr. Andreas Pfutzner, on
subjects with Type 2 diabetes and pre-diabetics, as well as at Soroka University Medical Center, Beer-Sheva, Israel, demonstrated
favorable results, which were presented on November 10, 2016 by the Company at the 16th annual Diabetes Technology Meeting (DTM),
Bethesda, MD in an invited presentation. Most notably, the presentation included data validating that GlucoTrack®’s
accuracy has increased significantly. Results from the trials show 99.7% of the study data points within the clinically
accepted A and B zones of the Consensus Error Grid (which is a new tool for evaluating the accuracy of a blood glucose meter)
(Type 2), 99.3% of the study data points were within the clinically accepted A and B zones of the Clarke Error Grid (which is
a tool used to quantify the clinical accuracy of blood glucose estimates generated by meters as compared to a reference value),
17.0% Mean Absolute Relative Difference, and 12.9% Median Absolute Relative Difference. In addition, the German trial concluded
that the data confirms the performance of the GlucoTrack® among its intended users, including pre-diabetic patients.
In
the second half of 2017 we conducted a strategic review of our previous commercial activities. We established a cross-functional
task force with the goal of reviewing the current commercial performance in all countries and identifying the critical success
factors (CSF’s) necessary for successful commercialization. The CSF’s that were determined to be most important to
our future commercial success include: 1) selecting the right distribution partners within countries that have knowledge and experience
in diabetes, the appropriate capabilities and proven performance in the sales, marketing, and customer service in support of medical
devices, and a commitment to investing the appropriate resources required for a successful launch and building of the business;
2) segmenting and targeting the right customers including key opinion leaders, treating physicians, and diabetes nurses within
the healthcare provider communities as well as those patient groups that will benefit most from the use of a non-invasive device;
3) revising the cost structure for GlucoTrack® so that it will be more affordable on a monthly basis for patients; and 4)
working with government authorities and health insurance companies to achieve full or partial reimbursement for GlucoTrack®
within covered medical plans.
We
have started the implementation of this new commercial program by selecting two countries where we will pilot this approach as
our proof-of-concept; the Netherlands and Israel. These countries were chosen based on the relatively smaller size of these marketplaces
that will allow us to be able to rapidly assess our performance and make adjustments as necessary. On December 22, 2017, we signed
an exclusive distribution agreement with a new partner in the Netherlands (MediReva B.V.) and are underway with launch preparations
for the second quarter of 2018. We have been working closely with our new distributor and have accomplished: product and disease
area training across the organization; segmentation of the local target audiences including key opinion leaders, treating physicians,
and diabetes nurses; and discussions with the majority of health insurance companies.
We
are also in negotiations with a new partner for Israel with the goal of launching in the third quarter of 2018. As soon as these
two pilots demonstrate that our new strategic approach is successful, we plan to rapidly rollout this approach across prioritized
European countries in the last quarter of 2018 and throughout 2019.
In
the meantime, we have assessed the performance of all of our current distributors in Europe and Asia. A number of these agreements
have been terminated given that they did not perform in the past and had minimal or no sales over the course of 2017. We are also
initiating discussions with our distributors in the remaining countries to focus on changes needed to address the CSF’s
for future success with implementation foreseen in the second half of 2018.
We
do not own commercial manufacturing facilities and do not intend to build commercial manufacturing facilities of our own in the
foreseeable future. We currently utilize a third-party manufacturer in Israel to manufacture the GlucoTrack® model DF-F.
Moreover, in July 2014, we entered into a manufacturing agreement with Wistron Corp. (“Wistron”), a Taiwanese entity
and the manufacturing arm of Acer Inc. Pursuant to such agreement, Wistron has agreed to mass produce and service, on a
non-exclusive basis, the GlucoTrack® model DF-F and any future products, if any, introduced by us. Pursuant to such
agreement, Wistron has also agreed to provide full turn-key manufacturing services for the GlucoTrack® model DF-F, including
components procurement, unit assembly, device integration, testing, packaging and delivery to customers (distributors).
In November 2015, we sent a delegation to Wistron’s main production facility in Taiwan to, among other things, inspect the
readiness of Wistron’s production line for the GlucoTrack® model DF-F. Wistron has produced a small pilot batch
and recently produced a second pilot batch of the GlucoTrack® model DF-F device. Following the receipt of an official
clearance from the Taiwanese authorities on January 11, 2017 and the successful completion of a GMP (Good Manufacturing Practice)
audit by the local regulatory authorities in July 2017, the production line for the GlucoTrack® model DF-F is now operational.
We intend to utilize the services of both Wistron and the Israeli third-party manufacturer to produce the GlucoTrack® model
DF-F.
In
support of the commercialization effort, we intend to conduct further post-market clinical trials, as well as publish scientific
and clinical studies, case studies, and white papers. To that end, we have engaged with a leading clinic in Germany, Pfutzner
Science & Health Institute, GmbH, headed by Prof. Dr. Andreas Pfutzner, to conduct additional clinical trials on
subjects with Type 2 diabetes and pre-diabetics. We anticipate adding additional sites in Europe.
As
part of our commercialization activities, in September 2016, we had a booth at the 52nd annual conference of the European Association
for Study of Diabetes (EASD) in Munich.
In
December 2016, we had a poster at the 9th Annual World Congress on Prevention of Diabetes and its Complications (WCPD) in Atlanta,
GA. This congress provided the Company with an opportunity to showcase GlucoTrack® model DF-F as a tool to fight diabetes
and its complications, as well as using GlucoTrack® model DF-F as a tool to assist pre-diabetics.
In
February 2017, the Company presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes
(ATTD 2017) in Paris, France. The Company presented key findings including (1) the latest generation GlucoTrack® algorithm,
which compensates for the tissue-lagging effect relative to blood glucose changes post-meal intake, significantly improves GlucoTrack®
accuracy at different post-prandial (post-meal) states, and equalizes accuracy for pre- and post-meal glucose readings; (2) GlucoTrack®
clinical accuracy as measured by Consensus Error Grid showed 100% of the pre-prandial readings in the A+B zones, and 98.2% of
the post-prandial readings in the A+B zones; (3) GlucoTrack® Model DF-F demonstrates consistent glucose measurement repeatability
between different GlucoTrack® devices and on each earlobe of the same subject; (4) the repeatability of different GlucoTrack®
devices is similar at all tested glucose ranges and post-prandial time periods; and (5) the GlucoTrack® mean precision absolute
relative difference (PARD) of 8.2% is equivalent or better than the independently reported PARD values of commercially available
continuous glucose monitoring systems.
On
June 12, 2017, we announced new data demonstrating the clinical performance of GlucoTrack®, further supporting its suitability
for people with type 2 diabetes across various medication regimes. The data was recently presented at the American Diabetes
Association’s (ADA) 77th Scientific Sessions in San Diego, CA.
In
September 2017, we presented key findings at the European Association for the Study of Diabetes Congress (EASD) in Lisbon, Portugal.
The study evaluated GlucoTrack®’s accuracy in 172 adults with type 2 diabetes who were prescribed one or more medications
for major medical conditions associated with diabetes. The experiment stratified participants into five medication groups,
focusing on anti-cholesterolemia, anti-hypertension, anti-thrombotic, and anti-diabetic (prolonged duration and short and mixed
duration) medications. The study demonstrated that the use of these common concomitant medications in diabetes had no effect on
the performance of GlucoTrack®. We also had a display booth at this conference that was well attended by hundreds of treating
physicians and diabetes nurses.
We
have not yet generated any material revenues from our operations and, as of March 31, 2018, have incurred an accumulated deficit
of $49,724,998, stockholders’ deficit of $16,286,538 and negative operating cash flows. We currently have no material sources
of recurring revenue and therefore are dependent upon external sources for financing our operations. There can be no assurance
that we will succeed in obtaining the necessary financing to continue our operations. As a result, substantial doubt exists regarding
our ability to continue as a going concern.
Market
Opportunity
Diabetes
Diabetes
is a chronic, life-threatening disease for which there is no known cure. Diabetes is caused by the body’s inability to produce
or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels.
Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit
optimal cell function and health. Normally, the pancreas provides control of blood glucose levels by secreting the hormone insulin
to decrease blood glucose levels when concentrations are too high. In people with diabetes, blood glucose levels fluctuate between
very high levels, a condition known as hyperglycemia, and very low levels, a condition known as hypoglycemia. Hyperglycemia can
lead to serious long-term complications, such as blindness, kidney disease, nervous system disease, amputations, stroke and cardiovascular
disease. Hypoglycemia can lead to confusion, loss of consciousness or death.
Diabetes
is typically classified into two major groups: Type 1 and Type 2. Type 1 diabetes is characterized by the body’s inability
to produce insulin, resulting from destruction of the insulin producing cells of the pancreas. Individuals with Type 1 diabetes
must rely on frequent insulin injections in order to regulate and maintain blood glucose levels. Type 1 diabetes is frequently
diagnosed during childhood or adolescence, although disease onset can occur at any age. Type 2 diabetes, the more common form
of diabetes, is characterized by the body’s inability to either properly utilize insulin or produce enough insulin. Type
2 diabetes is associated with older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose
metabolism, physical inactivity and race or ethnicity. Depending on the severity of Type 2 diabetes, individuals may require diet
and nutrition management, exercise, oral medications or insulin injections to regulate blood glucose levels.
According
to the Diabetes Atlas (Eighth Edition) published by the International Diabetes Federation in 2017, approximately 425 million adults
worldwide, between the ages of 20 and 79, or over 9% of the world’s adult population, were estimated to suffer from diabetes
in 2017 (not including those persons who suffer from impaired glucose tolerance or gestational diabetes, diabetic conditions first
arising during pregnancy). The International Diabetes Federation estimates that this number will grow to approximately 629 million
adults worldwide by 2035, a 55% increase from 2013. By 2045, the number of adults suffering from diabetes is estimated to increase
by 156% in Africa, 110% in the Middle East and North Africa, 84% in Southeast Asia, 62% in South and Central America, 15% in the
Western Pacific, 35% in North America and the Caribbean and 16% in Europe, over such regions’ respective 2017 levels.
Glucose
Monitoring
Blood
glucose levels can be affected by many factors, including the carbohydrate and fat content of meals, exercise, stress, illness
or impending illness, hormonal releases, variability in insulin absorption and changes in the effects of insulin in the body.
Given the many factors that affect blood glucose levels, maintaining glucose within a normal range can be difficult. Diabetics
generally manage their blood glucose levels by administering insulin or ingesting carbohydrates throughout the day to maintain
blood glucose within normal ranges. Normal ranges in diabetics vary from person to person. In order to maintain blood glucose
levels within normal ranges, diabetics must first measure their blood glucose levels so that they can make the proper therapeutic
adjustments. As adjustments are made, additional blood glucose measurements may be necessary to gauge the individual’s response
to the adjustments. More frequent testing of blood glucose levels provides patients with information that can be used to better
understand and manage their diabetes. Testing of blood glucose levels is usually done before meals, after meals and before going
to sleep. Diabetics who take insulin usually need to test more often than those who do not take insulin.
Clinical
data supports the recommendation that frequent monitoring of blood glucose levels is an important component of effective diabetes
management. The Diabetes Control and Complications Trial
1
, consisting of patients with Type 2 diabetes, and the 1993
UK Prospective Diabetes Study
2
, consisting of patients with Type 2 diabetes, demonstrated that patients who intensely
managed blood glucose levels delayed the onset and slowed the progression of diabetes-related complications. In the Diabetes Control
and Complications Trial, a major component of intensive management was monitoring blood glucose levels at least four times per
day using conventional spot finger stick blood glucose meters. The Diabetes Control and Complications Trial demonstrated that
intensive management reduced the risk of complications by 76% for eye disease, 60% for nerve disease and 50% for kidney disease.
Furthermore, a recent meta-analysis of over 25 prospective studies concluded that chronic hyperglycemia in type 2 diabetes is
associated with increased risks of all-cause mortality and cardiovascular outcomes independently from other conventional risk
factors.
3
However, despite the evidence that intensive glucose management reduces the long-term complications associated
with diabetes, Karter et al. reported in the 2000 issue of Diabetes Care that 67% of people with type 2 diabetes fail to routinely
monitor their glucose levels.
4
Spot
finger stick devices are the most prevalent devices for blood glucose monitoring. These devices require users to insert a strip
into a glucose meter, take a blood sample with a finger stick and place a drop of blood on a test strip that yields a single point
in time blood glucose measurement. Despite continued developments in the field of blood glucose monitors, the routine measurement
of glucose levels remains invasive, painful, inconvenient, difficult and costly. This has resulted in a sub-optimal and irregular
measurement regimen for many diabetics.
Manufacturing
The
FDA has approved continuous glucose monitoring system (“CGMS”) devices for blood glucose monitoring, when prescribed
by a doctor. CGMS devices use sensors inserted under the skin to check glucose levels in interstitial fluid. The sensor stays
in place for several days to a week and then must be replaced. A transmitter sends information about glucose levels via radio
waves from the sensor to a pager-like wireless monitor. According to the National Institute of Diabetes and Digestive
and Kidney Diseases at the National Institutes of Health, CGMS device users must check blood samples with a conventional glucose
meter to calibrate the CGMS devices, and because currently approved CGMS devices are not as accurate as standard blood glucose
meters, users should confirm glucose levels with a conventional glucose meter when making treatment decisions.
To
our knowledge, only one device other than the GlucoTrack® model DF-F is currently approved for use in the EU for spot non-invasive
blood glucose measurement. The FDA has previously approved a single non-invasive product for glucose trend analysis, the GlucoWatch®,
so long as the device was used with conventional finger stick glucose monitoring devices. However, the device is no longer available
commercially. We are not aware of any other devices that have been approved for use in either the United Stated or the EU for
spot or continuous non-invasive blood glucose measurement.
We
believe that a significant market opportunity exists for a reliable, inexpensive, non-invasive blood glucose measurement device
and that such a device could greatly increase compliance with blood glucose measurement recommendations and help many diabetics
better manage their disease, providing significant benefits to both patients and payors.
1
Group, U. P. D. S. (UKPDS); others Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS 33).
The Lancet
1998
,
352
, 837–853.
2
Diabetes Control and Complications Research Group; others The effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med
1993
,
329
,
977–986.
3
hang, Y.; Hu, G.; Yuan, Z.; Chen, L. Glycosylated Hemoglobin in Relationship to Cardiovascular Outcomes and Death in Patients
with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
PLOS ONE
2012
,
7
, e42551, doi:10.1371/journal.pone.0042551.
4
Karter, A. J.; Ferrara, A.; Darbinian, J. A.; Ackerson, L. M.; Selby, J. V. Self-monitoring of blood glucose: language and financial
barriers in a managed care population with diabetes.
Diabetes Care
2000
,
23
, 477–483.
The
Product
Our
non-invasive blood glucose monitor, the GlucoTrack® model DF-F, utilizes a patented combination of ultrasound, electromagnetic
and thermal technologies to obtain blood glucose measurements in less than one minute via a small sensor that is clipped onto
one’s earlobe and connected to a handheld control and display unit. See Figure A, below.
Figure
A
We
believe that the GlucoTrack® model DF-F addresses the unmet need for more frequent monitoring of blood glucose among people
with diabetes by overcoming two of the most significant challenges facing the market:
|
●
|
pain,
as the GlucoTrack® model DF-F is a truly non-invasive device; and
|
|
|
|
|
●
|
cost,
as, despite the relatively high upfront cost of purchasing a GlucoTrack® model DF-F, we anticipate that the total cost
of purchasing a device and purchasing replacement ear clips every six months (anticipated to be the only recurring cost, other
than calibration costs, which are expected to be minimal) over the useful life of the device will be significantly lower than
the cost of purchasing single use glucose sticks over that same period.
|
We
believe that the overall costs associated with owning and using a GlucoTrack® model DF-F device are expected to be substantially
lower than the cost of purchasing and using single use invasive devices over an extended period of time. Nonetheless, the significant
initial purchase price of a GlucoTrack® model DF-F might present a barrier to adoption of the GlucoTrack® system among
some patients. In light of this fact, we are suggesting to distributors of the GlucoTrack® model DF-F that they
consider offering end users financing and/or leasing options to lessen the initial financial burden associated with purchasing
a GlucoTrack® model DF-F. There can be no assurance that any such alternatives will be made available to end users. In addition,
we intend to seek reimbursement approval for the GlucoTrack® model DF-F from third-party payors, including government payors
(such as the Medicare and Medicaid programs in the United States, in the event the GlucoTrack® model DF-F is approved for
commercial sale in the United States), managed care organizations and other third-party payors. There can be no assurance that
such third party-payors will provide reimbursement coverage for the GlucoTrack® model DF-F or, if so, whether such reimbursement
coverage will be adequate. See “Risk Factors - If the GlucoTrack® model DF-F or our future product candidates, if any,
fail to achieve market acceptance or reimbursement coverage from managed care organizations or third-party payors, we may
not be able to generate significant revenue or achieve or sustain profitability”.
Instead
of directly measuring the glucose level of a user’s blood, as conventional spot finger stick devices do, the GlucoTrack®
model DF-F uses a small, non-invasive sensor that is clipped onto a user’s earlobe to obtain certain body measurements using
three technologies, which are then analyzed using a proprietary algorithm on a small, handheld control and display unit. Within
one minute, the GlucoTrack® model DF-F will produce a blood glucose measurement that can be simultaneously audibly announced
and displayed on the control unit, as well as recorded on internal flash memory. The two units of the device (main unit and personal
ear-clip) are connected through a multi-wire flexible cable. When and if we develop a continuous measurement model, we plan for
this connection to be wireless.
Since
the GlucoTrack® model DF-F non-invasive measurement does not directly measure glucose levels in the blood, but rather measures
a series of physiological characteristics that correlate with glucose levels, each patient must be calibrated by using a reference
to a measurement obtained from an invasive device. Calibration consists of comparing an individual patient’s physiological
measurements obtained using the GlucoTrack® model DF-F to measurements obtained from an invasive device under different
circumstances over a defined period 30 minute period (3 measurements that require approximately 10 minutes each).
The
three different technologies used by GlucoTrack® model DF-F, ultrasound, electromagnetic and thermal, simultaneously measure
three independent criteria. These three measurements (criteria) are combined together by a unique (on line) algorithm to produce
an acceptable measurement of a user’s blood glucose level.
The
technologies operate as follows:
|
●
|
Ultrasound
:
The GlucoTrack® model DF-F uses ultrasound technology to measure the change of speed of sound through the earlobe, which
is impacted by the glucose concentration in the capillary blood vessels.
|
|
●
|
Electromagnetic
:
The GlucoTrack® model DF-F’s electromagnetic technology uses a measurement of conductivity to measure the change
in tissue impedance, which is a function of glucose concentration. The GlucoTrack® model DF-F’s electromagnetic
technology analyzes criteria similar to those analyzed by conventional invasive devices, such as spot finger stick devices,
but does so in a non-invasive manner.
|
|
●
|
Thermal
:
The GlucoTrack® model DF-F’s thermal technology uses a measurement of heat capacity characteristics of the tissue,
which are influenced by glucose concentration.
|
Non-invasive
devices (under different stages of development) generally require frequent recalibration. The main reasons for calibration are
that tissue parameters generally fluctuate in the area of the measurement and are sensitive to the location of the sensor
and the impact of potential disturbances. Disturbances are less frequent in the earlobes, where the GlucoTrack® model DF-F
takes its measurements. Utilizing three channels simultaneously reduces the noise contribution in the measurement. In addition,
the personal ear-clip contains sensors to help users attach the device to the proper part of the ear lobe. The Notified
Body for our CE Mark approval has determined that the initial calibration of the GlucoTrack® model DF-F device is valid for
a period of six months which we believe is a significant competitive advantage, while to our knowledge, competing products require
recalibration significantly much more frequently. Therefore, we expect the GlucoTrack® model DF-F will require only an initial
calibration upon use of a new personal ear-clip (to be replaced every six months) and will not require further recalibration.
The
GlucoTrack® model DF-F does not use any optical method (either Infra Red (IR) or Near Infra Red (NIR) technology), which we
understand are being used by other developers of non-invasive blood glucose measurement devices. We believe that optical technologies
are less reliable than the GlucoTrack® model DF-F’s combination of ultrasound, electromagnetic and thermal technologies
due to inherent physiological limitations with optical technology. More specifically, optical technology is based on dispersion
of a beam that is analyzed by spectrometric methods. As such devices are non-invasive, the beam passes through other components
in the fingertip, such as skin, bone, muscle and fat tissue, which interfere with the measurements. Generally, most of these interferences
have been overcome, but not the epidermis, primarily due to roughness, pigmentation and perspiration, which act like lenses in
optical wavelengths.
Unlike
conventional spot finger stick devices, which require single-use glucose test strips, the GlucoTrack® model DF-F requires
no short- term disposables. We believe that the personal ear-clip that accompanies each GlucoTrack® model DF-F will need to
be replaced only once every six months, although regulatory authorities may require that replacement occur more frequently. Since
there is no additional cost or pain involved with each blood glucose measurement using the GlucoTrack® model DF-F, we believe
that users of our device would be encouraged to take multiple blood glucose measurements per day, significantly increasing compliance
with blood glucose measurement recommendations and helping diabetics better manage their disease. More frequent testing of blood
glucose levels may provide a patient with information that can be used to determine optimal timing and dosage for corrective treatments
such as insulin, and can also direct a patient to seek a clinical analysis or detailed testing and diagnosis.
The
GlucoTrack® model DF-F has received CE Mark approval, which allows us to market and sell the GlucoTrack® model DF-F glucose
monitoring device in EU member countries that have adopted the MDD without being subject to additional national regulations with
regard to demonstration of performance and safety. While the MDD is applicable throughout the EU, it requires only a minimum level
of harmonization among member countries. Accordingly, member countries may apply and enforce the MDD’s terms differently,
and certain EU member countries may request or require performance and/or safety data additional to the MDD’s requirements
from time to time, on a case-by-case basis. Moreover, the MDD notwithstanding, because the regulatory regimes of the EU member
countries are significantly diverse, it is difficult to predict future regulatory developments and risks. The GlucoTrack®
model DF-F has not yet been cleared or approved for commercial sale in the United States. See “
Government Regulatory
- Regulation of the Design, Manufacture and Distribution of Medical Devices
” below for a discussion of the approval
process for commercial sale in the United States. There can be no assurance that approval for commercial sale in any additional
jurisdiction will be obtained on a timely basis or at all.
We
do not have commercial manufacturing facilities and do not intend to build commercial manufacturing facilities of our own in the
foreseeable future. We currently utilize a third-party manufacturer in Israel and a manufacturer in Taiwan to manufacture the
GlucoTrack® model DF-F. Our suppliers and their manufacturing facilities must comply with applicable regulations in the jurisdictions
in which the GlucoTrack® model DF-F is being marketed (including ISO 13485 in the EU), current quality system regulations,
which include current good manufacturing practices, and to the extent laboratory analysis is involved, current good laboratory
practices. There can be no assurance that we will be able to enter into agreements with qualified manufacturers on terms acceptable
to us, or at all, or that, once contracted, such manufacturers will perform as expected.
Furthermore,
the manufacturing of the GlucoTrack® model DF-F may be impacted by the Recast Directive on the Restriction of Hazardous Substances
in Electrical and Electronic Equipment, 2011/65/EU (“RoHS 2”). RoHS 2 is a new EU directive that came into force
on July 22, 2014. Like the MDD, RoHS 2, a recast of Directive 2002/95/EC that will cover electrical and electronic
medical devices, is relevant in order to obtain CE Marking for certain products. RoHS 2 compliance requires medical device manufacturers
to: draw up required technical documentation; conduct an internal control procedure in accordance with Module A of Annex II to
Decision No. 768/2008/EC; prepare a Declaration of Conformity; and affix CE Marking to a finished product. Although these requirements
are similar to those of the MDD, RoHS 2 does not require a Notified Body assessment of compliance. However, if they are not compliant
with RoHS 2, medical device manufacturers face the risk of being barred from selling medical devices in the EU after July
22, 2014.
Sales
& Marketing
We
have a limited number of dedicated sales and marketing personnel, as we intend to collaborate with third parties with established
sales and marketing operations in the medical device industry (such as the distributors described below) to market and sell the
GlucoTrack® model DF-F to point of sale end users and/or local distributors.
The
GlucoTrack® model DF-F has been cleared and approved for commercial sale in the following jurisdictions: EU (subject to registration
by the local distributors with the respective countries), Israel, Turkey, South Korea, Hong Kong, New Zealand and some Arab countries.
We cannot provide any assurance that we will receive the required local regulatory approvals in any of the countries in which
such approvals are required, and therefore we may never be permitted to commence commercial sales of our products in such territories.
Further discussions with other potential distributors are in different stages. However, there can be no assurance that we will
be able to enter into additional distribution agreements on terms acceptable to us or at all or that, once contracted, our distributors
will perform as expected.
Our
distribution agreements entered into to date generally appoint the counterparty as the exclusive distributor of the GlucoTrack®
model DF-F in a stated territory. Where local regulatory approval of the device is required, such appointment is generally conditioned
upon receipt of such approval.
Research
and Development
We
focus significant time and resources on research and development in connection with our efforts to continue to develop, improve
and commercialize the GlucoTrack® model DF-F, as well as in connection with our development of other GlucoTrack® models.
Our continuing research and development activities are primarily focused on software and algorithm improvements intended to improve
the accuracy of the device, clinical trials to test the performance of the GlucoTrack® device when used by children and teenagers
between the ages of six and 18, preparation for future FDA trials, testing new characteristics of the device, development
of a new device in the GlucoTrack® family and seeking to streamline and continue to simplify the calibration process. See
“
Management’s Discussion and Analysis of Financial Condition and Results of Operation – Results of Operation
”
for a discussion of our recent research and development expenses.
We
recently
laid out our strategic priorities in terms of product enhancements and a future generation of products. As a result of the review
of our corporate strategy, we have decided to concentrate our research and development activities around 4 main strategic pillars:
We
have developed a wireless module (“WLM”) with embedded Bluetooth Low-Energy (BLE) and Wi-Fi technologies, which enables
the transmission of measurement data captured by the GlucoTrack® model DF-F to a cloud-based server or a smart device. We
expect this module and the related applications, to facilitate viewing of glucose related data and correlate it closely with lifestyle
choices made by the users, be that dietary choices or activity-based choices, among other things. The wireless module will also
facilitate sharing, viewing and analysis of GlucoTrack® measurements and profile by clinicians and others caregivers.
|
2.
|
Digital
Health Applications
|
We
will develop smart device applications (“Apps”) to facilitate the interaction of users with Glucotrack® and the
glucose data collected. We intend to develop Apps that support the management of Type 2 diabetics and pre-diabetic patients by
provided immediate feedback and insights as to the glucose measurements. The goal is to provide relevant information to guide
patients to change behavior and improve the management of their condition. The Apps will have a user-directed capability to connect
with third party healthcare providers (physicians, dieticians, and nurse practitioners), in order to receive professional guidance
based on the accumulated information ultimately leading to improved management of the condition and better disease outcomes.
While
the accuracy of the Glucotrack® DF-F is sufficient for the management of Type 2 diabetics and pre-diabetic patients (and approved
as such by the EU authorities), we strive to further improve the product in future iterations and maximize its potential by expanding
the addressable market, e.g. into Type 1 diabetes. The research projects include further improving the algorithms involved in
computing our glucose measurement data, as well as deeper research on the existing sensing technologies to improve sensitivity.
The ultimate goal being to eventually commercialize a non-invasive device for all types of diabetics.
The
objective of this project is to reduce the existing device to a simple, aesthetically designed, wireless ear-clip which would
measure glucose and communicate the results seamlessly to any other platform whether through a wireless connection to the cloud
or a Bluetooth connection to a smart device such as a smartphone, tablet or computer. As a result, the current handheld display
would be eliminated completely. The result would be a user- friendly, inconspicuous measuring device for the management of diabetes
and pre-diabetes. With a significantly cheaper cost to manufacture than our current device.
Simultaneously
we will be working to further simplify the calibration process eventually enabling self-calibration.
Government
Regulatory
Healthcare
is heavily regulated by federal, state and local governments in the United States, and by similar authorities in other countries.
Any product that we develop must receive all relevant regulatory approvals or clearances, as the case may be, before it may be
marketed in a particular country. The laws and regulations affecting healthcare change regularly, thereby increasing the uncertainty
and risk associated with any healthcare-related venture. The United States government has in the past considered, is currently
considering and may in the future consider healthcare policies and proposals intended to curb rising healthcare costs, including
those that could significantly and adversely affect reimbursement for healthcare products such as GlucoTrack® devices. These
policies have included and may in the future include: basing reimbursement policies and rates on clinical outcomes, the
comparative effectiveness and costs of different treatment technologies and modalities; imposing price controls and taxes on medical
device providers; and other measures. Future significant changes in the healthcare systems in any jurisdiction in which the GlucoTrack®
model DF-F or our future products, if any, may be cleared for sale could also have a negative impact on the demand for the GlucoTrack®
model DF-F or our future products, if any. These include changes that may reduce reimbursement or payment rates for such products.
In
the United States, the federal government regulates healthcare through various agencies, including but not limited to the following:
(i) the FDA, which administers the Food, Drug, and Cosmetic Act, as well as other relevant laws; (ii) the Centers for Medicare
& Medicaid Services (“CMS”), which administers the Medicare and Medicaid programs; (iii) the Office of Inspector
General, which enforces various laws aimed at curtailing fraudulent or abusive practices including, by way of example, the
Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to as the Stark Law, the Anti-Inducement Law, the Civil
Money Penalty Law, and the laws that authorize the Office of Inspector General to exclude health care providers and others from
participating in federal healthcare programs; and (iv) the Office of Civil Rights which administers the privacy and security aspects
of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). All of the aforementioned are agencies
within the Department of Health and Human Services. Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs under, among other laws, the Veterans Health Care Act
of 1992, the Public Health Service within the Department of Health and Human Services under the Public Health Service Act, the
Department of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid
program and their internal laws regulating all healthcare activities. If and when we receive FDA approval to market the GlucoTrack®
DF-F in the United States, we will be subject to regulation by some or all of the foregoing agencies.
The
applicable regulatory schemes in the EU are significantly more diverse than those in the United States and do not lend themselves
to similar summary. Although the CE Mark system and the MDD require a minimum level of harmonization in the EU, each EU member
country may impose additional regulatory requirements. Because there are numerous EU member countries with distinct legal systems,
the scope of potential regulatory requirements in each of the EU countries (additional to the harmonized EU requirements) is difficult
to summarize or predict.
Regulation
of the Design, Manufacture and Distribution of Medical Devices
Any
product that we develop must receive all relevant regulatory clearances or approvals, as the case may be, before it may be marketed
in a particular country.
Sales
of medical devices outside the United States are subject to foreign regulatory requirements that vary widely from country to country.
These laws and regulations range from simple product registration requirements in some countries to complex clearance and production
controls in others. As a result, the processes and time periods required to obtain foreign marketing approval may be longer or
shorter than those necessary to obtain FDA approval (as described below). These differences may affect the efficiency and timeliness
of international market introduction of GlucoTrack® model DF-F. For countries in the EU, medical devices must display a CE
Mark before they may be imported or sold and must comply with the requirements of the MDD or the Active Implantable Medical Device
Directive. On June 6 , 2013, we received our CE Mark approval for the GlucoTrack® model DF-F non-invasive glucose monitoring
device from the Notified Body. Receipt of the CE Mark allows us to market and sell the GlucoTrack® model DF-F glucose monitoring
device in EU member countries that have adopted the MDD without being subject to additional national regulations with regard to
demonstration of performance and safety. However, although the MDD is applicable throughout the EU, in practice it does not ensure
uniform regulation throughout the EU. Rather, the MDD requires only a minimum level of harmonization in the EU. Accordingly, member
countries may apply and enforce the MDD’s terms differently, and certain EU member countries may request or require performance
and/or safety data in addition to the MDD’s requirements from time to time, on a case-by-case basis. The CE Mark also permits
the sale in countries that have an MDD Mutual Recognition Agreement with the EU. On August 31, 2015, we received approval from
the Notified Body for improvements to the GlucoTrack® model DF-F which simplify and shorten (from approximately 2.5 hours
to approximately half an hour) the initial calibration process for the device. These improvements are intended to reduce the backlog
created as purchasers of the device await calibration. In addition, we received approval from the Notified Body on the updated
intended use for the device, which expands the intended user population to include not only Type 2 diabetics, but persons suffering
from pre-diabetes conditions as well, which we believe represents a material expansion of the potential market for the device.
In December 2015, we received approval from the Notified Body for further improvements to the GlucoTrack® model DF-F that
increase the accuracy and efficacy of the device. On February 19, 2016, we received an extension of our ISO 13485:2003 certificate
and Annex II certification from the EU. The ISO 13485:2003 certification signifies that we have met the standards required for
company-wide implementation of device quality management system(s). The scope of the certification is design, development,
manufacture and service of non-invasive glucose monitoring systems for home use. Annex II also addresses quality control
systems. The certification allows us to self-certify certain modifications and changes and simplifies some of the reporting to
and review by the relevant Notified Body. This can shorten CE-mark review process of future GlucoTrack® model DF-F enhancements
or revisions. Without an Annex II certification, each new device enhancement or modified version would be subject to the full
EU CE-mark review process. The ISO 13485:2003 and Annex II certifications enable us to potentially improve the time to market
for product sales on new, enhanced or modified GlucoTrack® model DF-F devices.
On
May 4, 2016, we received regulatory approval from the Korean Ministry of Food and Drug Safety (KMFDS, formerly KFDA) for the GlucoTrack®
model DF-F. In October 2016, we received the final approval from South Korea, which enables us to commence sales of the GlucoTrack®
model DF-F in South Korea.
After months of protracted
negotiations with our China distributor, we finally reached an impasse on several critical issues and decided that it would be
in the best interests of the Company to terminate the existing agreements with such distributor due to various breaches of the
distributor. On May 14, 2018, the Company sent notices to the distributor regarding the Company’s intention to terminate
the agreement unless the breaches are cured within 30 days. On June 6, 2018, the Company received a response from the distributor
denying all the allegations of breaches. The distributor plays a critical role in assisting the Company to obtain regulatory
approval by the CFDA for the GlucoTrack® model DF-F. If the breaches are not cured within the given timeframe and the relationship
is terminated, the registration of GlucoTrack® in China will be delayed significantly while we seek new partnering options; and
as a result of the breaches of the distributor and the termination of such relationship, the Company may likely be unable to re-submit
the file to the CFDA for the current product for a period of up to five years. While the Company is of the opinion that
such termination will have little adverse effect on its future business opportunities in China, as it believes that
it should be able to file applications with the CFDA for its next generation products through another distributor in
China, there can be no assurance that the Company will be successful in this endeavor. If we were unable to partner with
another distributor in China on terms mutually agreed upon by us and receive CFDA clearance to sell its future
products in China, we would not have the ability to distribute our products in China and accordingly our business potential
could be materially adversely affected.
We
currently are not seeking regulatory approval in Japan. We may also seek regulatory approval to market the GlucoTrack® devices
in other foreign countries that do not rely on the CE Mark. To the extent that we seek to market our devices in other non-CE Mark
countries in the future, we will be required to comply with the applicable regulatory requirements in each such country. Such
regulatory requirements vary by country and may be onerous. As a result, no assurance can be given that we will be able to satisfy
the regulatory requirements to sell our products in any such country.
In
the United States, under Section 201(h) of the Food, Drug, and Cosmetic Act, a medical device is an article which, among other
things, is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment or prevention
of disease in man or other animals. We believe that GlucoTrack® devices will be classified as medical devices and subject
to regulation by numerous agencies and legislative bodies, including the FDA and its foreign counterparts. Devices are subject
to varying levels of regulatory control, the most comprehensive of which requires that a clinical evaluation be conducted before
a device receives approval for commercial distribution. The FDA classifies medical devices into one of three classes. Class I
devices are relatively simple and can be manufactured and distributed with general controls. Class II devices are somewhat more
complex and require greater scrutiny. Class III devices are new and frequently help sustain life.
In
the United States, a company generally can obtain permission to distribute a new device in two ways – through a so-called
“510(k)” premarket notification application or through a Section 515 premarket approval (“PMA”) application.
The 510(k) submission applies to any device that is substantially equivalent to a device first marketed prior to May 28, 1976
or to another device marketed after that date, but which was substantially equivalent to a pre-May 28, 1976 device. These devices
are either Class I or Class II devices. Under the 510(k) submission process, the FDA will issue an order finding substantial equivalence
to a predicate device (pre-May 28, 1976 or post-May 28, 1976 device that was substantially equivalent to a pre- May 28, 1976 device)
and permitting commercial distribution of that device for its intended use. A 510(k) submission must provide information supporting
its claim of substantial equivalence to the predicate device. The FDA permits certain low risk medical devices to be marketed
without requiring the manufacturer to submit a premarket notification. In other instances, the FDA may require that a premarket
notification not only be submitted, but also be accompanied by clinical data. If clinical data from human experiments are required
to support the 510(k) submissions, these data must be gathered in compliance with investigational device exemption regulations
for investigations performed in the United States. The FDA review process for premarket notifications submitted pursuant to section
510(k) should take about 90 days, but it can take substantially longer if the FDA has concerns, and there is no guarantee that
the FDA will clear the device for marketing, in which case the device cannot be lawfully distributed in the United States. If
the FDA finds that the device subject to the premarket notification is substantially equivalent to a proper predicate device,
then the FDA may “clear” that device for marketing. These devices are not “approved” by the FDA. There
is no guarantee, however, that the FDA will deem the device subject to the 510(k) process, as opposed to the more time-consuming,
resource intensive and problematic PMA application process described below.
The more comprehensive
PMA process applies to a new device that either is not substantially equivalent to a pre-May 28, 1976 product or is to be used
in supporting or sustaining life or preventing impairment. These devices are normally Class III devices and can only be marketed
following approval of a PMA application. For example, most implantable devices are subject to the PMA approval process. Two steps
of FDA approval generally are required before a company can market a product in the U.S. that is subject to Section 515 PMA approval,
as compared to a Section 510(k) clearance. First, a company must comply with investigational device exemption regulations in connection
with any human clinical investigation of the device; however , those regulations permit a company to undertake a clinical
study of a “non-significant risk” device without formal FDA approval. Prior express FDA approval is required if the
device is a significant risk device. If there is any doubt as to whether a device is a “non-significant risk” device,
companies normally seek prior approval from the FDA. Normally, clinical studies of new diagnostic products are conducted in tandem
with a cleared or approved device and treatment decisions are based on the results from the existing diagnostic device. In such
a setting, the FDA may consider the clinical trial as one not posing a significant risk. However, FDA action is always
uncertain and dependent on the contours of the design of the clinical trial and the device and there is no assurance that the
FDA would consider any proposed clinical trial as one posing a non-significant risk. Moreover, before undertaking any clinical
trial, the company sponsoring the trial and the investigator conducting the trial are required by federal law to seek and obtain
the approval of institutional review boards (“IRB”). An IRB weighs the risks and benefits of a proposed trial to ensure
that the human subjects are not exposed to unnecessary risk and reviews the informed consent form to ensure that it meets federal
requirements and accurately describes the risks and benefits, if any, of the clinical trial. IRB review occurs annually and annual
re-approval is required. University medical centers as well as other entities maintain and operate IRB. Second, the FDA must review
a company’s PMA, which contains, among other things, clinical information acquired under the investigational device exemption.
The FDA will approve the PMA if it finds there is reasonable assurance that the device is safe and effective for its intended
use. The premarket approval process takes substantially longer than the 510(k) processes.
The
GlucoTrack® model DF-F has not yet been approved for commercial sale in the United States. In discussions with the FDA regarding
the regulatory pathway, the FDA is not yet entirely sure whether a de novo pathway is acceptable and recommended that the Company
should plan to support this approach through risk analysis and an explanation of why the new measurement paradigm it is proposing
does not introduce greater risks. FDA noted that no decision has been made that a PMA will be required.
On
August 10, 2015, we submitted pre-submission documents to the FDA in connection with our proposed future application for FDA approval
of our U.S. clinical trial protocol. The pre-submission documentation was submitted to the FDA in order to obtain the FDA’s
guidance regarding the U.S. regulatory pathway for the GlucoTrack® model DF-F, the proper approach to refining the trial protocol,
and preparing the pre-marketing application. On October 19, 2015, we met with the FDA to discuss the pre-submission documents,
including the approach to and details of the clinical trial protocol for the GlucoTrack® Model DF-F. On May 10, 2016, we submitted
a pre-submission supplement (including clinical trial protocol) to the FDA which modifies the pre-submission documentation to
reflect the feedback received from the FDA at the meeting. On July 18, 2016, we completed a teleconference with the FDA to further
discuss our pre-submission supplement. At the end of this discussion, we received verbal confirmation from the FDA that clinical
trials of the GlucoTrack® model DF-F constitute non-significant risk device studies, which allows the trials to proceed without
an Investigational Device Exemption (IDE) application. Such trials are assessed by the FDA and not considered to present a potential
for serious risk to the health, safety or the welfare of subjects. Subject to raising adequate financing, we would expect to be
able to begin clinical trials in the United States quite rapidly thereafter.
Even
when a clinical study has been approved or cleared by the FDA or a notified body or deemed approved, the study is subject to factors
beyond a manufacturer’s control, including, but not limited to the fact that the IRB at a given clinical site might not
approve the study, might decline to renew approval which is required annually, or might suspend or terminate the study before
the study has been completed. Also, the interim results of a study may not be satisfactory, in which case the sponsor may terminate
or suspend the study on its own initiative or the FDA or a notified body may terminate or suspend the study. There is no assurance
that a clinical study at any given site will progress as anticipated; there may be an insufficient number of patients who qualify
for the study or who agree to participate in the study, or the investigator at the site may have priorities other than the study.
Also, there can be no assurance that the clinical study will provide sufficient evidence to assure the FDA or a notified body
that the product is safe and effective, a prerequisite for FDA approval of a PMA, or substantially equivalent in terms of safety
and effectiveness to a predicate device, a prerequisite for clearance under 510(k). Even if the FDA or a notified body approves
or clears a device, it may limit its intended uses in such a way that manufacturing and distributing the device may not be commercially
feasible.
After
clearance or approval to market is given, the FDA and foreign regulatory agencies, upon the occurrence of certain events, are
authorized under various circumstances to withdraw the clearance or approval or require changes to a device, its manufacturing
process or its labeling or additional proof that regulatory requirements have been met.
A
manufacturer of a device approved through the PMA process is not permitted to make changes to the device which affects its safety
or effectiveness without first submitting a supplement application to its PMA and obtaining FDA approval for that supplement.
In some instances, the FDA may require clinical trials to support a supplement application. A manufacturer of a device cleared
through a 510(k) submission must submit another premarket notification if it intends to make a change or modification in the device
that could significantly affect the safety or effectiveness of the device, such as a significant change or modification
in design, material, chemical composition, energy source or manufacturing process. Any change in the intended uses of a PMA device
or a 510(k) device requires an approval supplement or cleared premarket notification. Exported devices are subject to the regulatory
requirements of each country to which the device is exported, as well as certain FDA export requirements.
The
Patient Protection and Affordable Care Act was signed into law on March 23, 2010, and on March 30, 2010, a reconciliation bill
that modifies certain provisions of the same was signed into law. These two laws are jointly referred to as the “Affordable
Care Act” or “ACA.”
The
principal aim of the ACA was to expand health insurance coverage to approximately 32 million Americans who were uninsured. The
law’s most far-reaching changes did not take effect until 2014, including a requirement that most Americans carry health
insurance. The consequences of these significant coverage expansions on the sales of our products is still unknown and speculative
at this point, although the ACA and certain state initiatives may compel private insurers to reduce coverage or reimbursement
for various items and services, including medical devices of the type that we contemplate distributing.
This
legislation contains many provisions designed to generate the revenues necessary to fund the coverage expansions. The most relevant
of these provisions are those that impose fees or taxes on certain health-related industries, including medical device manufacturers.
Beginning in 2013, each medical device manufacturer is required to pay an excise tax (or sales tax) in an amount equal to 2.3%
of the price for which such manufacturer sells its medical devices. The tax applies to all medical devices, including our products
and product candidates. The ACA also provides for increased enforcement of the fraud and abuse regulations previously mentioned.
In
January 2017, Congress voted in favor of a budget resolution that will produce legislation that would repeal certain aspects of
the
ACA
if
enacted into law. Congress is also considering subsequent legislation to replace or repeal elements or all of the
ACA
.
In addition, there have been recent public announcements by members of Congress and the new presidential administration regarding
their plans to repeal and replace the
ACA
. Further, President Trump signed an Executive
Order directing federal agencies with authorities and responsibilities under the
ACA
to
waive, defer, grant exemptions from, or delay the implementation of any provision of the
ACA
that
would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of
pharmaceuticals or medical devices.
In October 2017, President Trump signed a second executive order allowing for
the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans sold
through the ACA exchanges.
At this time, it is not clear whether the
ACA
will
be repealed in whole or in part, and, if it is repealed, whether it will be replaced in whole or in part by another plan, and
what impact those changes will have on coverage and reimbursement for healthcare items and services covered by plans that were
authorized by the
ACA
. We expect that additional state and federal healthcare reform
measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, and also indirectly affect the amounts that private payers are willing to pay. In addition, any healthcare
reforms enacted in the future may be phased in over a number of years but, if enacted, could impact our revenue, increase our
costs, or require us to revise the ways in which we conduct business or put us at risk for loss of business. In addition, our
future results of operations, financial position and cash flows could be materially adversely affected by changes under the
ACA
and changes under any federal or state legislation adopted in the future.
On
August 2, 2011, President Obama and Congress enacted the Budget Control Act of 2011 to increase the federal government’s
borrowing authority (the so-called “debt ceiling”) and reduce the federal government’s projected operating deficit.
To implement this legislation, President Obama and members of Congress have proposed various spending cuts and tax reform initiatives,
some of which could result in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage
Plans. Under the agreement reached to allow the federal government to raise the debt ceiling in August 2011, a 12-member, bipartisan
committee was given a deadline of November 23, 2011 to develop recommendations for reducing the federal budget deficit by a total
of at least $1.2 trillion over ten years. However, the committee was not able to agree on a plan and, therefore, $1.2 trillion
in automatic spending cuts, including a two-percent reduction in Medicare payments to dialysis facilities went into effect on
January 1, 2013. In November 2013, CMS released a final rule that included a 12% cut for reimbursement of dialysis intravenous
services. While CMS created other offsets to make the first two years of the cut budget neutral, the adjustment itself in
the bundle went down by 3.3% starting in January 2014, as part of a 3-4 year transition period to reach the 12% reduction. This
means that Medicare dialysis rates in an environment of increasing expenses. These measures and any future federal legislation
relating to the debt ceiling or deficit reduction could have a material adverse effect on us.
There
are ongoing discussions in the EU regarding amending the relevant regulatory framework. It is difficult to predict what effect
any amendments to the existing EU legislation may have. Furthermore, each individual EU member country has the authority to amend
its regulations and requirements additional to the minimum harmonization required by the MDD. Because the EU member countries
have diverse legal systems, it is difficult to predict what, if any, amendments may be implemented in each of the EU member countries
and whether they may adversely affect us.
We
anticipate that sales volumes and prices of the GlucoTrack® model DF-F and any other products we commercialize will depend
in large part on the availability of reimbursement from third-party payors. Third-party payors include governmental programs such
as Medicare and Medicaid, private insurance plans and workers’ compensation plans. These third-party payors may deny reimbursement
for a product or therapy if they determine that the product was not medically appropriate or necessary. Also, third-party payors
are increasingly challenging the prices charged for medical products and services. Some third-party payors must also approve coverage
for new or innovative devices before they will reimburse health care providers who use the products. Even though a new product
may have been cleared for commercial distribution, it may find limited demand for the device until reimbursement approval has
been obtained from governmental and private third-party payors.
Inasmuch
as a percentage of the projected patient population that could potentially benefit from the GlucoTrack® model DF-F is elderly,
Medicare would likely be a potential source of reimbursement in the United States. Medicare is a federal program that provides
certain hospital and medical insurance benefits to persons age 65 and over, certain disabled persons, persons with end-stage renal
disease and those suffering from Lou Gehrig’s Disease. In contrast, Medicaid is a medical assistance program jointly funded
by United States federal and state governments and administered by each state pursuant to which benefits are available to certain
indigent patients. The Medicare and Medicaid statutory framework is subject to administrative rulings, interpretations and discretion
that affect the amount and timing of reimbursement made under Medicare and Medicaid.
Medicare
reimburses for medical devices in a variety of ways depending on where and how the device is used. However, Medicare only provides
reimbursement if CMS determines that the device should be covered and that the use of the device is consistent with the coverage
criteria. A coverage determination can be made at the local level by the Medicare administrative contractor (formerly called carriers
and fiscal intermediaries) or a private contractor that processes and pays claims on behalf of CMS for the geographic area where
the services were rendered, or at the national level by CMS. There are new statutory provisions intended to facilitate coverage
determinations for new technologies under the Medicare Prescription Drug Improvement and Modernization Act of 2003 §731 and
§942, but it is unclear how these new provisions will be implemented. Coverage presupposes that the device has been cleared
or approved by the FDA and, further, that the coverage will be no broader than the approved intended uses of the device (i.e.,
the device’s label) as cleared or approved by the FDA, but coverage can be narrower. In that regard, a narrow Medicare coverage
determination may undermine the commercial viability of a device.
Obtaining
a coverage determination, whether local or national, is a time-consuming, expensive and highly uncertain proposition, especially
for a new technology, and inconsistent local determinations are possible. On average, according to an industry report, Medicare
coverage determinations for medical devices lag 15 months to five years or more behind FDA approval for respective devices. Moreover,
Medicaid programs and private insurers are frequently influenced by Medicare coverage determinations. A key component in the reimbursement
decision by most private insurers will be whether the GlucoTrack® model DF-F is reimbursed by virtue of a national coverage
determination by CMS. We may negotiate contracted rates for the GlucoTrack® model DF-F with private insurance providers for
the purchase of the GlucoTrack® model DF-F by their members pending a coverage determination by CMS. Our inability to obtain
a favorable coverage determination for the GlucoTrack® model DF-F may adversely affect our ability to market the GlucoTrack®
model DF-F and thus, the commercial viability of the product. In international markets, reimbursement and healthcare payment systems
vary significantly by country and many countries have instituted price ceilings on specific product lines. Distributors expressly
support the reimbursement process and, depending on the distribution agreement and geographic area, may assume responsibility
for the process.
We
believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased
pressures on the healthcare industry to reduce the costs of products and services. Furthermore, deficit reduction and austerity
measures in the United States and abroad may put further pressure on governments to limit coverage of, and reimbursement for,
our products. There can be no assurance that third-party reimbursement and coverage will be available or adequate, or that future
legislation, regulation, or reimbursement policies of third-party payors will not adversely affect the demand for our products
or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or
reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement
or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack®. Third-party coverage may
be particularly difficult to obtain while the GlucoTrack® model DF-F is not approved by the FDA as a replacement for existing
single-point finger stick devices.
Outside
the United States, availability of reimbursement from third parties varies widely from country to country. Within the EU, member
countries’ medical reimbursement and healthcare coverage regulations and systems differ significantly. It is, therefore,
difficult to analyze and predict the prospect of consistent availability of adequate reimbursement in the various EU member countries.
Until
a reimbursement code is achieved, in order to reduce out of pocket expenses for users and increase the number of devices sold,
we are suggesting to distributors of the GlucoTrack® model DF-F in the United States (and would anticipate suggesting to our
distributors in the United States in the future if and when we receive FDA approval to market the GlucoTrack® model DF-F in
the United States) that they consider offering end users financing and/or leasing options to lessen the initial financial burden
associated with purchasing a GlucoTrack® device. There can be no assurance that any such alternatives will be made available
to end users.
Anti-Fraud
and Abuse Rule
There
are extensive United States federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that
can result in significant criminal and civil penalties that can materially affect us, if and when we receive FDA approval to market
the GlucoTrack® model DF-F in the United States. These federal laws include, by way of example, the following:
|
●
|
The
anti-kickback statute (Section 1128B(b) of the Social Security Act), which prohibits certain business practices and relationships
that might affect the provision and cost of healthcare services reimbursable under Medicare, Medicaid and other federal healthcare
programs, including the payment or receipt of remuneration for the referral of patients whose care will be paid by Medicare
or other governmental programs;
|
|
●
|
The
physician self-referral prohibition (Ethics in Patient Referral Act of 1989, as amended, commonly referred to as the Stark
Law, Section 1877 of the Social Security Act), which prohibits referrals by physicians of Medicare or Medicaid patients to
providers of a broad range of designated healthcare services in which the physicians (or their immediate family members) have
ownership interests or with which they have certain other financial arrangements;
|
|
●
|
The
anti-inducement provisions of the Civil Monetary Penalties Law (Section 1128A(a)(5) of the Social Security Act), which prohibit
providers from offering anything to a Medicare or Medicaid beneficiary to induce that beneficiary to use items or services
covered by either program;
|
|
●
|
The
False Claims Act (31 U.S.C. § 3729 et seq.), which prohibits any person from knowingly presenting or causing to be presented
false or fraudulent claims for payment to the federal government (including the Medicare and Medicaid programs); and
|
|
●
|
The
Civil Monetary Penalties Law (Section 1128A of the Social Security Act), which authorizes the United States Department of
Health and Human Services to impose civil penalties administratively for fraudulent or abusive acts.
|
Sanctions
for violating these federal laws include criminal and civil penalties that range from punitive sanctions, damage assessments,
monetary penalties, imprisonment and/or denial of Medicare and Medicaid payments or exclusion from the Medicare and Medicaid programs,
or both. These laws also impose an affirmative duty on those receiving Medicare or Medicaid funding to ensure that they do not
employ or contract with persons excluded from the Medicare and other government programs.
Many
states have adopted or are considering legislative proposals similar to the federal fraud and abuse laws, some of which extend
beyond the Medicare and Medicaid programs, to prohibit the payment or receipt of remuneration for the referral of patients and
physician self-referrals regardless of whether the service was reimbursed by Medicare or Medicaid. Many states have also adopted
or are considering legislative proposals to increase patient protections, such as limiting the use and disclosure of patient specific
health information. These state laws also impose criminal and civil penalties similar to the federal laws.
Similarly,
the EU and EU member countries may have similar fraud and abuse laws which would regulate our business in those jurisdictions.
However, given the diversity of legal systems within the EU, it is difficult to predict with specificity what anti-fraud legislation
and regulations may be implemented and the penalties that they impose.
In
the ordinary course of their business, medical device manufacturers and suppliers have been and are subject regularly to inquiries,
investigations and audits by federal and state agencies that oversee these laws and regulations. Recent federal and state legislation
has greatly increased funding for investigations and enforcement actions, which have increased dramatically over the past several
years. This trend is expected to continue. Private enforcement of healthcare fraud also has increased due in large part to amendments
to the civil False Claims Act in 1986 that were designed to encourage private persons to sue on behalf of the government. These
whistleblower suits by private persons, known as qui tam relators, may be filed by almost anyone, including present and former
patients or nurses and other employees, as well as competitors. HIPAA, in addition to its privacy provisions, created a series
of new healthcare-related crimes.
As
federal and state budget pressures continue, federal and state administrative agencies may also continue to escalate investigation
and enforcement efforts to root out waste and to control fraud and abuse in governmental healthcare programs. A violation of any
of these federal and state fraud and abuse laws and regulations could have a material adverse effect on a supplier’s liquidity
and financial condition. An investigation into the use of a device by physicians may dissuade physicians from recommending that
their patients use the device. This could have a material adverse effect on our ability to commercialize the GlucoTrack® model
DF-F.
The
Privacy Provisions of HIPAA
In
the United States, HIPAA, among other things, protects the privacy and security of individually identifiable health information
by limiting its use and disclosure. HIPAA directly regulates “covered entities,” such as healthcare providers, insurers
and clearinghouses, and regulates “business associates,” with respect to the privacy of patients’ medical information.
All entities that receive and process protected health information are required to adopt certain procedures to safeguard the security
of that information. It is uncertain whether we would be deemed to be a covered entity under HIPAA and, owing to changes in the
law, it is uncertain, based on our current business model, whether we would be a business associate. Nevertheless, we will likely
be contractually required to physically safeguard the integrity and security of any patient information that we receive, store,
create or transmit in the United States. If we fail to adhere to our contractual commitments, then our physician, hospital or
insurance customers may be subject to civil monetary penalties, which could adversely affect our ability to market our devices.
Changes in the law wrought by the provisions of Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted
as part of the American Recovery and Reinvestment Act of 2009, increase the duties of business associates and covered entities
with respect to protected health information that thereby subject them to direct government regulation, increasing its compliance
costs and exposure to civil monetary penalties and other government sanctions. While HITECH does not alter the definition of a
business associate, it makes it more likely that covered entities with whom we are likely to do business in the United States,
if and when we receive FDA approval to market the GlucoTrack® model DF-F in the United States, will require us to enter into
business associate agreements.
Intellectual
Property
We
have received the following patents:
A
Method Of Monitoring Glucose Level
Country
|
Patent
Number
|
Australia
|
2004264570
|
Canada
|
2,536,133
|
China
|
ZL200480023885.1
|
Europe
|
1656065
|
India
|
249084
|
Israel
|
173695
|
Japan
|
4538691
|
Korea
|
926155
|
Mexico
|
279290
|
Philippines
|
1-2006-500331
|
Russia
|
2376927
|
South
Africa
|
2006/00989
|
USA
|
6,954,662
|
Device
For Non-Invasively Measuring Glucose
Country
|
Patent
Number
|
Australia
|
2011246910
|
China
|
ZL
201180021344.5
|
Europe
|
EP
2 563 222
|
Hong
Kong
|
1180204
|
Israel
|
222464
|
Japan
|
5585801
|
Korea
|
10-1754941
|
Russia
|
2532498
|
South
Africa
|
2012/07766
|
Taiwan
|
I
445519
|
USA
|
8235897
|
Canada
|
2797623
|
Individual
Measuring Channels For Non-Invasively Measuring Glucose
Country
|
Patent
Number
|
Australia
|
2014202341
|
China
|
2014
10289 7261
|
Japan
|
6032444
|
Taiwan
|
103121838
|
Hong
Kong
|
15100403.4
|
Ear
Clip For Medical Monitoring Device
Country
|
Patent
Number
|
Australia
|
2014229190
|
China
|
2014
8000 17994
|
Europe
|
2967345
|
Israel
|
225182
|
Korea
|
10-1650910
|
USA
|
9713446
|
Japan
|
6202290
|
Design
Registrations
Hinge
Pin Joint
Country
|
Patent
Number
|
China
|
ZL
201330108244.8
|
China
|
ZL
201330108248.6
|
Europe
|
2216028-0001
|
Europe
|
2216028-0002
|
India
|
256225
|
Israel
|
53821
|
Japan
|
2013-021104
|
Korea
|
30-2013-0046668
|
Philippines
|
3-2013-001024
|
Taiwan
|
102305953
|
USA
|
D747173
|
Ear
Clip
Country
|
Patent
Number
|
China
|
2013
3051 28883
|
Europe
|
2321547-0001
|
India
|
257578
|
Japan
|
1503898
|
Korea
|
30-0789229
|
Philippines
|
3-2013-001218
|
Taiwan
|
102307257
|
Brazil
|
BR30
2013 005388 1
|
Measuring
Device
Country
|
Patent
Number
|
China
|
ZL201330512460.9
|
Temperature
Sensor
Country
|
Patent
Number
|
China
|
ZL
201330512636.0
|
Europe
|
2341057-0001
|
We
believe that intellectual property is important to our business and to the medical device industry overall. We rely on a combination
of patent, copyright and other intellectual property laws, trade secrets, nondisclosure agreements and other measures to protect
our intellectual property and proprietary rights.
We
understand the importance of obtaining patent and trade secret protection for new technologies, products and processes. Our success
will depend in large part on our ability to file for and obtain patent protection of our principal products and procedures, to
defend existing or future patents, to maintain trade secrets and to operate without infringing upon the proprietary rights of
others.
We
believe that intellectual property is important to our business and to the medical device industry overall. We rely on a combination
of patent, copyright and other intellectual property laws, trade secrets, nondisclosure agreements and other measures to protect
our intellectual property and proprietary rights.
We
understand the importance of obtaining patent and trade secret protection for new technologies, products and processes. Our success
will depend in large part on our ability to file for and obtain patent protection of our principal products and procedures, to
defend existing or future patents, to maintain trade secrets and to operate without infringing upon the proprietary rights of
others.
We
have obtained the above-mentioned issued patents covering our technologies related to the GlucoTrack® measurement process
and our devices in the United States, and depending on the patent, in various countries in Europe, the Far East, the Pacific,
Africa and Latin America. Our patents expire between 2023 and 2031. Patent applications for these products are pending in
several jurisdictions. We have also obtained a patent for our ear clip in a smaller number of jurisdictions and have applications
pending for this product in a number of jurisdictions. We also have design patents granted and pending for various aspects of
our device.
We have obtained trademark
registrations for GlucoTrack® in 24 countries, including the US, Europe, China and Israel, and also own an allowed trademark
application for GlucoTrack® in Canada. Trademark registrations were issued in ten countries for “JUST CLIP
IT,” including France and China, and additional applications are pending in three countries, including the United States.
In addition, trademark registrations were issued in seven countries for “YOUR TRACK TO HEALTH,” including France and
China, and additional applications are pending in three countries, including the United States. Trademark registrations have been
issued in Israel to register “Integrity,” the Company’s logo and the GlucoTrack logo. Registration have issued
in Hong Kong and Taiwan and are pending in China and Singapore to register GlucoTrack in Chinese characters. Our application in
South Korea to register GlucoTrack in Korean characters has been allowed.
We
believe that our patents and products do not and will not infringe patents or violate proprietary rights of others, although it
is possible that our existing patent rights may not be valid or that infringement of existing or future patents or proprietary
rights may occur. Litigation may be necessary to defend or enforce our patent rights or to determine the scope and validity of
the proprietary rights of others. Defense and enforcement of patent claims can be expensive and time consuming, even in those
instances in which the outcome is favorable and could result in the diversion of substantial resources and management time
and attention from our other activities. An adverse outcome could subject us to significant liability to third parties, require
us to obtain licenses from third parties, require us to alter our products or processes, or require that we cease altogether any
related research and development activities or product sales.
Patent
protection is highly uncertain and involves complex legal and factual questions and issues. The patent application and issuance
process can be expected to take several years and entails considerable expense. There can be no assurance that patents will be
issued as a result of any applications or that any patents resulting from such applications or our existing patents will be sufficiently
broad to afford protection against competitors with similar or competing technology. Patents that we obtain may be challenged,
invalidated or circumvented, or the rights granted under such patents may not provide us with any competitive advantages.
Competition
The
market for blood glucose monitoring devices is intensely competitive, subject to rapid change and significantly affected by new
product introductions. Four companies, Roche Diesetronic, a division of Roche Diagnostics; LifeScan, Inc., a division of Johnson
& Johnson; Abbott Laboratories; and Ascensia, a spin off from the Bayer Corporation, currently account for substantially all
of the worldwide sales of self-monitored glucose testing systems. These competitors’ products use a meter and disposable
test strips to test blood obtained by pricking the finger or, in some cases, the palm or forearm.
Within
the last few years, Continuous Glucose Monitoring (CGM) devices have been introduced into the market and will compete with the
GlucoTrack® model DF-F and our future devices, if any. Currently, three different brands have obtained FDA clearance to market,
and are selling, CGM devices in the U.S. and EU markets. These brands are sold by Medtronic plc., Abbott Laboratories (not available
in the U.S.) and Dexcom, Inc.. CGM devices are invasive devices, in which a needle is inserted under the skin (either in the abdomen
or the upper arm) and measures interstitial fluid. Although we cannot predict what standards will be employed by applicable regulatory
authorities as we seek FDA clearance, the results achieved by the GlucoTrack® model DF-F in our safety and performance clinical
trial conducted in 2012 and 2013 were similar to the results obtained from the CGM devices that have been introduced to the market,
as of the time of their introduction.
Abbott
FreeStyle Libre is a relatively new device which was introduced to the market during 2014 and is targeted for Type 1 and Type
2 diabetics. It comprises a disk-shaped glucose sensor that is inserted into the upper arm and must be replaced every two weeks.
In order to receive a reading, the user scans the device over the sensor and receives an immediate reading.
In
addition, other companies are developing non-invasive glucose testing devices and technologies that could compete with our devices.
There are also a number of academic and other institutions involved in various phases of technology development regarding blood
glucose monitoring devices. We believe that the majority of non-invasive glucose monitors in development require frequent calibrations
(from a few hours to a few days, compared to the GlucoTrack® model DF-F, which has a demonstrated efficacy period of six months
from the initial calibration). Among the companies developing non-invasive glucose testing devices is Echo Therapeutics, Inc.
Other companies developing continuous measurement devices, based on minimally invasive methods, such as implants or subdermal
needles include Medtronic, Inc., Abbot Laboratories and Dexcom, Inc.
Some
of our competitors are either publicly traded or are divisions of publicly-traded companies, and they enjoy several competitive
advantages, including:
|
●
|
significantly
greater name recognition;
|
|
|
|
|
●
|
established
relations with healthcare professionals, customers and third-party payors;
|
|
|
|
|
●
|
established
distribution networks;
|
|
|
|
|
●
|
additional
lines of products, and the ability to offer rebates or bundle products to offer higher
discounts or incentives to gain a competitive advantage;
|
|
|
|
|
●
|
greater
experience in conducting research and development, manufacturing, clinical trials, obtaining regulatory approval for products
and marketing approved products; and
|
|
|
|
|
●
|
greater
financial and human resources for product development, sales and marketing, and patent litigation.
|
Some
of our other non-publicly traded competitors also enjoy these competitive advantages. As a result, we cannot assure that we will
be able to compete effectively against these companies or their products.
To
our knowledge, a summary of potential competitors with non-invasive products in development is set forth below in Figure B.
Figure
B
Company
|
Product
|
Technology
|
Calibration
Required
|
Measurement
Type
|
Technology
Description
|
Mediwise
|
Glucowise
|
Radiowave
spectroscopy
|
Yes
|
Spot
|
Measures
blood glucose in capillaries using high-frequency radio waves. Includes a wearable sensor and displays the data on smartphone.
Integrates a range of measurements including exercise, diet, body mass index, medication and illness and includes cloud-based
data management system to store historical Glucowise data.
|
Cnoga
|
TensorTip
CGM Combo Glucometer
|
Optical
lookup table
|
Yes
|
Spot
|
Four
LED signals are beamed through the finger; color image sensor executes a special algorithm
|
Diamontech
|
DMT
Pocket / DMT Band
|
Mid-infrared
absorption spectroscopy
|
Yes
|
Spot
|
Uses
mid-infrared pulses from an infrared laser to excite glucose molecules in the interstitial layer of skin. Absorption of these
pulses depends on the concentration of glucose and results in a heat wave migrating to the skin surface, where it is picked
up by photo-thermal detection.
|
Eser
|
GlucoGenius
|
Metabolic
heat confirmation (MHC)
|
Yes
|
Spot
|
Combination
of 9 independent measurements that are performed simultaneously and based on method of metabolic heat conformation (MHC) by
radiation, convection and evaporation with electromagnetic technologies. The device integrates 3 types of sensors: temperature,
humidity and infrared.
|
The
GlucoTrack® model DF-F does not directly measure the glucose level concentration in the blood. Rather, it measures several
physiological phenomena that are correlated with the glucose level. In order to correlate between the measured signal and the
glucose level, a translation is needed. This translation is accomplished through the individual calibration of the device by reference
to a measurement obtained from an invasive device.
Non-invasive
devices under different stages of development generally require frequent recalibration. For example, GlucoWatch, a single non-invasive
product for glucose trend analysis that was previously approved for sale by the FDA, but which is no longer available commercially,
required recalibrations approximately every 13 hours. The main reasons for calibration are that tissue parameters generally fluctuate
in the area of the measurement and are sensitive to the location of the sensor and the impact of potential disturbances. Disturbances
are less frequent in the earlobes, where the GlucoTrack® model DF-F takes its measurements. Utilizing three channels
simultaneously reduces the noise contribution in the measurement. In addition, the personal ear clip contains sensors to help
users attach the device to the proper part of the ear lobe.
The
GlucoTrack® model DF-F has received CE Mark approval, which allows us to market and sell the GlucoTrack® model DF-F glucose
monitoring device in EU member countries that have adopted the MDD without being subject to additional national regulations with
regard to demonstration of performance and safety. While the MDD is applicable throughout the EU, it requires only a minimum level
of harmonization among member countries. Accordingly, member countries may apply and enforce the MDD’s terms differently,
and certain EU member countries may request or require performance and/or safety data additional to the MDD’s requirements
from time to time, on a case-by-case basis. Moreover, the MDD notwithstanding, because the regulatory regimes of the EU member
countries are significantly diverse, it is difficult to predict future regulatory developments and risks. The GlucoTrack®
model DF-F has not yet been cleared or approved for commercial sale in any other jurisdiction, including the United States. See
“
Government Regulation - Regulation of the Design, Manufacture and Distribution of Medical Devices
” above for
a discussion of the approval process for commercial sale in the United States. There can be no assurance that approval
for commercial sale in any additional jurisdiction will be obtained on a timely basis or at all.
Recent
Corporate Developments
On
March 23, 2017, the Board of Directors of the Company (the “Board”) appointed Angela Strand, who
has
served as one of Company’s directors since March 2016, as Vice Chairperson of the Board.
On
April 7, 2017, the Board approved an amendment to the 2010 Incentive Compensation Plan of the Company (the “Plan”)
to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 1,000,000 shares
to 5,625,000 shares.
On February 15, 2018, the Board approved another amendment to the Plan
to further increase the number of shares of common stock reserved for issuance under the Plan to 7,000,000 shares. On March 23,
2018, stockholders of the Company approved the two amendments to the Plan adopted by the Board as of April 7, 2017 and February
15, 2018.
Effective
April 7, 2017 (the “Gal Effective Date”), the Company and Integrity Israel entered into a letter agreement with Avner
Gal whereby Mr. Gal separated from his employment and directorship at the Company to act as a part time consultant to the Company
(the “Gal Agreement”). Pursuant to the terms of the Gal Agreement, and as consideration for Mr. Gal’s
separation from employment and services as a consultant, the Company agreed, among other things, to (a) pay Mr. Gal an amount
equal to his salary and other financial benefits Mr. Gal was entitled to receive under the Employment Agreement entered into by
and between Integrity Israel and Mr. Gal in October 2010 (the “Gal Employment Agreement”), that would have been paid
to Mr. Gal during the 180-day period from the date of a written termination notice, in lieu of such prior notice; (b) modify the
payment subsequent to the termination of the employment from six-month salary to 24-month salary, including all the benefits mentioned
in the Gal Employment Agreement, provided Mr. Gal does not work or provide services to a company in direct competition with the
Company; (c) accelerate the vesting of 88,259 outstanding unvested options to purchase shares of Common Stock, at an exercise
price per share equal to $6.25, held by Mr. Gal as of the Gal Effective Date (since the original performance conditions were not
expected to be satisfied as of the date of the modification of the terms, the fair value of such grant was measured based on the
fair value of the modified award at the modification date; such amount was measured as approximately $51,000); (d) extend
the term of all outstanding vested and unvested options held by Mr. Gal to be exercisable for five years from the Gal Effective
Date (with respect to all vested options, at the modification date the company recognized compensation cost in an amount equal
to the excess amount of the fair value of the modified award as of the modification date over the fair value of the original award
immediately); and (e) grant Mr. Gal an option to purchase up to 300,000 shares of Common Stock of the Company having an exercise
price per share equal to $4.50 and an option to purchase up to an additional 50,000 shares of Common Stock of the Company having
an exercise price per share equal to $7.75. These options vest monthly over a 24 months period following the date of grant.
Effective
April 7, 2017, the Company entered into an amendment to the employment agreement (the “Graham Employment Amendment”)
with John Graham, whom the Company appointed as Chief Executive Officer on March 20, 2017, to modify the base compensation provision
and the equity compensation provision under that certain Employment Agreement, dated March 20, 2017 (the “Graham Effective
Date”), by and between the Company and Mr. Graham. Pursuant to the terms of the Graham Employment Amendment, (a) Mr. Graham’s
base compensation was modified such that he receives a base salary of $500,000 per year, as well as a one-time payment of $375,000
paid to Mr. Graham upon commencement of Mr. Graham’s employment with the Company which amount was recognized as an expense
as of the employment commencement date, and (b) the vesting periods of Mr. Graham’s options to purchase Common Stock were
modified whereby (1) 307,754 shares of Common Stock underlying Mr. Graham’s option to purchase Common Stock at an exercise
price of $4.50 per share (the “$4.50 Options”) vested immediately, (2) 923,262 of the $4.50 Options vest on the six
month anniversary of the Graham Effective Date, and (3) the remaining 442,980 of the $4.50 Options as well as Mr. Graham’s
remaining unvested options granted pursuant to the Graham Employment Amendment vest on the two (2) year anniversary of the Graham
Effective Date. According to the agreement between the Company and Graham, Mr. Graham is also
eligible
to earn an annual performance bonus between 35-72% of his base salary (of which $225,000 is guaranteed as performance bonus for
his first year), subject to certain performance criteria approved and adopted in September 2017 by the Compensation Committee
and the Board and, provided that Mr. Graham continues to be an employee through and on March 15, 2018.
Effective
April 7, 2017, Integrity Israel entered into an amended and restated personal employment agreement (the “Malka Employment
Agreement”) with David Malka for his continued service as Vice President of Operations of the Company and Integrity Israel,
effective as of March 20, 2017 (the “Malka Effective Date”). Pursuant to the terms of the Malka Employment Agreement,
Mr. Malka (a) receives a base monthly salary of NIS 20,000 (approximately $5,508 based on an exchange rate of 3.63 NIS / 1 USD
in effect on August 8, 2017), which may increase to NIS 35,000 per month (approximately $9,639 using the same exchange rate) in
the event certain performance milestones are met; (b) is eligible to earn an annual performance bonus between 420-864% of his
base salary, subject to certain performance criteria to be established by the Board within the first ninety (90) days of each
fiscal year; (c) is eligible to earn a retention bonus equal to 60% of his aggregate base salary earned through the one-year anniversary
of the Malka Effective Date, payable thirty days following the one-year anniversary of the Malka Effective Date and provided that
Mr. Malka remains employed with Integrity Israel through and on the one-year anniversary of the Malka Effective Date; (d) received
a modification to the terms of his option to purchase 26,478 shares of Common Stock at an exercise price per share equal to $6.25
whereby the unvested portion of such options will accelerate and will be immediately exercisable, effective as of the Malka Effective
Date (since the original performance conditions were not expected to be satisfied as of the date of the modification of the terms,
the fair value of such grant was measured based on the fair value of the modified award at the modification date); and (e)
received 361,875 options as certain additional equity awards pursuant to the Plan and under the terms and conditions as set forth
in the Malka Employment Agreement. In addition, the Malka Employment Agreement provides for the payment of certain social
benefits and the use of a company car. The Malka Employment Agreement is terminable by Integrity Israel and Mr. Malka on
90 days’ prior written notice (the “Malka Notice Period”), without cause, or immediately by Integrity Israel
for cause as defined in the Malka Employment Agreement. Integrity Israel may terminate Mr. Malka’s employment without
cause prior to the expiration of the Malka Notice Period, but will be required to pay Mr. Malka a severance fee equal to his base
salary plus the financial value of all other benefits Mr. Malka would have been entitled to receive in respect of the portion
of the Malka Notice Period which was forfeited.
On
May 4, 2017, the Board unanimously voted to appoint Angela Strand, a member of the Board of Directors, as the interim Chief Strategy
Officer of the Company, effective as of May 1, 2017 through September 30, 2017. On May 5, 2017, the Company entered into a letter
agreement with Ms. Angela Strand confirming her appointment as interim Chief Strategy Officer of the Company. Pursuant to
the terms of the letter agreement, Ms. Strand received aggregate compensation of $150,000 for her service during the term of employment,
paid monthly on the schedule mutually agreed upon by the parties.
On
May 23, 2017, the Board approved the salary increase to NIS 35,000 per month pursuant to the Malka Employment Agreement, notwithstanding
the foregoing performance goal requirement, as consideration for Mr. Malka’s continued service as Vice President of Operations
of the Company and Integrity Israel.
On
May 23, 2017, the Board approved the following compensation for all non-employee directors and interim officers serving on the
Board:
|
●
|
an
annual cash payment to each non-employee director and interim officer of the Company in the amount of $35,000, payable in
four equal quarterly installments of $8,750 each on the last day of each calendar quarter commencing with the fourth quarter
of 2017, subject to their continued service as of each such date;
|
|
|
|
|
●
|
an
additional annual cash payment to each member of a Board committee who is not the Chairperson of that particular committee
in the amount of $5,000, payable in four equal quarterly installments of $1,250 each on the last day of each calendar quarter
commencing with the second quarter of 2017, subject to their continued service as of each such date;
|
|
|
|
|
●
|
an
additional annual cash payment to the chairperson of a Board committee in the amount of $12,500, payable in four equal quarterly
installments of $3,125 each on the last day of each calendar quarter commencing with the second quarter of 2017, subject to
their continued service as of each such date;
|
|
|
|
|
●
|
the
grant to each non-employee director and each interim officer of the Company of a one-time award of options to purchase up
to an aggregate of 14,894 shares of Common Stock, at an exercise price of $4.50, under and pursuant to the Plan, which options
vest in 12 equal monthly increments commencing as of June 1, 2017 (subject to their continued service as of each such date)
and have a term of 10 years;
|
|
|
|
|
●
|
the
grant to each non-employee director and each interim officer of the Company of an award of Restricted Stock Units (“RSUs”),
to be granted on June 1, 2017 and vesting on June 1, 2018, with a fair value of $45,000 based on the 30-day volume weighted
average price of the Company’s Common Stock on June 1, 2017, subject to their continued service on and through such
date; and
|
|
|
|
|
●
|
an
additional annual fair value payment to the vice chairperson of the Board in the amount of $20,000, payable in RSUs under
the same vesting terms.
|
On
May 23, 2017, the Board appointed Michael Hauck to serve as a director of the Company, effective on that date. The Board
further appointed Mr. Hauck to serve as a member of the Nominating and Corporate Governance Committee of the Board as well as
on the Compensation Committee of the Board. There are no arrangements or understandings between Mr. Hauck and any other person
pursuant to which Mr. Hauck was selected as a director. There are no relationships between Mr. Hauck and the Company that
would require disclosure under Item 404(a) of Regulation S-K of the Exchange Act.
On
May 23, 2017, the Board established an Audit Committee of the Board and appointed each of Leslie Seff and Revan Schwartz to serve
as members of the committee. Mr. Schwartz will serve as chairperson of the Audit Committee. The Board determined that each
of the members of the Audit Committee designated above is independent pursuant to the required standards set forth in Rule 10A-3(b)
of the Exchange Act, based on an evaluation of the relationships between the Company and each of the members.
On
June 7, 2017, the Board appointed David Podwalski as the Chief Commercial Officer of the Company, effective as of June 26, 2017
(the “Podwalski Effective Date”). On June 26, 2017, the Company entered into an employment agreement (the “CCO
Employment Agreement”) with Mr. Podwalski to serve as Chief Commercial Officer of the Company. Under the CCO Employment
Agreement, Mr. Podwalski (1) receives a base salary of $240,000 per year; (2) receives a sign-on bonus of $25,000, payable on
the six month anniversary of the Podwalski Effective Date, subject to his continued employment through and on such payment date;
(3) is eligible to receive an annual performance bonus, having a minimum bonus opportunity equal to 20% of his current base salary
based upon 80% achievement of performance criteria (the “Minimum Performance Goal”), a target bonus opportunity equal
to 25% of his current base salary based upon 100% achievement of performance criteria, and a maximum bonus opportunity equal to
37.5% of his current base salary based upon 150% achievement of performance criteria (the “Maximum Performance Goal”),
provided, however, that such performance bonus will be determined using straight-line interpolation of the level of achievement
between the Minimum Performance Goal and the Maximum Performance Goal; and (4) receive an initial stock option grant to purchase
shares of Common Stock equal to 1% of the total fully diluted shares of Common Stock as of the Podwalski Effective Date, with
an exercise price of $4.50 per share or the fair market value of a share of Common Stock on the grant date, whichever is greater,
vesting monthly over a three year period commencing on the Podwalski Effective Date, subject to his continued employment through
and on each such vesting date (the total fair value of the grant as of the Podwalski Effective Date is approximately $270,000).
The
CCO Employment Agreement is terminable by the Company on 90 days written notice and by Mr. Podwalski on 30 days written notice.
The CCO Employment Agreement is immediately terminable by the Company for cause, as defined in the CCO Employment Agreement, without
the payment of severance. The CCO Employment Agreement contains non-compete obligations applicable during the term of the
agreement and for one year thereafter and confidentiality obligations that survive the termination of the agreement indefinitely.
In
September 2017, the Compensation Committee and the Board approved an increase of Sami Sassoun, Chief Financial Officer, and Eugene
Naidis’s, V.P of Research and Development, base salaries to NIS 47,250 per month (approximately US$161,513 annually) and
NIS 43,200 (US$147,660 annually), respectively, which shall only start to take effect after the Company has completed the next
round of financing and has sufficient funds to finance operations. The Compensation Committee and the Board also approved certain
on-target performance bonus at 35% of Mr. Sassoun and Mr. Naidis’s respective annual base salary and grant of stock options
(pursuant to the Company’s 2010 Incentive Compensation Plan, as amended) equating to 1% (292,924 options) of the fully diluted
number of shares of the Company after the closing of the offering of Series C Units, with a strike price of US$4.50, with three-year
monthly vesting commencing on the first month after the effective date.
Director
Appointments
On
March 17, 2016, the Board approved an increase in the size of the Board from four directors to five directors and appointed Leslie
Seff and Angela Strand to serve as directors of the Company to fill the vacancies created by the resignation of Zvi Cohen and
by the increase in the size of the Board, effective upon their acceptance of such appointments. Mr. Seff and Ms. Strand accepted
their appointments effective March 23, 2016.
On
November 9, 2016, the Board approved an increase in the size of the Board from five directors to seven directors and appointed
Philip Darivoff and Revan Schwartz to serve as directors of the Company to fill the vacancies created by the increase in the size
of the Board, effective on that date.
There
are no arrangements or understandings between Mr. Darivoff, Ms. Strand and Mr. Seff and any other person pursuant to which Mr.
Darivoff, Ms. Strand and Mr. Seff were selected as directors. Mr. Schwartz was appointed to the Board by Andrew Garrett, Inc.
(“AGI”), pursuant to the terms of a placement agent agreement between AGI and the Company.
The
Company entered into letter agreements with each of Ms. Strand, Mr. Seff, Mr. Darivoff and Mr. Schwartz establishing their compensation.
On
March 20, 2017, the Board unanimously voted to appoint John Graham as the Chief Executive Officer and Director of the Company
commencing on March 20, 2017. On March 26, 2017, the Board voted to appoint Mr. Graham as the Chairman of the Board of the Company.
On
May 23, 2017, the Board appointed Michael Hauck to serve as a director of the Company, effective on that date. The Board
further appointed Mr. Hauck to serve as a member of the Nominating and Corporate Governance Committee of the Board as well as
on the Compensation Committee of the Board. There are no arrangements or understandings between Mr. Hauck and any other person
pursuant to which Mr. Hauck was selected as a director. There are no relationships between Mr. Hauck and the Company that
would require disclosure under Item 404(a) of Regulation S-K of the Exchange Act.
On
May 23, 2017, the Board established an Audit Committee of the Board and appointed each of Leslie Seff and Revan Schwartz to serve
as members of the committee. Mr. Schwartz was also appointed chairperson of the Audit Committee. The Board determined that
each of the members of the Audit Committee designated above is independent pursuant to the required standards set forth in Rule
10A-3(b) of the Exchange Act, based on an evaluation of the relationships between the Company and each of the members.
Director
Resignations
On
March 20, 2017, David Malka resigned from his position as a director of the Company. Mr. Malka will continue as the Vice President
of Operations and as a director of Integrity Israel. Mr. Malka will also act as an observer to all Board meetings, except as may
be prohibited by the attorney-client privilege under applicable law. Mr. Malka resigned as part of the reorganization of management
and his resignation is not a result of any disagreement with the Company regarding its operations, policies or practices.
On
March 26, 2017, Philip Darivoff resigned as a director of the Company, effective immediately. Mr. Darivoff’s resignation
was not a result of any disagreement with the Company regarding its operations, policies or practices.
Corporate
Information
Our
principal offices are located at 19 Ha’Yahalomim St., Ashdod, Israel 7760049 and our telephone number is 972-8-675-7878.
Our website address is http://www.integrity-app.com; the reference to such website address does not constitute incorporation by
reference of the information contained on the website and such information should not be considered part of this prospectus. There
is no relationship between us and Integrity Applications, Incorporated, the engineering and software services company based in
Chantilly, Virginia.
Board
and Committees
We
have six members on our Board, four of whom are independent. The Board has an Audit Committee, Compensation Committee and
a Nominating and Corporate Governance Committee, each consisting solely of independent directors. We are continuing to consider
expansion of the Board and the establishment of additional appropriate Board committees to support the Company.
Employees
As of June 7 , 2018,
we had 23 full-time employees and 1 part-time employees. None of our employees are represented by a collective bargaining agreement.
In addition, as of June 7 , 2018, we had 2 full-time consultants.
Property
Integrity
Israel leases approximately 5,500 square feet of office space in the city of Ashdod, Israel for its principal offices. The lease
term began on December 1, 2015 for a period of 5 years which can be extended for an additional 5 years at the option of the Company.
Monthly lease payments including maintenance are approximately $10,000. The Company estimates that its minimal rent and maintenance
payments will be approximately $120,000 per year over each of the next 5 years. In connection with the lease agreement, Integrity
Israel provided the landlord a bank guarantee in the amount of approximately $38,500 (NIS 137,162 based on an exchange
rate of 3.56 as of May 28, 2018) that can be exercised by the landlord in the case Integrity Israel fails to pay the monthly rent
payments. The guarantee is renewed on an annual basis for a period of 5 years and is secured by funds on deposit with the bank,
which generally must be sufficient to cover the principal amount guarantee.
Legal
Proceedings
We
are not presently a party to any material litigation. We may, however, become involved in litigation from time to time relating
to claims arising in the ordinary course of our business. These claims, even if not meritorious, could result in the expenditure
of significant financial and managerial resources.
Significant
Accounting Policies
Our
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States
(“U.S. GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions
and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue,
expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current
trends and other factors that management believes to be relevant at the time our consolidated financial statements are prepared.
On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial
statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot
be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.
As
applicable to the consolidated financial statements included in this Registration Statement, the most significant estimates and
assumptions relate to (i) the fair value estimate of the warrants with down-round protection, (ii) the allocation of the proceeds
and the related issuance costs of the Series D Units, (iii) the going concern assumption, (iv) measurement of stock based
compensation, and (v) determination of net realizable value of inventory.
Our
significant accounting policies are described in Note 2, Summary of Significant Accounting Policies, of the Notes to the Consolidated
Financial Statements appearing in our Annual Report on Form 10-K for the year ended December 31, 2017 and the Quarterly Report
on Form 10-Q for the period ended March 31, 2018. Our management believes that, as for the financial statements for the periods
included in this report, the going concern assessment is a critical accounting policy. However, due to the early stage of operations
of the Company, there are no other accounting policies that are considered to be critical accounting policies by management.
Going
Concern Uncertainty
The
development and commercialization of our product will require substantial expenditures. We have not yet generated any material
revenues and have incurred substantial accumulated deficit and negative operating cash flows. We currently have no sources
of recurring revenue and are therefore dependent upon external sources for financing our operations. There can be no assurance
that we will succeed in obtaining the necessary financing to continue our operations. As a result, our independent registered
public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.
SECURITY
OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS, DIRECTORS AND EXECUTIVE OFFICERS
The
following table sets forth information known to us regarding the beneficial ownership of shares of our Common Stock and Preferred
Stock as of the date of this prospectus by: (i) each person known by us to be the beneficial owner of more than 5% of the outstanding
shares of Common Stock and/or Preferred Stock; (ii) each of our executive officer and director; and (iii) all executive officers
and directors as a group. In accordance with the rules and regulations of the SEC, in computing the number of shares
of Common Stock or Preferred Stock (as applicable) beneficially owned by a person and the percentage ownership of that person,
shares issuable through the exercise of any option, warrant or right, through conversion of any security held by that person that
are currently exercisable or that are exercisable within 60 days are included. These shares are not, however, deemed
outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated,
we believe that all persons named in the table below have sole voting and investment power with respect to all securities that
they beneficially own (within the meaning of Rule 13d-3 of the Exchange Act). Holders of shares of our Preferred Stock
are entitled to vote such shares on an as converted to Common Stock basis; the Preferred Stock does not entitle the holders thereof
to separate voting rights.
Name
of Beneficial Owner
|
|
Class
of Security
|
|
Number
of
Shares
Beneficially
owned
|
|
|
Percent of Class (1)
|
|
John
Graham (2)
|
|
Common
Stock
|
|
|
1,231,016
|
|
|
|
8.3
|
%
|
Dr.
Robert Fischell (3)
|
|
Common
Stock
|
|
|
78,457
|
|
|
|
0.6
|
%
|
Angela
Strand (4)
|
|
Common
Stock
|
|
|
53,133
|
|
|
|
0.4
|
%
|
Leslie
Seff (5)
|
|
Common
Stock
|
|
|
38,688
|
|
|
|
0.3
|
%
|
Revan
Schwartz (6)
|
|
Common
Stock
|
|
|
29,243
|
|
|
|
0.2
|
%
|
Michael
Hauck
(7)
|
|
Common
Stock
|
|
|
8,688
|
|
|
|
0.1
|
%
|
David
Malka (8)
|
|
Common
Stock
|
|
|
363,962
|
|
|
|
2.6
|
%
|
Sami
Sassoun (9)
|
|
Common
Stock
|
|
|
85,436
|
|
|
|
0.6
|
%
|
Eugene
Naidis (10)
|
|
Common
Stock
|
|
|
110,303
|
|
|
|
0.8
|
%
|
David
Podwalski (11)
|
|
Common
Stock
|
|
|
104,933
|
|
|
|
0.8
|
%
|
All
Executive Officers and Directors as a group (10 persons)
|
|
Common
Stock
|
|
|
2,103,859
|
|
|
|
14.6
|
%
|
Principal
Stockholders
|
|
|
|
|
|
|
|
|
|
|
Y.H
Dimri Holdings ( 12 )
|
|
Common
Stock
|
|
|
1,160,650
|
|
|
|
8.5
|
%
|
Vayikra
Capital LLC ( 13 )
|
|
Common
Stock , Series B Preferred Stock and Series C Preferred Stock
|
|
|
868,026
|
|
|
|
6.3
|
%
|
(1) Subject to a
9.99% beneficial ownership limitation applicable to all holders of the Preferred Stock, holders of Series A Preferred Stock, Series
B Preferred Stock and Series C Preferred Stock will vote together with the holders of Common Stock on an as-converted basis. Accordingly,
the percentages are based on an aggregate of 13,678,0341 shares, consisting of 7,588,715 shares of Common Stock, 83,556 shares
of Common Stock as fully converted from 376 shares of Series A Preferred Stock, 3,340,252 shares of common stock as fully converted
from 15,031 shares of Series B Preferred Stock and 2,667,511 shares of Common Stock as fully converted from 12,004 shares of Series
C Preferred Stock, each outstanding as of June 7 , 2018.
(2)
Of the options to purchase an aggregate of 3,077,540 shares of Common Stock granted to Mr. Graham under the Plan, 1,231,016 options
will be deemed vested within 60 days from the date of this prospectus. Pursuant to an employment agreement dated March 20, 2017,
amended on April 7, 2017, the Company issued to Mr. Graham upon his appointment as Chief Executive Officer of the Company (i)
a ten-year non-qualified stock option for the purchase of 559,414 shares of Common Stock at an exercise price of $5.41 per share,
vesting in full on March 20, 2019; (ii) a ten-year non-qualified stock option for the purchase of 844,130 shares of Common Stock
at an exercise price of $7.75 per share, vesting in full on March 20, 2019; (iii) an option to purchase 307,754 shares of Common
Stock at an exercise price of $4.50 per share, vested on April 7, 2017; (iv) an option to purchase 923,262 shares of Common Stock
at an exercise price of $4.50 per share, vest on September 20, 2017; and (v) an option to purchase 442,980 shares of Common Stock
at an exercise price of $4.50 per share, vest on March 20, 2019.
(3)
Of the options to purchase an aggregate of 41,560 shares of Common Stock granted to Mr. Fischell under the Plan, 34,113 options
will be deemed vested within 60 days from the date of this prospectus. In addition to vested options, this number also includes
43,103 shares of Common Stock owned by Mr. Fischell.
(4)
Of the options to purchase an aggregate of 41,560 shares of Common Stock granted to Ms. Strand under the Plan, 34,113 options
will be deemed vested within 60 days from the date of this prospectus. In addition to vested options, this number also includes
17,779 shares of Common Stock owned by Ms. Strand.
(5)
Of the options to purchase an aggregate of 41,560 shares of Common Stock granted to Mr. Seff under the Plan, 34,113 options will
be deemed vested within 60 days from the date of this prospectus. In addition to vested options, this number also includes 3,334
shares of Common Stock owned by Mr. Seff.
(6)
Of the options to purchase an aggregate of 41,560 shares of Common Stock granted to Mr. Schwartz under the Plan, 28,002 options
will be deemed vested within 60 days from the date of this prospectus.
(7)
Of the options to purchase an aggregate of 14,894 shares of Common Stock granted to Mr. Hauck under the Plan, 7,447 options will
be deemed vested within 60 days from the date of this prospectus.
(8)
Of the options to purchase an aggregate of 441,309 shares of Common Stock granted to Mr. Malka under the Plan, 220,163 options
will be deemed vested within 60 days from the date of this prospectus. In addition to vested options, this number also includes
123,695 shares of Common Stock owned by Mr. Malka.
(9)
Of the options to purchase an aggregate of 292,924 shares of Common Stock granted to Mr. Sassoun under the Plan, 69,163 options
will be deemed vested within 60 days from the date of this prospectus.
(10)
Of the options to purchase an aggregate of 292,924 shares of Common Stock granted to Mr. Naidis under the Plan, 69,163 options
will be deemed vested within 60 days from the date of this prospectus. In addition to vested options, this number also includes
24,867 shares of Common Stock owned by Mr. Naidis.
(11)
Of the options to purchase an aggregate of 290,585 shares of Common Stock granted to Mr. Podwalski under the Plan, 88,790 options
will be deemed vested within 60 days from the date of this prospectus.
(12)
The address of Y.H. Dimri Holdings is 1 Jerusalem St. Netivot, 87710 Israel. Y.H. Dimri is entitled to these subject to
the fulfillment of certain requirements. Yigal Dimri has voting and investment control over the shares held by Y.H. Dimri
Holdings.
(13)
Includes the following: (i) 440,248 shares of Common Stock; (ii) 138,889 shares of Common Stock issuable upon the conversion of
shares of Series B Preferred Stock; and (iii) 288,889 shares of Common Stock issuable upon the conversion of shares of Series
C Preferred Stock. The percentage of ownership is calculated based on the number of shares of Common Stock as converted. This
number does not include Series B-1 and Series B-2 Warrants owned by Vayikra Capital, LLC, the conversion of which is limited by
a beneficial ownership limitation that Vayikra Capital, LLC will not be permitted to exercise such warrants if such conversion
would cause such holder to beneficially own more than 9.99% of the outstanding number of shares of our Common Stock outstanding
after giving effect to such conversion. The address of Vayikra Capital, LLC is 1 Farmstead Road, Short Hills NJ, 07078. Philip
M. Darivoff has voting and investment control over the shares held by Vayikra Capital, LLC.
SELLING STOCKHOLDERS
The
following table sets forth the name of each selling stockholder and the number of shares of Common Stock that each selling stockholder
may offer pursuant to this prospectus. The majority of the shares of Common Stock being offered by the selling stockholders
hereunder were acquired by the selling stockholders in a private placement, which was completed on July 31, 2017. The
shares of Common Stock being offered by the selling stockholders hereunder consist of 2,667,540 shares of Common Stock issuable
upon conversion of our Series C Preferred Stock; 5,335,080 shares issuable upon the exercise of warrants. Except as
otherwise indicated, we believe that each of the beneficial owners and selling stockholders listed below has sole voting and investment
power with respect to such shares, subject to community property laws, where applicable. Unless otherwise noted, the
address of each stockholder is c/o Integrity Applications, Inc., PO Box 12143 Ashdod L3 7760049, Israel.
None
of the selling stockholders has had a material relationship with us other than as a stockholder at any time within the past three
years or has ever been one of our officers or directors. To the best of our knowledge, each of the selling stockholders
has purchased its shares of our Common Stock to be resold hereunder in the ordinary course of business and, at the time of
purchase, none of the selling stockholders was party to any agreement or understanding, directly or indirectly, with any person
to distribute the shares of our Common Stock to be resold by such selling stockholder under this Registration Statement.
In
accordance with the rules and regulations of the SEC, in computing the number of shares of Common Stock (as applicable) beneficially
owned by a person and the percentage ownership of that person, shares issuable through the exercise of any option, warrant or
right, through conversion of any security held by that person that are currently exercisable or that are exercisable within 60
days are included. These shares are not, however, deemed outstanding for the purpose of computing the percentage ownership
of any other person. Moreover, the chart below does not take reflect that holders of the Series C Preferred Stock will
not be permitted to convert their shares of Series C Preferred Stock if such conversion would cause such holder to beneficially
own more than 9.99% of the outstanding Common Stock.
|
|
Shares
Owned Prior to the Offering
|
|
|
Number
of Shares Offered
|
|
|
Shares
Owned After the Offering
|
|
Name
of Beneficial Owner
|
|
Number
|
|
|
Percent
(1)
|
|
|
|
|
|
Number
|
|
|
Percent
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AARON
HILLMAN
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
ADAM
BORIS DDS
|
|
|
8,467
|
|
|
|
*
|
|
|
|
-
|
|
|
|
8,467
|
|
|
|
*
|
|
ADAM
SACKSTEIN
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
AHARON
ORLANSKY
|
|
|
6,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
6,667
|
|
|
|
*
|
|
ALAN
ARMBRUST
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
ALAN
GARIN
|
|
|
18,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
18,667
|
|
|
|
*
|
|
ALAN
REIN
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
ALMA
DIVERSIFIED HOLDINGS LLC (2)
|
|
|
12,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
12,000
|
|
|
|
*
|
|
ALVIN
FUND LLC (3)
|
|
|
333,333
|
|
|
|
2.6
|
%
|
|
|
-
|
|
|
|
333,333
|
|
|
|
2.6
|
%
|
ANDREW
L PEARLMAN & DEBORAH
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
ANTHONY
P GULATI
|
|
|
5,100
|
|
|
|
*
|
|
|
|
-
|
|
|
|
5,100
|
|
|
|
*
|
|
ANTHONY
TOWEII & MRS JACQUELINE TOWELL JOINT WROS
|
|
|
32,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
32,667
|
|
|
|
*
|
|
ARNOLD
HILLIER
|
|
|
100,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
100,000
|
|
|
|
*
|
|
ARON
GREEN
|
|
|
43,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
43,333
|
|
|
|
*
|
|
BARRY
SHEMARIA
|
|
|
36,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
36,000
|
|
|
|
*
|
|
BERNARD
SISKIN
|
|
|
166,667
|
|
|
|
1.2
|
%
|
|
|
-
|
|
|
|
166,667
|
|
|
|
1.2
|
%
|
BILL
MINKLER
|
|
|
36,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
36,000
|
|
|
|
*
|
|
BIN
ZHANG & YING HUANG JT TEN
|
|
|
22,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
22,000
|
|
|
|
*
|
|
BRYAN
W CHETELAT
|
|
|
5,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
5,333
|
|
|
|
*
|
|
CARL
LUSTIG SEGREGATED ROLLOVER IRA (4)
|
|
|
6,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
6,667
|
|
|
|
*
|
|
CHARLES
CHRISTOPHER HAM
|
|
|
36,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
36,000
|
|
|
|
*
|
|
CHARLES
MORSE
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
CHRISTINE
MITTMAN
|
|
|
150,000
|
|
|
|
1.2
|
%
|
|
|
-
|
|
|
|
150,000
|
|
|
|
1.2
|
%
|
CLARENCE
KNIGHT ALDRICH TRUST (5)
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
CRAIG
ROBERTS
|
|
|
6,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
6,667
|
|
|
|
*
|
|
D
CARL LUSTIG III
|
|
|
391,333
|
|
|
|
3.0
|
%
|
|
|
-
|
|
|
|
391,333
|
|
|
|
3.0
|
%
|
DAREN
MASSAD
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
DAVID
JEWELL
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
DENNIS
K LARSON TRUST
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
DON
B MOSKOVITZ LIVING TRUST UAD 08/05/2002 (6)
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
DR
DAVID STAFFENBERG
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
DR
JAMES J SHEN AND LOUISE L SHEN JT WROS
|
|
|
100,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
100,000
|
|
|
|
*
|
|
DR
JAMES SHEN MDPC 401K PROFIT SHARING PLAN UAD 1/1/1994 (7)
|
|
|
156,667
|
|
|
|
1.2
|
%
|
|
|
-
|
|
|
|
156,667
|
|
|
|
1.2
|
%
|
DR
TOM D TODD
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
EARL
DAHLKOETTER
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
ERNEST
J CHORNYEI
|
|
|
166,667
|
|
|
|
1.3
|
%
|
|
|
-
|
|
|
|
166,667
|
|
|
|
1.3
|
%
|
GARY
A GELBFISH
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
GEOFFREY
GREEN
|
|
|
233,333
|
|
|
|
1.7
|
%
|
|
|
-
|
|
|
|
233,333
|
|
|
|
1.7
|
%
|
GOREN
BROTHERS LP (8)
|
|
|
120,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
120,000
|
|
|
|
*
|
|
GREGORY
S GENETTI
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
H
APPLEBAUM FAMILY TRUST DTD DECEMBER 29 2011 (9)
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
HIGH
CAPITAL FUNDING LLC (10)
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
IAN
SCOTT
|
|
|
22,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
22,000
|
|
|
|
*
|
|
IRA
F LEVY SEPERATE PROPERTY ACCOUNT (11)
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
J&C
JOHNSTONE LTD (12)
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
JAG
MUTI INVESTMENTS LLC (13)
|
|
|
152,000
|
|
|
|
1.1
|
%
|
|
|
-
|
|
|
|
152,000
|
|
|
|
1.1
|
%
|
JAM
123 LLC (14)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
JAMES
C CZIRR TRUST UAD 02202004 (15)
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
JAMES
F AND MARY L RYAN JT TEN/WROS
|
|
|
6,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
6,667
|
|
|
|
*
|
|
JAMES
J SHEN & LOUISE L SHEN JT WROS
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
JAMES
J SHEN MDPC401(K)PROFIT SHARING PLAN UAD 1/1/1994 (16)
|
|
|
136,667
|
|
|
|
1.1
|
%
|
|
|
-
|
|
|
|
136,667
|
|
|
|
1.1
|
%
|
JAMIE
P LEVINE
|
|
|
133,333
|
|
|
|
1.0
|
%
|
|
|
-
|
|
|
|
133,333
|
|
|
|
1.0
|
%
|
JAY
EISEN
|
|
|
6,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
6,667
|
|
|
|
*
|
|
JERRY
P HARMON
|
|
|
100,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
100,000
|
|
|
|
*
|
|
JOHN
BALLANYTNE
|
|
|
1,000,000
|
|
|
|
7.5
3%
|
|
|
|
-
|
|
|
|
1,000,000
|
|
|
|
7.3
|
%
|
JOHN
G KORMAN
|
|
|
38,600
|
|
|
|
*
|
|
|
|
-
|
|
|
|
38,600
|
|
|
|
*
|
|
JOHN
H ENGLISH & MORTEZ R ENGLISH JT TEN/WROS
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
JOHN
W BABICH
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
JOHN
W CLINGMAN
|
|
|
260,000
|
|
|
|
1.9
|
%
|
|
|
-
|
|
|
|
260,000
|
|
|
|
1.9
|
%
|
KENNETH
CHARTIER
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
KEYS
1996 FAMILY TRUST (17)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
LARRY
ROHER
|
|
|
23,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
23,333
|
|
|
|
*
|
|
MANJULA
MUKHOPADHYAY
|
|
|
76,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
76,667
|
|
|
|
*
|
|
MARK
POLLACK
|
|
|
50,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
50,000
|
|
|
|
*
|
|
MARTIN
ROSENMAN
|
|
|
137,667
|
|
|
|
1.0
|
%
|
|
|
-
|
|
|
|
137,667
|
|
|
|
1.0
|
%
|
MICHAEL
& PATRICIA PORTER JOINT TEN WROS
|
|
|
70,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
70,000
|
|
|
|
*
|
|
MICHAEL
KATZ
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
MICHAEL
ZARRA & AMY ZARRA JT TEN/WROS
|
|
|
46,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
46,667
|
|
|
|
*
|
|
MICHEAL
GINDER
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
MIKE
AVERY
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
MILAN
DESAI
|
|
|
20,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,333
|
|
|
|
*
|
|
MOORE
FAMILY TRUST (18)
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
O
BERNARD STARKMAN LIVING TRUST UAD 04/27/1998 (19)
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS CUST FOR KENNETH I RABOY IRA (20)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS CUSTODIAN FBO GARY J FADEN SEP IRA (21)
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUST FBO DR MORRIS FRANKLIN JR IRA
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUST FBO JAMES DENNY IRA (22)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUST FBO JAMES W DENNY III IRA (23)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUST FBO JAY EISEN ROTH IRA (24)
|
|
|
4,867
|
|
|
|
*
|
|
|
|
-
|
|
|
|
4,867
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUST FBO ROBERTA DENNY IRA (25)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO BRYAN W CHETELAT ROTH IRA (26)
|
|
|
5,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
5,000
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO DAVID MOORE IRA (27)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO ERIC FRANK IRA (28)
|
|
|
16,500
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,500
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO HALL B WHITAKER IRA (29)
|
|
|
3,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
3,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO JONATHAN MAYO IRA (30)
|
|
|
9,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
9,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO PAUL RUTHS IRA (31)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO ROBERTA DENNY IRA (32)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
RBC
CAPITAL MARKETS LLC FBO MARK RUTHS IRA (33)
|
|
|
166,667
|
|
|
|
1.2
|
%
|
|
|
-
|
|
|
|
166,667
|
|
|
|
1.2
|
%
|
RBCCM
CUSTODIAN FOR DEBORAH THOMAS STARNS IRA (34)
|
|
|
23,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
23,333
|
|
|
|
*
|
|
RBCCM
CUSTODIAN FOR DOUGLAS L STARNS IRA (35)
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
RBCCM
CUSTODIAN FOR MICHAEL DUCH IRA (36)
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
RICHARD
& JODI KURTZ REV TRUST (37)
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
ROBERT
DELISLE
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
ROBERT
FAIRBAIRN
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
ROBERT
FAMILY TRUST (38)
|
|
|
133,333
|
|
|
|
1.0
|
%
|
|
|
-
|
|
|
|
133,333
|
|
|
|
1.0
|
%
|
ROBERT
LERMAN
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
ROGER
W CLARK
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
SAM
BUCK JR
|
|
|
26,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
26,667
|
|
|
|
*
|
|
SEAVIEW
ORTHOPAEDIC 401(K) FBO DR ARON GREEN (39)
|
|
|
10,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
10,000
|
|
|
|
*
|
|
SEAVIEW
ORTHOPAEDIC 401K PSDA ARON GREEN (40)
|
|
|
20,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
20,000
|
|
|
|
*
|
|
SEAVIEW
ORTHOPAEDICS 401K PLAN UAD 06/30/1986 FBO ARRON GREEN (41)
|
|
|
24,000
|
|
|
|
*
|
|
|
|
-
|
|
|
|
24,000
|
|
|
|
*
|
|
SOONER
RANCH INVESTMENTS (42)
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
SUNIL
THACKER
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
THE
KENNETH M SUTIN MD REVOCABLE TRUST UAD 01/01/2012 (43)
|
|
|
166,667
|
|
|
|
1.3
|
%
|
|
|
-
|
|
|
|
166,667
|
|
|
|
1.3
|
%
|
THEODORE
STORTZ
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
THOMAS
PIDCOK
|
|
|
33,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
33,333
|
|
|
|
*
|
|
THOMAS
SMITH
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
THOMAS
WOLLSCHLAGER
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
TODD
ZAHNOW
|
|
|
16,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
16,667
|
|
|
|
*
|
|
VAYIKRA
CAPITAL LLC (44)
|
|
|
866,667
|
|
|
|
6.3
|
%
|
|
|
-
|
|
|
|
866,667
|
|
|
|
6.3
|
%
|
WILLIAM
FREES
|
|
|
68,753
|
|
|
|
*
|
|
|
|
-
|
|
|
|
68,753
|
|
|
|
*
|
|
WILLIAM
STEVENSON
|
|
|
66,667
|
|
|
|
*
|
|
|
|
-
|
|
|
|
66,667
|
|
|
|
*
|
|
WILLIAM
WERNER
|
|
|
13,333
|
|
|
|
*
|
|
|
|
-
|
|
|
|
13,333
|
|
|
|
*
|
|
Total
(45):
|
|
|
8,002,620
|
|
|
|
|
|
|
|
|
|
|
|
8,002,620
|
|
|
|
|
(1)
Subject to a 9.99% beneficial ownership limitation applicable to all holders of the Preferred Stock, holders of Series A Preferred
Stock, Series B Preferred Stock and Series C Preferred Stock will vote together with the holders of Common Stock on an as-converted
basis. Accordingly, the percentages are based on an aggregate of 13,678,034 shares, consisting of 7,5886,715 shares of Common
Stock, 83,556 shares of Common Stock as fully converted from 376 shares of Series A Preferred Stock, 3,340,252 shares of common
stock as fully converted from 15,031 shares of Series B Preferred Stock and 2,667,540 shares of Common Stock as fully converted
from 12,003 shares of Series C Preferred Stock, each outstanding as of the date of this prospectus.
(2)
Sharon Sycoff
has voting and investment control over the shares held by
ALMA
DIVERSIFIED HOLDINGS LLC.
(3)
George Melas-Kyriazi
has voting and investment control over the shares held by
ALVIN
FUND LLC.
(4)
Carl Lusting has voting and investment control over the shares held by
CARL
LUSTIG SEGREGATED ROLLOVER IRA.
(5)
Clarence Knight Aldrich has voting and investment control over the shares held by
CLARENCE
KNIGHT ALDRICH TRUST.
(6)
Don Moskovitz has voting and investment control over the shares held by
DON B MOSKOVITZ
LIVING TRUST UAD 08/05/2002.
(7)
James J. Shen & Louise L. Shen share voting
and investment control over
the shares held by
DR JAMES SHEN MDPC 401K PROFIT
SHARING PLAN UAD 1/1/1994.
(8)
Alexander Goren and James Goren
have
voting and investment control over the shares held by
GOREN BROTHERS LP.
(9)
Howard Applebaum
has
voting and investment control over the shares held by
H APPLEBAUM FAMILY TRUST DTD DECEMBER 29 2011.
(10)
Frank E. Hart
has
voting and investment control over the shares held by
HIGH CAPITAL FUNDING LLC.
(11)
Ira F Levy has voting and investment control over the shares held by
IRA
F LEVY SEPERATE PROPERTY ACCOUNT.
(12)
James E. Johnstone and Cynthia Johnstone
have
voting and investment control over the shares held by
J&C JOHNSTONE LTD.
(13)
Alexander M. Goren and James G. Goren h
ave
voting and investment control over the shares held by
JAG MUTI INVESTMENTS LLC.
(14)
Mark S. Pollack
has
voting and investment control over the shares held by
JAM 123 LLC.
(15)
James C Czirr has voting and investment control over the shares held by
JAMES
C CZIRR TRUST UAD 02202004.
(16)
James Shen has voting and investment control over the shares held by
JAMES
J SHEN MDPC401(K)PROFIT SHARING PLAN UAD 1/1/1994.
(17)
Claudia Keys and William Conklin
have
voting and investment control over the shares held by
KEYS 1996 FAMILY TRUST.
(18)
David Moore and Marilyn Moore
have
voting and investment control over the shares held by
MOORE FAMILY TRUST.
(19)
O Bernard Starkman has voting and investment control over the shares held by
O
BERNARD STARKMAN LIVING TRUST UAD 04/27/1998.
(20)
Kenneth I Raboy has voting and investment control over the shares held by
RBC
CAPITAL MARKETS CUST FOR KENNETH I RABOY IRA.
(21)
Gary J Faden has voting and investment control over the shares held by
RBC
CAPITAL MARKETS CUSTODIAN FBO GARY J FADEN SEP IRA.
(22)
James Denny has voting and investment control over the shares held by
RBC CAPITAL
MARKETS LLC CUST FBO JAMES DENNY IRA.
(23)
James Denny has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUST FBO JAMES W DENNY III IRA.
(24)
Jay Eisen has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUST FBO JAY EISEN ROTH IRA.
(25)
Roberta Denny has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUST FBO ROBERTA DENNY IRA.
(26)
Bryan Chetelat has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO BRYAN W CHETELAT ROTH IRA.
(27)
David Moore has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO DAVID MOORE IRA.
(28)
Eric Frank has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO ERIC FRANK IRA.
(29)
Hall Whitaker has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO HALL B WHITAKER IRA.
(30)
Jonathan Mayo has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO JONATHAN MAYO IRA.
(31)
Paul Ruths has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO PAUL RUTHS IRA.
(32)
Roberta Denny has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC CUSTODIAN FBO ROBERTA DENNY IRA.
(33)
Mark Ruths has voting and investment control over the shares held by
RBC
CAPITAL MARKETS LLC FBO MARK RUTHS IRA.
(34)
Thomas Starns has voting and investment control over the shares held by
RBCCM
CUSTODIAN FOR DEBORAH THOMAS STARNS IRA.
(35)
Douglas Starns has voting and investment control over the shares held by
RBCCM
CUSTODIAN FOR DOUGLAS L STARNS IRA.
(36)
Michael Duch has voting and investment control over the shares held by
RBCCM
CUSTODIAN FOR MICHAEL DUCH IRA.
(37)
Richard and Jodi Kurtz have voting and investment control over the shares held by
RICHARD
& JODI KURTZ REV TRUST.
(38)
Michael Robert and Patricia Ochoa
have
voting and investment control over the shares held by
ROBERT FAMILY TRUST.
(39)
Aron Green has voting and investment control over the shares held by
SEAVIEW
ORTHOPAEDIC 401(K) FBO DR ARON GREEN.
(40)
Aron Green has voting and investment control over the shares held by
SEAVIEW
ORTHOPAEDIC 401K PSDA ARON GREEN.
(41)
Arron Green has voting and investment control over the shares held by
SEAVIEW
ORTHOPAEDICS 401K PLAN UAD 06/30/1986 FBO ARRON GREEN.
(42)
Ronald T Evans has voting and investment control over the shares held by
SOONER
RANCH INVESTMENTS.
(43)
Kenneth Sutin has voting and investment control over the shares held by
THE
KENNETH M SUTIN MD REVOCABLE TRUST UAD 01/01/2012.
(44)
Phillip Darivoff has voting and investment control over the shares held by
VAYIKRA
CAPITAL LLC.
(45)
The total number of shares listed in this table does not include the 180,502 shares issued and 644,359 shares issuable as stock
dividends on the Series C Preferred Stock.
MANAGEMENT
OUR
DIRECTORS
The
table below sets forth (1) the names and ages of our Directors as of the date of this Registration Statement, (2) all positions
with the Company presently held by each such person and (3) the positions held by, and principal areas of responsibility of, each
such person during the last five years.
Name
|
|
Age
|
|
Position
|
|
|
|
|
|
Dr.
Robert Fischell
|
|
87
|
|
Director,
Member of the Compensation Committee and the Nominating and Corporate Governance Committee
|
John
Graham
|
|
56
|
|
Chairman
and Chief Executive Officer
|
Leslie
Seff
|
|
66
|
|
Director,
Chair of the Compensation Committee, and Member of the Audit Committee
|
Angela
Strand
|
|
49
|
|
Vice
Chairperson, Chair of the Nominating and Corporate Governance Committee and Member of the Audit Committee
|
Revan
Schwartz
|
|
72
|
|
Director,
Chair of the Audit Committee
|
Michael
Hauck
|
|
62
|
|
Director,
Member of the Compensation Committee and Nominating and Corporate Governance Committee
|
Dr.
Robert Fischell
has served as one of Integrity’s directors since 2010. He also serves on Integrity’s Nominating
and Corporate Governance Committee and Compensation Committee. Dr. Fischell is an inventor and serial entrepreneur with over 160
issued U.S. patents. Starting in 1959, Dr. Fischell spent over 30 years with the Johns Hopkins University Applied Physics Laboratory,
which resulted in 53 patents in both aerospace and biomedical technology. His interests at Johns Hopkins then turned to the invention
of new medical devices such as pacemakers and implantable heart defibrillators. Starting in 1969, Dr. Fischell began the formation
of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (purchased
by Siemens and now part of St. Jude Medical, Inc.), IsoStent, Inc. (merged with Cordis Company, a Johnson and Johnson Company),
NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc., and Svelte Medical Systems, Inc. As it relates to diabetes management
devices, he was the inventor of the first implantable insulin pump (which became Minimed, which was sold to Medtronic). Dr. Fischell’s
honors include Inventor of the Year for the USA in 1984, election to the National Academy of Engineering in 1989, the Distinguished
Physics Alumnus Award of the University of Maryland, and several medals for distinguished accomplishments in science, engineering
and innovation. In 2004, Discover magazine gave Dr. Fischell their annual Technology for Humanity award. In 2008, Dr. Fischell
received the honorary degree of Doctor of Humane Letters from the Johns Hopkins University in recognition of his many lifesaving
inventions. From June 2009 until March 2011, Dr. Fischell was a director of InspireMD, Inc. (OTCBB: NSPR), a medical device company
focusing on the development and commercialization of its proprietary stent system, MGuard. Dr. Fischell received his BSME degree
from Duke University and MS and Sc.D. degrees from the University of Maryland.
John
Graham
joined Integrity in March of 2017 as its Chairman and Chief Executive Officer. Prior to joining the Company, and
beginning in January 2016, Mr. Graham was the Managing Director and Senior Advisor of Torreya Partners, a New York based M&A
advisory firm. From November 2008 to December 2015, Mr. Graham was the Chief Executive Officer of the Invida Group, a pan-Asian
specialty pharmaceutical company based in Singapore, which was sold to the Menarini Group in 2011. Mr. Graham has three decades
of global executive and leadership experience including 18 years with Aventis and predecessor companies, where he held responsibilities
in Germany, Latin America and the United States. While at Aventis, John contributed to the market strategy and development for
the Aventis’ Diabetes franchise, which included the global launch of oral antidiabetic, Amaryl. He also participated in
the development and launch of Lantus, a long-acting insulin analogue. Mr. Graham holds a B.Sc. in Biochemistry from the Imperial
College of Science and Technology, University of London.
Leslie
Seff
has served as one of Integrity’s directors since March 2016. Mr. Seff also serves on Integrity’s Audit
Committee and Compensation Committee. Mr. Seff currently serves as founder and chief operating officer of AIMPaaS LLC, a technology
firm that provides trade execution facility, risk assessment, performance monitoring, and compliance oversight for hedge funds,
brokerage firms and other asset managers. Mr. Seff is also the founder and president of the consulting firm, Matthew B. Management,
Inc. Prior to this, Mr. Seff served as Chief Operating Officer and Managing Director, Capital Markets, of BrokerageAmerica LLC,
a provider of trade execution services to broker/dealers and institutional investors. In 1996, Mr. Seff started the NASDAQ trading
department at Fidelity Investments and subsequently managed that department from 1996 to 1998. Mr. Seff has also served as the
managing member of his own NASD Member Firm and is a former Allied Member of the New York Stock Exchange. Mr. Seff holds
a BBA in Finance from Hofstra University and an MBA from Bernard Baruch College (City University of New York). Lastly, in 2017
Mr. Seff was appointed to “The Dean’s Advisory Council” of the Zicklin School of Business, which is the graduate
business school for Baruch College, of The CUNY System.
Angela
Strand
has served as one of Integrity’s directors since March 2016 and was appointed Vice Chairperson of the Board
in March of 2017. Ms . Strand also serves as Integrity’s Chairperson of the Nominating and Corporate Governance Committee
and a member of the Audit Committee. Ms. Strand previously served as a founder and senior executive of Nohm, a joint venture between
Smith Electric Vehicles and FDG Electric Vehicles Ltd. (HK: 729HK), and the founder of Strand Strategy, a healthcare management
and consulting firm. Ms. Strand is also a named inventor with seven issued patents. From 2011 to 2015, Ms. Strand served as the
chief marketing officer and head of business development and government affairs for Smith Electric Vehicles. Ms. Strand has also
served as vice president of market development for Proteus Digital Health, and in various executive roles at Aerogen (acquired
by Nektar Therapeutics, NASDAQ:NKTR), Novacept (acquired by Cytyc, NASDAQ: CYTC, now NASDAQ: HOLX) and FemRx (acquired by Johnson
& Johnson, NYSE: JNJ). Ms. Strand holds a B.Sc. in Communications and an MBA in Marketing from the University of Tennessee.
Revan
Schwartz, JD
has served as one of Integrity’s directors since November 2016. He is also Chair of Integrity’s
Audit Committee. Mr. Schwartz was appointed to the Board of Directors by Andrew Garrett, Inc. (“AGI”), pursuant to
the terms of a placement agent agreement executed by AGI and the Company. Mr. Schwartz is an attorney and currently maintains
a private law practice. Mr. Schwartz has acted as a sole practitioner lawyer for the last five years. Mr. Schwartz has more than
30 years of experience in corporate and securities law. He held the position of General Counsel for AAA Computer, Hafco International
Trading Corporation, Bermil Industries, Viking Credit Corp and The Pride Group. Most recently, Mr. Schwartz was Senior Vice President
and General Counsel for Andrew Garrett, Inc., a boutique securities and investment banking firm. While with Andrew Garrett, Mr.
Schwartz possessed NASD/FINRA Series 4, 7, 24, 27, 53 and 55 licenses. Mr. Schwartz began his career with the East New York Savings
Bank (ENYSB) where he held several administrative and management positions, including a position overseeing a life insurance subsidiary.
Mr. Schwartz received a BS, with a major in accounting and a minor in economics, summa cum laude, from New York Institute of Technology,
and a JD, cum laude, from St. John’s University. Mr. Schwartz is currently a member of the New York and Florida Bars.
Michael
Hauck
has served on our board since May 2017. Mr. Hauck also serves on Integrity’s Compensation Committee and Nominating
and Corporate Governance Committee. He is the Executive Director of The Getz Group, a $1 billion privately owned pan-Asian trading
company focused on healthcare, industrial products, consumer distribution and retailing. Mr. Hauck has previously held executive
and director level positions at companies including, ERM, Interpharma Investments Ltd., Zuellig Pharma Group, Invida Holdings,
Target Worldwide Express, 3i plc, Springboard, and Business Health Group Ltd. Additionally, he has served as CEO of Walsh International
for eight years, where he led the company’s IPO and eventual sale to IMS Health. Through his extensive leadership experience,
Mr. Hauck has developed expertise across a wide range of industries and functions, including healthcare distribution services,
product launch, and commercialization; pharma, medical device, consumer health, and wellness; data aggregation and data solutions;
business development, mergers and acquisitions; and personnel and finance. Mr. Hauck received an MA in politics, philosophy, and
economics from St. Catherine’s College, Oxford University, as well as an MBA in marketing and finance from Cranfield School
of Management, one of the oldest and most reputable business schools in the United Kingdom.
OUR
EXECUTIVE OFFICERS
The
table below sets forth the names and ages of our executive officers as of the date of this Registration Statement and all positions
with the Company presently held by each such person. Immediately following the table is biographical information for each of our
executive officers (other than John Graham, our Chairman and Chief Executive Officer), including the positions held by, and principal
areas of responsibility of, each such person during the last five years. Biographical information for Mr. Graham is included above
under the caption “Our Directors.”
Name
|
|
Age
|
|
Position
|
David
Malka
|
|
51
|
|
Vice
President of Operations
|
Sami
Sassoun
|
|
50
|
|
Chief
Financial Officer
|
David
Podwalski
|
|
65
|
|
Chief
Commercial Officer
|
Eugene
Naidis
|
|
49
|
|
Vice
President of Research and Development
|
David
Malka
has served as Integrity’s Vice President of Operations since March 2012. From 2003 to 2012, Mr. Malka was
a director and Integrity’s Vice President of Operations. Prior to joining us, Mr. Malka served as a vice president of operations
for Solid Systems from 2000 to 2003. From 1994 to 2000, Mr. Malka served as a manager of production and purchasing at Kollmorgen-Servotronix,
an Israeli company specializing in the design, development and manufacture of digital servo control systems. From 1991 to 1993,
Mr. Malka was a production design and inspection worker at TFL Time & Frequency Systems Ltd. Mr. Malka has a degree in practical
engineering - industrial management from the Institute of Work & Production Productivity, Tel-Aviv and a Bachelor of Arts
degree in management from the Open University in Israel.
Sami
Sassoun
joined Integrity in February 2017 as its Chief Financial Officer. Prior to joining Integrity, Mr. Sassoun served
as the Founder of Bedrock Enterprises Ltd., a boutique consulting firm. Previously Mr. Sassoun held the position of chief financial
officer for multiple public and private companies in several industries. Mr. Sassoun served as the CFO of EZTD Inc. from 2014
until 2015. Prior to that Mr. Sassoun served as a Managing Director of YesCFO from 2010 to 2014. Mr. Sassoun began his career
as an accountant with Cohn Reznick, an accounting, tax and advisory firm, followed by serving as the Vice President of finance
and operations with Brean Murray & Co, an investment banking firm based in New York City. Mr. Sassoun obtained his Certified
Public Accountant certificate in 1992, and holds a B.S. in accounting from Rutgers University.
David
Podwalski
joined Integrity in June 2017 as its Chief Commercial Officer. David is a seasoned pharmaceutical and life sciences
executive with more than 20 years of experience in global commercial leadership, most notably with insulin-based therapies. Before
joining Integrity, from February 2005 to June 2017, he served at Ernst & Young as Senior Consultant and Subject Matter Expert,
Life Sciences, where he assisted major pharmaceutical, animal health, diagnostic, and medical device companies in developing innovative
go-to-market commercial strategies, sales and marketing excellence programs, product launch roadmaps, commercial operations and
analytics support, and enhanced patient and physician support services. Previously, from September 1976 to February 2005, Mr.
Podwalski was Senior Director of Global Commercial Effectiveness at Aventis Pharmaceuticals, where he designed and established
leading practices in sales and marketing capabilities in the US, Europe, Asia and Latin America. Earlier in his career, Mr. Podwalski
served in various capacities at Hoechst Marion Roussel Inc., including senior commercial leadership positions in both pharmaceutical
and consumer healthcare products, most notably in diabetes. Mr. Podwalski holds a BS in Marine Biology and Animal Behavior and
a post-graduate diploma in Finance & International Marketing at McGill University.
Eugene
Naidis
has served as Integrity’s Vice President of Research and Development since 2010 and has an extensive experience
in software development and management of R&D projects. Over the past 15 years, he has lead complex projects in the field
of industrial and medical measurement devices and applications. Mr. Naidis was involved (software development and management)
in the invention of a symbiotic approach, revolutionary vibration-based percussion technology to determine the presence of content
inside pipes; electromagnetic based, high-precision thickness measurement system; a system for non-contact, continuous measurement
of liquid and solid levels in storage containers, based on ultrasonic technology. Mr. Naidis holds BSc. in Metallurgy Engineering
and Masters of Science in Metallurgy and Computer Engineering.
CORPORATE
GOVERNANCE
Section
16(a) Beneficial Ownership Reporting Compliance
Section
16(a) of the Exchange Act and regulations of the SEC thereunder
requires our officers and
directors, and persons who own more than 10% of a registered class of our equity securities to file reports of ownership and changes
of ownership with the SEC. Our officers, directors and 10% shareholders are required by SEC regulation to furnish us with copies
of all Section 16(a) forms so filed.
Based
solely on a review of copies of such forms received and written representation letters from our executive officers and directors,
we believe that, during the fiscal year ended December 31, 2017, all executive officers and directors complied with the Section
16(a) reporting requirements except the following:
Name
of Reporting Person
|
|
Form
Type
|
|
Date
of Filing
|
Michael
Hauck
|
|
Form
4
|
|
6/9/2017
|
Michael
Hauck
|
|
Form
3
|
|
6/8/2017
|
Angela
Strand
|
|
Form
4
|
|
6/7/2017
|
Robert
Fischell
|
|
Form
4
|
|
6/7/2017
|
Leslie
Seff
|
|
Form
4
|
|
6/6/2017
|
Revan
Schwartz
|
|
Form
4
|
|
6/6/2017
|
Philip
Darivoff
|
|
Form
4
|
|
3/14/2017
|
Sami
Sassoun
|
|
Form
3
|
|
2/9/2017
|
Philip
Darivoff
|
|
Form
4
|
|
1/13/2017
|
Code
of Business Conduct and Ethics
Integrity
has adopted a code of ethics that applies to its Chief Executive Officer and its senior financial officers (currently consisting
only of the Chief Financial Officer). This code of ethics is available on Integrity’s website at
www.integrity-app.com
.
If Integrity makes any substantive amendments to the code or grants any waiver, including any implicit waiver, from a provision
of the code to its principal executive, financial or accounting officer, it will disclose the nature of the amendment or waiver
on its website or in a report on a Current Report on Form 8-K filed in accordance with the rules and regulations of the SEC. The
Company will provide to any person without charge, upon five days’ written request, a copy of the code of ethics.
Nominating
and Corporate Governance Committee
The
members of the Nominating and Corporate Governance Committee of the Board are Ms. Angela Strand (Chairperson), Mr. Robert Fischell
and Mr. Michael Hauck. Our Board has determined that these directors are “independent” as defined by the rules of
the SEC. The purposes and powers of the Nominating and Corporate Governance Committee include (i) identifying potential qualified
nominees for director and recommend to the Board for nomination candidates for the Board, (ii) developing the Company’s
corporate governance guidelines and additional corporate governance policies, and (iii) exercising such other powers and authority
as shall from time to time be assigned thereto by resolution of the Board. The Nominating and Corporate Governance Committee adopted
the Nominating and Corporate Governance Committee charter on July 5, 2016, which sets forth the duties and responsibilities of
the Nominating and Corporate Governance Committee.
Compensation
Committee
The
members of the Compensation Committee of the Board are Mr. Leslie Seff (Chairperson), Mr. Robert Fischell, Mr. Michael Hauck.
Our Board has determined that all three of these directors are “independent” as defined by the rules of the SEC. The
primary responsibilities of the Compensation Committee include reviewing compensation and other benefits for our executive officers,
and periodically reviewing and making recommendations to our Board with respect to director compensation.
Audit
Committee and Audit Committee Financial Expert
The
members of the Audit Committee of the Board are Mr. Revan Schwartz (Chairman), Mr. Leslie Seff and Ms. Angela Strand. Our Board
has determined that all three of these directors are “independent” as defined by the rules of the SEC. The primary
role of the Committee is to oversee the financial reporting and disclosure process. To fulfill this obligation, the Committee
relies on: management for the preparation and accuracy of the Company’s financial statements; both management and the Company’s
internal audit department/management for establishing effective internal controls and procedures to ensure the Company’s
compliance with accounting standards, financial reporting procedures and applicable laws and regulations; and the Company’s
independent auditors for an unbiased, diligent audit or review, as applicable, of the functions of the audit committee are performed
by the full Board. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the
Exchange Act and the NASDAQ Listing Rules. No member of the Committee can have participated in the preparation of the Company’s
or any of its subsidiaries’ financial statements at any time during the past three years.
The
Board has determined that Mr. Schwartz is an “Audit Committee Financial Expert” as that term is defined in Item 407(d)(5)(ii)
of Regulation S-K.
EXECUTIVE
COMPENSATION
Summary
Compensation Table
The
following table summarizes compensation of our named executive officers, as of December 31, 2017 and 2016.
Name and Principal Position
|
|
Year
|
|
Salary
|
|
|
Signing Bonus
|
|
|
Option Awards
|
|
|
All other Compensation
|
|
|
Total Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Graham
|
|
2017
|
|
$
|
266,449
|
|
|
$
|
375,000
|
|
|
$
|
1,590,635
|
|
|
|
-
|
|
|
$
|
2,232,084
|
|
Chief Executive Officer
|
|
2016
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Podwalski
|
|
2017
|
|
$
|
94,545
|
|
|
|
|
|
|
$
|
130,814
|
|
|
|
-
|
|
|
$
|
225,359
|
|
Chief Commercialization Officer
|
|
2016
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sami Sassoun
|
|
2017
|
(1)
|
$
|
109,276
|
|
|
$
|
-
|
|
|
$
|
82,432
|
|
|
|
64,013
|
(2)
|
|
$
|
255,721
|
|
Chief Financial Officer
|
|
2016
|
(5)
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Malka
|
|
2017
|
(1)
|
$
|
105,000
|
|
|
|
|
|
|
$
|
110,904
|
|
|
|
67,385
|
(3)
|
|
$
|
283,289
|
|
Vice President of Operations
|
|
2016
|
(5)
|
$
|
63,114
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
48,046
|
(6)
|
|
$
|
111,160
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Eugene Naidis
|
|
2017
|
(1)
|
$
|
96,418
|
|
|
$
|
-
|
|
|
$
|
82,432
|
|
|
|
49,326
|
(4)
|
|
$
|
228,176
|
|
Vice President of R&D
|
|
2016
|
(5)
|
$
|
79,656
|
|
|
$
|
-
|
|
|
|
|
|
|
|
40,776
|
(7)
|
|
$
|
120,432
|
|
|
(1)
|
Calculated
based on the average exchange rate for the year of New Israeli Shekels to U.S. Dollars of NIS 3.576 = U.S. $1.00
|
|
|
|
|
(2)
|
Includes
$16,107 in automobile expenses paid by Integrity, including leasing costs, insurance premiums, gasoline and/or repairs incurred
in connection with the executive’s automobile, $336 in cellular communications expenses paid by Integrity, representing
the estimated costs of our cellular communications expenses attributable to the executive, $14,060 in tax gross-up payments,
and contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel),
(c) disability insurance (Ovdan Kosher Avoda) and (d) and statutory national insurance (Bituach Leumi) in the aggregate total
amount of $33,510.
|
|
|
|
|
(3)
|
Includes
$21,745 in automobile expenses paid by Integrity, including leasing costs, insurance premiums, gasoline and/or repairs incurred
in connection with the executive’s automobile, $336 in cellular communications expenses paid by Integrity, representing
the estimated costs of our cellular communications expenses attributable to the executive, $14,060 in tax gross-up payments,
and contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel),
(c) disability insurance (Ovdan Kosher Avoda) and (d) statutory national insurance (Bituach Leumi) in the aggregate total
amount of $31,244.
|
|
|
|
|
(4)
|
Includes
$15,101 in automobile expenses paid by Integrity, including leasing costs, insurance premiums, gasoline and/or repairs incurred
in connection with the executive’s automobile, $336 in cellular communications expenses paid by Integrity, representing
the estimated costs of our cellular communications expenses attributable to the executive, $10,705 in tax gross-up payments,
and contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel),
(c) disability insurance (Ovdan Kosher Avoda) and (d) statutory national insurance (Bituach Leumi) in the aggregate total
amount of $23,184.
|
|
(5)
|
Calculated
based on the average exchange rate for the year of New Israeli Shekels to U.S. Dollars of NIS 3.832 = U.S. $1.00
|
|
|
|
|
(6)
|
Includes
$20,292 in automobile expenses paid by Integrity, including leasing costs, insurance premiums, gasoline and/or repairs incurred
in connection with the executive’s automobile, $313 in cellular communications expenses paid by Integrity, representing
the estimated costs of our cellular communications expenses attributable to the executive, $11,574 in tax gross-up payments,
and contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel),
(c) disability insurance (Ovdan Kosher Avoda) and (d) statutory national insurance (Bituach Leumi) in the aggregate total
amount of $15,867.
|
|
|
|
|
(7)
|
Includes
$14,405 in automobile expenses paid by Integrity, including leasing costs, insurance premiums, gasoline and/or repairs incurred
in connection with the executive’s automobile, $313 in cellular communications expenses paid by Integrity, representing
the estimated costs of our cellular communications expenses attributable to the executive, $8,455 in tax gross-up payments,
and contributions to the (a) Severance Pay- Fund, (b) retirement plan feature of Managers’ Insurance (Kupat Gemel),
(c) disability insurance (Ovdan Kosher Avoda) and (d) statutory national insurance (Bituach Leumi) in the aggregate total
amount of $17,603.
|
Employment
Agreements
Set
forth below are summaries of the material terms of the employment agreements of our named executive officers.
John
Graham
Effective
April7, 2017, the Company entered into an amendment to the employment agreement (the “Graham Employment Amendment”)
with John Graham, whom the Company appointed as Chief Executive Officer on March 20, 2017, to modify the base compensation provision
and the equity compensation provision under that certain Employment Agreement, dated March 20, 2017 (the “Graham Effective
Date”), by and between the Company and Mr. Graham. Pursuant to the terms of the Graham Employment Amendment, (a) Mr. Graham’s
base compensation was modified such that he receives a base salary of $500,000 per year, as well as a one-time payment of $375,000
paid to Mr. Graham upon commencement of Mr. Graham’s employment with the Company which amount was recognized as an expense
as of the employment commencement date, and (b) the vesting periods of Mr. Graham’s options to purchase Common Stock were
modified whereby (1) 307,754 option at an exercise price of $4.50 per share vested as of the Graham Effective Date, (2) 923,262
options at an exercise price of $4.50 per share vest on the six month anniversary of the Graham Effective Date, (3) 442,980 options
at an exercise price of $4.50 per share vest on the two (2) year anniversary of the Graham Effective Date, (4)
559,414
options at an exercise price of $5.41 per share
vest on the two (2) year anniversary of the Graham Effective Date
,
and (5) 844,130 options at an exercise price of $7.75 per share
vest on the two (2) year anniversary of the Graham Effective
Date. According to the agreement between the Company and Graham, Mr. Graham is also
eligible
to earn an annual performance bonus between 35-72% of his base salary (of which $225,000 is guaranteed as performance bonus for
his first year), subject to certain performance criteria approved and adopted in September 2017 by the Compensation Committee
and the Board of Directors and, provided that Mr. Graham continues to be an employee through and on March 15, 2018
.
David
Podwalski
On
June 26, 2017, the Company entered into an employment agreement (the “CCO Employment Agreement”) with with Mr. Podwalski
to serve as Chief Commercial Officer of the Company. Under the CCO Employment Agreement, Mr. Podwalski (1) receives a base salary
of $240,000 per year; (2) receives a sign-on bonus of $25,000, payable on the six month anniversary of the Podwalski Effective
Date, subject to his continued employment through and on such payment date; (3) is eligible to receive an annual performance bonus,
having a minimum bonus opportunity equal to 20% of his current base salary based upon 80% achievement of performance criteria
(the “Minimum Performance Goal”), a target bonus opportunity equal to 25% of his current base salary based upon 100%
achievement of performance criteria, and a maximum bonus opportunity equal to 37.5% of his current base salary based upon 150%
achievement of performance criteria (the “Maximum Performance Goal”), provided, however, that such performance bonus
will be determined using straight-line interpolation of the level of achievement between the Minimum Performance Goal and the
Maximum Performance Goal; and (4) receive an initial stock option grant to purchase shares of Common Stock equal to 1% of the
total fully diluted shares of Common Stock as of the Podwalski Effective Date, with an exercise price of $4.50 per share or the
fair market value of a share of Common Stock on the grant date, whichever is greater, vesting monthly over a three year period
commencing on the Podwalski Effective Date, subject to his continued employment through and on each such vesting date (the total
fair value of the grant as of the Podwalski Effective Date is approximately $270,000).The CCO Employment Agreement is terminable
by the Company on 90 days written notice and by Mr. Podwalski on 30 days written notice. The CCO Employment Agreement is immediately
terminable by the Company for cause, as defined in the CCO Employment Agreement, without the payment of severance. The CCO Employment
Agreement contains non-compete obligations applicable during the term of the agreement and for one year thereafter and confidentiality
obligations that survive the termination of the agreement indefinitely.
David
Malka
David
Malka entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Malka agreed to continue to
serve as the Vice President of Operations of Integrity Israel. Mr. Malka’s employment agreement provides for an annual salary
of NIS 240,000, or approximately $68,985 based on the exchange rate of 3.479 NIS / $1.00 USD in effect on March 21, 2018, and
an annual bonus to be determined by the Board of Directors and an additional sum provided that Mr. Malka reaches certain milestones
approved by the Board of Directors, as well as the payment of certain social and insurance benefits and the use of a company car.
The agreement also provides that Mr. Malka’s annual salary shall be subject to increase from time to time at the discretion
of the Board of Directors. We expect that Mr. Malka’s bonus formula, as previously determined by the Board of Directors,
will be renegotiated once Integrity Israel has begun commercialization of its products. The agreement is terminable by either
party on 90 days’ notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary,
or immediately by Integrity Israel for cause (as defined in the agreement) without the payment of severance. Mr. Malka’s
employment agreement contains non-compete and confidentiality provisions effective during the term of the agreement and for one
year thereafter.
Pursuant
to his employment agreement, in March 2012, Mr. Malka was granted options to purchase 79,434 shares of Common Stock at an exercise
price per share $6.25 per share. Mr. Malka’s options vested (or in the case of clause (iii) below, will vest) in one-third
increments upon (i) submission of clinical trials’ results to the Notified Body; (ii) the receipt of CE mark approval; and
(iii) the receipt of FDA approval, subject to immediate vesting in the event of a change of control.
Effective
April 7, 2017, Integrity Israel entered into an amended and restated personal employment agreement (the “Malka Employment
Agreement”) with David Malka for his continued service as Vice President of Operations of the Company and Integrity Israel,
effective as of March 20, 2017 (the “Malka Effective Date”). Pursuant to the terms of the Malka Employment Agreement,
Mr. Malka (a) receives a monthly base salary of NIS 20,000 (approximately $5,749 based on an exchange rate of 3. 479 NIS / 1 USD
in effect on March 21, 2018), which may increase to NIS 35,000 per month (approximately $10,060 using the same exchange rate)
in the event certain performance milestones are met; (b) is eligible to earn an annual performance bonus between 420-864% of his
base salary, subject to certain performance criteria to be established by the Board of Directors within the first ninety (90)
days of each fiscal year; (c) is eligible to earn a retention bonus equal to 60% of his aggregate base salary earned through the
one-year anniversary of the Malka Effective Date, payable thirty days following the one-year anniversary of the Malka Effective
Date and provided that Mr. Malka remains employed with Integrity Israel through and on the one-year anniversary of the Malka Effective
Date; (d) received a modification to the terms of his options to purchase 79,434 shares of Common Stock at an exercise price per
share equal to $6.25 whereby the unvested portion of such options will accelerate and will be immediately exercisable, effective
as of the Malka Effective Date (since the original performance conditions were not expected to be satisfied as of the date of
the modification of the terms, the fair value of such grant was measured based on the fair value of the modified award at the
modification date); and (e) received options to purchase
361,875 shares of
Common
Stock, granted under the Plan, with
an exercise price $4.50 per share, which shall vest
over a three-year period
. In addition, the Malka Employment Agreement provides for the payment of certain social benefits
and the use of a company car. The Malka Employment Agreement is terminable by Integrity Israel and Mr. Malka on 90 days’
prior written notice, without cause, or immediately by Integrity Israel for cause as defined in the Malka Employment Agreement.
Integrity Israel may terminate Mr. Malka’s employment without cause prior to the expiration of the 90-day notice period,
but will be required to pay Mr. Malka a severance fee equal to his base salary plus the financial value of all other benefits
Mr. Malka would have been entitled to receive in respect of the portion of the notice period which was forfeited.
Sami
Sassoun
Mr.
Sassoun’s appointment as Chief Financial Officer was made pursuant to an employment agreement (the “Sassoun Employment
Agreement”) with Integrity Israel, dated February 1, 2017. The Sassoun Employment Agreement provides for a monthly base
gross salary of NIS 30,000 (approximately $8,623 based on the exchange rate of NIS 3.479 /$1.00 USD in effect on March 21, 2018),
as well as the payment of certain social benefits and the use of a company car. The Sassoun Employment Agreement is terminable
by either party on 90 days’ notice or immediately by Integrity Israel for cause without the payment of severance. The Sassoun
Employment Agreement contains non-compete obligations applicable during the term of the agreement and for one year thereafter
and confidentiality obligations that survive the termination of the agreement indefinitely.
In
addition, pursuant to the Sassoun Employment Agreement, the Company has agreed to grant to Mr. Sassoun, on the one-year anniversary
of the commencement of his employment with the Company, options to purchase such number of shares of Common Stock of the Company,
at an exercise price of $4.50 per share, with the number of options to be issued and the vesting provisions applicable thereto
to be determined by the Board of Directors of the Company.
In
September 2017, the Compensation Committee and the Board of Directors approved an increase of Mr. Sassoun’s base salary
to NIS 47,250 per month (approximately US$161,513 annually), which shall only start to take effect after the Company has completed
the next round of financing and has sufficient funds to finance operations. The Compensation Committee and the Board of Directors
also approved certain on-target performance bonus at 35% of Mr. Sassoun’s annual base salary and grant of stock options
(pursuant to the Company’s 2010 Incentive Compensation Plan, as amended) equating to 1% of the fully diluted number of shares
of the Company after the closing of the offering of Series C Units, with a strike price of US$4.50, with three-year monthly vesting
commencing on the first month after the effective date.
Eugene
Naidis
Eugene
Naidis entered into an employment agreement with Integrity Israel in July 2010 pursuant to which Mr. Naidis agreed to continue
to serve as the Vice President of Research and Development of Integrity Israel. Mr. Naidis’s employment agreement provides
for an annual salary of NIS 276,000, or approximately $79,333 based on the exchange rate of 3.479 NIS / $1.00 USD in effect on
March 21, 2018, as well as the payment of certain social and insurance benefits and the use of a company car. The agreement also
provides that Mr. Naidis’s annual salary shall be subject to increase from time to time at the discretion of the Board of
Directors. We expect that Mr. Naidis’s bonus formula, as previously determined by the Board of Directors, will be renegotiated
once Integrity Israel has begun commercialization of its products. The agreement is terminable by either party on 90 days’
notice, immediately by Integrity Israel with the payment of an amount equal to 90 days of annual salary, or immediately by Integrity
Israel for cause (as defined in the agreement) without the payment of severance. Mr. Naidis’s employment agreement contains
non-compete and confidentiality provisions effective during the term of the agreement and for one year thereafter.
In
September 2017, the Compensation Committee and the Board of Directors approved an increase of Mr. Naidis’s base salary to
NIS 43,200 (US$147,660 annually), which shall only start to take effect after the Company has completed the next round of financing
and has sufficient funds to finance operations. The Compensation Committee and the Board of Directors also approved certain on-target
performance bonus at 35% Mr. Naidis’s annual base salary and grant of stock options (pursuant to the Company’s 2010
Incentive Compensation Plan, as amended) equating to 1% of the fully diluted number of shares of the Company after the closing
of the offering of Series C Units, with a strike price of US$4.50, with three-year monthly vesting commencing on the first month
after the effective date.
Outstanding
Equity Awards as of December 31, 2017
The
following table sets forth for each of Integrity’s named executive officers certain information regarding unexercised options
as of December 31, 2017:
Name
|
|
Number
of Securities Underlying Unexercised Options (#) Exercisable
|
|
|
Number
of Securities Underlying Unexercised Options (#) Unexercisable
|
|
|
Option
Exercise Price($)
|
|
Option
Expiration Date
|
|
|
|
|
|
|
|
|
|
|
|
John
Graham, Chief Executive Officer
|
|
|
1,231,016
|
|
|
|
1,846,524
|
|
|
$
|
4.5-$7.75
|
(1)
|
March
16, 2027
|
David
Podwalski, Chief Commercialization Officer
|
|
|
56,503
|
|
|
|
234,082
|
|
|
$
|
4.50
|
(2)
|
June
22, 2027
|
Sami
Sassoun, Chief Financial Officer
|
|
|
24,410
|
|
|
|
268,514
|
|
|
$
|
4.50
|
(3)
|
September
15, 2027
|
David
Malka, Vice president of Operations
|
|
|
167,891
|
|
|
|
755,673
|
|
|
$
|
4.5-$6.25
|
(4)
|
April
3, 2027
|
Eugene
Naidis, Vice President of Research and Development
|
|
|
24,410
|
|
|
|
268,514
|
|
|
$
|
4.50
|
(5)
|
September
15, 2027
|
|
(1)
|
the
vesting periods of Mr. Graham’s options to purchase Common Stock are as follows: (i) 307,754 shares of Common Stock
underlying the option to purchase Common Stock at an exercise price of $4.50 per share (the “$4.50 Options”) vested
on March 20, 2017, (ii) 923,262 of the $4.50 Options vest on September 20, 2017, and (iii) the remaining 442,980 of the $4.50
Options as well as
559,414 options at an exercise price of $5.41 per share and 844,130
options at an exercise price of $7.75 per share
will vest on March 20, 2019.
|
|
|
|
|
(2)
|
Mr.
Podwalski’s options vested or will vest in 12 equal quarterly installments beginning June 22, 2017.
|
|
|
|
|
(3)
|
Mr.
Sassoun’s options vested or will vest in 12 equal quarterly installments beginning September 15, 2017.
|
|
|
|
|
(4)
|
Mr.
Malka’s options to purchase 79,434 shares of Common Stock at an exercise price per share equal to $6.25 all vested as
of April 3, 2017, pursuant to an amendment to his employment agreement. 361,875 of Mr. Malka’s options vested or will
vest in 12 equal quarterly installments beginning April 7, 2017.
|
|
|
|
|
(5)
|
Mr.
Naidis’s options vested or will vest in 12 equal quarterly installments beginning September 15, 2017.
|
DIRECTOR
COMPENSATION
The
following table sets forth information with respect to the compensation of our directors (other than Mr. Gal and Mr. Malka, whom
did not receive separate compensation for their service as directors) as of December 31, 2017:
Name
|
|
Fees
earned
or paid in
cash
|
|
|
Payment
for
services in
Common
Shares
(2)
|
|
|
Other
Compensation (3)
|
|
|
Options
Awards
Vested (1)
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Angela Strand
|
|
$
|
38,868
|
|
|
$
|
15,000
|
|
|
$
|
60,000
|
|
|
$
|
21,724
|
|
|
$
|
135,592
|
|
Robert Fischell
|
|
$
|
24,150
|
|
|
|
|
|
|
|
|
|
|
$
|
21,724
|
|
|
$
|
45,874
|
|
Leslie Seff
|
|
$
|
40,200
|
|
|
$
|
15,000
|
|
|
|
|
|
|
$
|
21,724
|
|
|
$
|
76,924
|
|
Revan Schwartz
|
|
$
|
28,333
|
|
|
|
|
|
|
|
|
|
|
$
|
35,249
|
|
|
$
|
63,582
|
|
Michael
Hauck
|
|
$
|
22,900
|
|
|
|
|
|
|
|
|
|
|
$
|
16,821
|
|
|
$
|
39,721
|
|
|
|
$
|
154,451
|
|
|
$
|
30,000
|
|
|
$
|
60,000
|
|
|
$
|
117,244
|
|
|
$
|
361,695
|
|
(1)
The dollar value recognized for the stock option awards was determined in accordance with FASB ASC Topic 718. For information
on the determination of the fair value of each option granted as of the grant date, and of assumptions made with respect to the
value of the option awards, see Note 10 to our Consolidated Financial Statements for the year ended December 31, 2017 and calculated
based on 41,560 options outstanding as of December 31, 2017.
(2)
On March 20, 2017, the Board authorized the payment of $20,000, 25% of which shall be paid in cash and 75% of which shall be paid
by the grant of 3,334 shares of Common Stock, par value $0.001 per share, of the Company, to Leslie Seff, an independent member
of the Board. The payment was authorized as consideration for the consulting services provided by Mr. Seff to the Company for
the month of March 2017.
(3)
On May 4, 2017, the Board of Directors unanimously voted to appoint Angela Strand, a member of the Board of Directors, as the
interim Chief Strategy Officer of the Company, effective as of May 1, 2017 through September 30, 2017. On May 5, 2017, the Company
entered into a letter agreement with Ms. Angela Strand confirming her appointment as interim Chief Strategy Officer of the Company.
Pursuant to the terms of the letter agreement, Ms. Strand received aggregate compensation of $150,000 for her service during the
term of employment, paid monthly on the schedule mutually agreed upon by the parties. For the year ended December 31, 2017, Ms.
Strand received $60,000 of this fee and the balance was deferred and scheduled for payment in 2018.
On
May 23, 2017, the Board approved the following compensation for all non-employee directors serving on the Board of Directors:
|
●
|
an
annual cash payment to each non-employee director and interim officer of the Company in the amount of $35,000, payable in
four equal quarterly installments of $8,750 each on the last day of each calendar quarter commencing with the fourth quarter
of 2017, subject to their continued service as of each such date;
|
|
|
|
|
●
|
an
additional annual cash payment to each member of a Board committee who is not the Chairperson of that particular committee
in the amount of $5,000, payable in four equal quarterly installments of $1,250 each on the last day of each calendar quarter
commencing with the second quarter of 2017, subject to their continued service as of each such date;
|
|
|
|
|
●
|
an
additional annual cash payment to the chairperson of a Board committee in the amount of $12,500, payable in four equal quarterly
installments of $3,125 each on the last day of each calendar quarter commencing with the second quarter of 2017, subject to
their continued service as of each such date; and
|
|
|
|
|
●
|
the
grant to each non-employee director and each interim officer of the Company of a one-time award of options to purchase up
to an aggregate of 14,894 shares of Common Stock, at an exercise price of $4.50, under and pursuant to the Plan, which options
vest in 12 equal monthly increments commencing as of June 1, 2017 (subject to their continued service as of each such date)
and have a term of 10 years.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Except
as set forth below, Integrity is not aware of any transactions since the beginning of its last fiscal year or any proposed transactions
in which Integrity was or is a party, in which (1) the amount involved exceeded the lesser of $120,000 or 1% of the average of
Integrity’s total assets at year end for the last two completed fiscal years and (2) in which a director, director nominee,
executive officer, holder of more than 5% of Integrity’s Common Stock or Preferred Stock or any member of the immediate
family of any of the foregoing persons had or will have a direct or indirect material interest.
On
February 6, 2017, the Company entered into an amended and restated consulting agreement with Strand Strategy, a healthcare consulting
firm (“Strand Strategy”), relating to the retention of Strand Strategy’s services as an independent contractor
on a temporary basis, effective as of December 1, 2016. The founder and managing director of Strand Strategy, Angela Strand, is
an independent member of the Board of Directors, a member of the Audit Committee of the Board. Pursuant to the terms of the consulting
agreement, Strand Strategy agreed to assist the Company with its corporate strategy, business development and communication management
for a 90-day period. As consideration for the services provided under the consulting agreement, the Company agreed to pay Strand
Strategy a fee of $60,000, 25% of which shall be paid in cash and 75% of which shall be paid by the grant to Strand Strategy of
10,000 shares of Common Stock of the Company. The consulting agreement may be terminated immediately by either party, upon written
notice to the other party, if the other party materially breached the consulting agreement, and such breach is incapable of cure.
With respect to a breach capable of cure, the nonbreaching party may terminate the consulting agreement if the breaching party
fails to cure within five (5) days after receipt of written notice of breach. The consulting agreement contains confidentiality
obligations that survive the termination of the consulting agreement indefinitely.
On
March 20, 2017, the Board authorized the payment of $20,000, 25% of which shall be paid in cash and 75% of which shall be paid
by the grant of 3,334 shares of Common Stock to Strand Strategy as additional consideration for the consulting services provided
by Strand Strategy to the Company for the month of March 2017. The Company had originally agreed to such services, pursuant to
the previously reported amended and restated consulting agreement between Strand Strategy and the Company, but the term of such
agreement expired on February 28, 2017.
On
March 20, 2017, the Board authorized the payment of $20,000, 25% of which shall be paid in cash and 75% of which shall be paid
by the grant of 3,334 shares of Common Stock to Leslie Seff, an independent member of the Board. The payment was authorized as
consideration for the consulting services provided by Mr. Seff to the Company for the month of March 2017.
On
May 4, 2017, the Board unanimously voted to appoint Angela Strand, a member of the Board of Directors, as the interim Chief Strategy
Officer of the Company, effective as of May 1, 2017 through September 30, 2017. On May 5, 2017, the Company entered into a letter
agreement with Ms. Angela Strand confirming her appointment as interim Chief Strategy Officer of the Company. Pursuant to the
terms of the letter agreement, Ms. Strand received aggregate compensation of $150,000 for her service during the term of employment,
paid monthly on the schedule mutually agreed upon by the parties.
DESCRIPTION
OF SECURITIES
General
The
following description of our capital stock and provisions of our certificate of incorporation and bylaws are summaries and are
qualified by reference to our certificate of incorporation, bylaws and, with respect to the anti-dilution provision described
under
“—Common Stock
”, the form of subscription agreement between us and the investors in the private
placement.
Common
Stock
As of June 7 , 2018, the Company had
40,000,000 shares of Common Stock authorized and 7,586,715 shares of Common Stock issued and outstanding, held of record by 363
stockholders.
Description
of the rights attached to the Common Stock
Each
share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval
of the Company’s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. As described
below, holders of Preferred Stock are entitled to vote together with the holders of Common Stock on an as-converted basis. Accordingly,
the holders of the Company’s Common Stock together with the holders of the Preferred Stock who hold, in the aggregate, more
than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining
shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares
of Common Stock, voting together with the holders of the Preferred Stock on an as converted basis, are entitled to vote thereon
is sufficient to authorize, affirm, ratify or consent to any act or action submitted to the vote of the Company’s stockholders,
except as otherwise provided by law.
Preferred
Stock
As of June 7 , 2018, the Company had
10,000,000 shares of Preferred Stock authorized, of which 376 shares of Series A Preferred Stock, 15,031 shares of Series B Preferred
Stock and 12,004 shares of Series C Preferred Stock were issued and outstanding, respectively.
Description
of the rights attached to the Series A Preferred Stock
Holders
of Series A Preferred Stock are entitled to receive cumulative dividends at a rate of 5% per annum, based on the stated value
per share of the Series A Preferred Stock, which was initially $1,000 per share. Dividends on the Series A Preferred Stock are
payable quarterly on March 31, June 30, September 30 and December 31 of each year, beginning on March 31, 2013, and on each conversion
date (with respect to the shares of Series A Preferred Stock being converted). Until September 13, 2013, dividends were payable
only in cash. Thereafter, dividends on the Series A Preferred Stock became payable, at the option of the Company, in cash and/or,
if certain conditions are satisfied (including, among others, that the volume weighted average trading price for the Common Stock
on its principal trading market is equal to or greater than 110% of the then current conversion price for the Series A Preferred
Stock for five consecutive trading days prior to the dividend payment date), in shares of Common Stock, valued at the then current
conversion price of the Series A Preferred Stock. The Company will incur a late fee of 9% per annum, payable in cash, on dividends
that are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2017,
2016, 2015 the Company paid an aggregate of $5,731 , $13,529 and $57,061, respectively, in cash dividends to its Series
A Preferred Stockholders.
The
Company may become obligated to redeem the Series A Preferred Stock in cash upon the occurrence of certain triggering events,
including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series A Preferred
Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company,
or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities
exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series
A Preferred Stock will have the option to require the Company to redeem such holder’s shares of Series A Preferred Stock
for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder’s
outstanding Series A Preferred Stock.
Subject
to certain conditions, the Company will have the option to force the conversion of the Series A Preferred Stock (in whole or in
part) if the volume weighted average price for the Common Stock on its principal trading market exceeds $11.60 for each of any
20 trading days during any 30 consecutive trading day period and the average daily dollar trading value for the Common Stock during
such 30 day period exceeds $100,000.
If
the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series A Preferred
Stock (the “Series A Conversion Shares”) and, as a result, the holder is required by its brokerage firm to purchase
shares of Common Stock to deliver in satisfaction of a sale by such holder of the Series A Conversion Shares (a “Buy-In”),
the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if any, by which such holder’s
total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds the product of
(i) the aggregate number of Series A Conversion Shares due to the holder, multiplied by (ii) the actual sale price at which the
sell order giving rise to such purchase obligation was executed (including any brokerage commissions); and (b) at the option of
such holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number of shares of Series A
Preferred Stock submitted for conversion (in which case, such conversion will be deemed rescinded) or deliver to such holder the
number of shares of Common Stock that would have been issued if the Company had timely complied with its delivery requirements.
In
addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares
of Series A Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series
A Conversion Shares by the eighth trading day following the applicable conversion date.
Subject
to the beneficial ownership limitation described below, holders of Series A Preferred Stock will vote together with the holders
of Common Stock, Series B Preferred Stock and Series C Preferred Stock on an as-converted basis. Holders will not be permitted
to convert their Series A Preferred Stock if such conversion would cause such holder to beneficially own more than 4.99% of the
outstanding number of shares of Common Stock outstanding after giving effect to such conversion (subject to increase to 9.99%,
at the option of the holder, upon no less than 61 days prior written notice to the Company) (the “Beneficial Ownership Limitation”).
In addition, no holder may vote any shares of Series A Preferred Stock (on an as converted to Common Stock basis) in excess of
the Beneficial Ownership Limitation.
Subject
to certain limitations, so long as any initial Series A Unit purchaser holds any shares of Series A Preferred Stock, if (1) the
Company sells any shares of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (2) a holder
then holding Series A Preferred Stock, Series A Warrants, Series A Conversion Shares or shares of Common Stock issuable upon exercise
of Series A Warrant reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable
to the holder in such subsequent sale of securities than are the terms and conditions granted to such Purchaser, then the holder
will be permitted to require the Company to amend the terms of this Series A transaction (only with respect to such holder) so
as to match the terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or
may be less favorable to such holder).
The
conversion price of the shares of Series A Preferred Stock that were included in the Series A Units is subject to adjustment for
certain issuances of Common Stock or other securities of the Company at an effective price per share that is lower than the conversion
price then in effect, as well as for stock splits, stock dividends, combinations of shares, similar recapitalization transactions
and certain pro-rata distributions to common stockholders.
As
a result of the initial issuance and sale of the Series C Units, pursuant to the terms of the certificates of designations for
our Series A Preferred Stock, on April 8, 2016, the conversion price per share of Series A Preferred Stock decreased from $5.80
to $4.50 per share.
Description
of the rights attached to the Series B Preferred Stock
Holders
of Series B Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value
per share of Series B Preferred Stock. Dividends on the Series B Preferred Stock are payable quarterly on March 31, June 30, September
30 and December 31 of each year, beginning on September 30, 2014, and on each conversion date (with respect to the shares of Series
B Preferred Stock being converted). For so long as required under the terms of the certificate of designations for the Company’s
outstanding Series A Preferred Stock, dividends on Series B Preferred Stock will be payable only in shares of Common Stock. Thereafter,
dividends on the Series B Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions
are satisfied, shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be
valued at the lower of (a) the then current conversion price of the Series B Preferred Stock or (b) the average of the volume
weighted average price for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior
to the applicable dividend payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that
are not paid within three trading days of the applicable dividend payment date. During the years ended December 31, 2017, 2016
and 2015, the Company issued a total of 359,505, 272,282 and 168,926 shares of Common Stock, respectively, at an estimated
fair value of $854,647, $647,215 and $390,219, respectively, as in-kind dividends to holders of Series B Preferred Stock.
Subject
to certain ownership limitations described below, the Series B Preferred Stock is convertible at the option of the holder at any
time and from time to time into shares of Common Stock at a conversion price of $5.80 per share (calculated by dividing the stated
value per share of Series B Preferred Stock, which is initially $1,000, by the conversion price per share). The conversion price
of the Series B Preferred Stock is subject to adjustment for certain issuances of Common Stock or other securities of the Company
at an effective price per share that is lower than the conversion price then in effect, as well as for stock splits, stock dividends,
combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. In addition,
the holders of Series B Preferred Stock will be entitled to receive any securities or rights to acquire securities or property
granted or issued by the Company pro rata to the holders of Common Stock to the same extent as if such holders of Series B Preferred
Stock had converted all of their shares of Series B Preferred Stock prior to such distribution. In the event of a fundamental
transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations
of the Company, the holders of Series B Preferred Stock will be entitled to receive, upon conversion of their shares of Series
B Preferred Stock, any securities or other consideration received by the holders of the Common Stock pursuant to the fundamental
transaction.
Subject
to certain conditions contained in the certificate of designations for the Series B Preferred Stock, the Company will have the
option to force the conversion of the Series B Preferred Stock (in whole or in part) if (a) the volume weighted average price
for the Common Stock on its principal trading market exceeds $10.00 for each of any 20 trading days during any 30 consecutive
trading day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or
(b) the Company receives approval to list the Common Stock on a national securities exchange.
If
the Company fails to timely deliver certificates for shares of Common Stock issuable upon conversion of the Series B Preferred
Stock (the “Series B Conversion Shares”) which results in a Buy-In, the Company will be required to: (a) pay the converting
holder in cash an amount equal to the amount, if any, by which such holder’s total purchase price (including any brokerage
commissions) for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series B Conversion
Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation
was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the
shares of Series B Preferred Stock equal to the number of shares of Series B Preferred Stock submitted for conversion (in which
case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have
been issued if the Company had timely complied with its delivery requirements.
In
addition, the Company will be required to pay partial liquidated damages of $10 for each $1,000 of stated value of any shares
of Series B Preferred Stock which have been converted by a holder and in respect of which the Company fails to deliver Series
B Conversion Shares by the eighth trading day following the applicable conversion date.
As
long as at least 35% of the originally issued shares of Series B Preferred Stock are outstanding, without the written consent
of the holders of a majority in stated value of the outstanding Series B Preferred Stock, the Company will not be permitted to,
among other things, incur indebtedness or liens not permitted under the certificate of designations for the Series B Preferred
Stock; repay, repurchase, pay dividends on or otherwise make distributions in respect of any shares of Common Stock or other securities
junior to the Series B Preferred Stock; or enter into certain transactions with affiliates of the Company.
Subject
to any limitations under the terms of the Certificate of Designations for the Company’s outstanding Series A Preferred Stock,
the Company may become obligated to redeem the Series B Preferred Stock in cash upon the occurrence of certain triggering events,
including, among others, a material breach by the Company of certain contractual obligations to the holders of the Series B Preferred
Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company,
or the failure of the Common Stock to continue to be listed or quoted for trading on one or more specified United States securities
exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering events, each holder of Series
B Preferred Stock will have the option to require the Company to redeem such holder’s shares of Series B Preferred Stock
for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all of such holder’s
outstanding Series B Preferred Stock.
Subject
to the Beneficial Ownership Limitation, holders of Series B Preferred Stock will vote together with the holders of Common Stock,
Series A Preferred Stock and Series C Preferred Stock on an as-converted basis. Holders will not be permitted to convert their
Series B Preferred Stock if such conversion would cause such holder to beneficially own shares of outstanding Common Stock in
excess of the Beneficial Ownership Limitation.
Subject
to certain limitations, so long as any holder holds any shares of Series B Preferred Stock, if (a) the Company sells any shares
of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a holder then holding Series
B Preferred Stock, Series B Warrants, Series B Conversion Shares or shares of Common Stock issuable upon exercise of Series B
Warrants believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the holder in
such subsequent sale of securities than are the terms and conditions granted to such holder, then the holder will be permitted
to require the Company to amend the terms of this transaction (only with respect to such holder) so as to match the terms of the
subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to such
holder).
As
a result of the initial issuance and sale of the Series C Units, pursuant to the terms of the certificates of designations for
our Series B Preferred Stock, on April 8, 2016, the conversion price per share of Series B Preferred Stock decreased from $5.80
to $4.50 per share.
Description
of the rights attached to the Series C Preferred Stock
Holders
of Series C Preferred Stock are entitled to receive cumulative dividends at a rate of 5.5% per annum, based on the stated value
per share of Series C Preferred Stock. Dividends on the Series C Preferred Stock are payable quarterly on March 31, June 30, September
30 and December 31 of each year, beginning on June 30, 2016, and on each conversion date (with respect to the shares of Preferred
Stock being converted). For so long as required under the terms of the certificate of designations for the Company’s outstanding
Series A Preferred Stock or Series B Preferred Stock, dividends will be payable only in shares of Common Stock. Thereafter, dividends
on the Series C Preferred Stock will be payable, at the option of the Company, in cash and/or, if certain conditions are satisfied,
shares of Common Stock or a combination of both. Shares of Common Stock issued as payment of dividends will be valued at the lower
of (a) the then current conversion price of the Series C Preferred Stock or (b) the average of the volume weighted average price
for the Common Stock on the principal trading market therefor for the 10 trading days immediately prior to the applicable dividend
payment date. The Company will incur a late fee of 9% per annum, payable in cash, on dividends that are not paid within three
trading days of the applicable dividend payment date. During the years ended December 31, 2017 and 2016, the Company issued a
total of 237,169 shares and 64,148 shares of Common Stock, at an estimated fair value of $566,033 and $152,480, respectively,
as in kind dividends to holders of Series C Preferred Stock.
Subject
to any limitations under the terms of the certificate of designations for the Company’s outstanding Series A Preferred Stock
or Series B Preferred Stock, the Company may become obligated to redeem the Series C Preferred Stock in cash upon the occurrence
of certain triggering events, including, among others, a material breach by the Company of certain contractual obligations to
the holders of the Series C Preferred Stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency
events relating to the Company, or the failure of the Common Stock to continue to be listed or quoted for trading on one or more
specified United States securities exchanges or a regulated quotation service. In addition, upon the occurrence of certain triggering
events, each holder of Series C Preferred Stock will have the option to require the Company to redeem such holder’s shares
of Preferred Stock for a redemption price payable in shares of Common Stock or receive an increased dividend rate of 9% on all
of such holder’s outstanding Series C Preferred Stock.
Subject
to certain conditions contained in the certificate of designations for the Series C Preferred Stock, the Company will have the
option to force the conversion of the Series C Preferred Stock (in whole or in part) if (a) the volume weighted average price
for the Common Stock on its principal trading market exceeds $7.00 for each of any 20 trading days during any 30 consecutive trading
day period and the average daily dollar trading value for the Common Stock during such 30 day period exceeds $50,000 or (b) the
Company receives approval to list the Common Stock on a national securities exchange.
Subject
to certain exceptions contained in the certificate of designations, if the Company fails to timely deliver certificates for shares
of Common Stock issuable upon conversion of the Series C Preferred Stock (the “Series C Conversion Shares”) which
results in a Buy-In, the Company will be required to: (a) pay the converting holder in cash an amount equal to the amount, if
any, by which such for the shares of Common Stock so purchased exceeds the product of (i) the aggregate number of Series C Conversion
Shares due to the holder, multiplied by (ii) the actual sale price at which the sell order giving rise to such purchase obligation
was executed (including any brokerage commissions); and (b) at the option of such holder, either reissue (if surrendered) the
shares of Series C Preferred Stock equal to the number of shares of Series C Preferred Stock submitted for conversion (in which
case, such conversion will be deemed rescinded) or deliver to such holder the number of shares of Common Stock that would have
been issued if the Company had timely complied with its delivery requirements. In addition, the Company will be required to pay
partial liquidated damages of $10 for each $1,000 of stated value of any shares of Series C Preferred Stock which have been converted
by a holder and in respect of which the Company fails to deliver Series C Conversion Shares by the fifth trading day following
the applicable conversion date and the Company will continue to pay such partial liquidated damages for each trading day after
such eighth trading day until such certificates are delivered or the holder rescinds such conversion.
As
long as at least 35% of the originally issued shares of Series C Preferred Stock are outstanding, without the written consent
of the holders of a majority in stated value of the outstanding Series C Preferred Stock, the Company will not be permitted to,
among other things, incur indebtedness or liens not permitted under the certificate of designations; repay, repurchase, pay dividends
on or otherwise make distributions in respect of any shares of Common Stock or other securities junior to the Series C Preferred
Stock; enter into certain transactions with affiliates of the Company; or enter into any agreement with respect to the foregoing.
Subject
to the beneficial ownership limitation described below, holders of Series C Preferred Stock will vote together with the holders
of Common Stock, Series A Preferred Stock and Series B Preferred Stock on an as-converted basis. Holders will not be permitted
to convert their Series C Preferred Stock above the Beneficial Ownership Limitation. In addition, no holder may vote any shares
of Series C Preferred Stock (on an as-converted to Common Stock basis) in excess of the Beneficial Ownership Limitation.
Subject
to certain limitations, so long as any holder holds any shares of Series C Preferred Stock, if (a) the Company sells any shares
of Common Stock or other securities convertible into, or rights to acquire, Common Stock and (b) a holder then holding Series
C Preferred Stock, Series C Warrants, Series C Conversion Shares or shares of Common Stock issuable upon exercise of Series C
Warrants reasonably believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the
holder in such subsequent sale of securities than are the terms and conditions granted to such holder, then the holder will be
permitted to require the Company to amend the terms of this transaction (only with respect to such holder) so as to match the
terms of the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable
to such holder).
Stock
Options
We
maintain the Integrity Applications, Inc. 2010 Incentive Compensation Plan (the “Plan”), which was approved by the
Board of Directors in July 2010 and by the shareholders on July 22, 2010, to provide a means for us and our related entities to
attract, motivate and reward elite executives, officers, directors, consultants and other persons who to provide services to us
and our related entities, as well as to provide a means by which those individuals can acquire and maintain stock ownership, resulting
in a strengthening of their commitment to our welfare and the welfare of our related entities and promoting the mutuality of interests
between those individuals who provide services to us and our stockholders. The plan provides those individuals with additional
incentive and reward opportunities designed to enhance our profitable growth and provide those individuals with annual and long-term
performance incentives to expend their maximum efforts in the creation of stockholder value. The plan provides for the issuance
of stock options, stock appreciation rights, restricted stock awards, deferred stock awards, shares granted as a bonus or in lieu
of another award, dividend equivalents, other stock-based awards or performance awards.
We
initially reserved 529,555 shares of Common Stock for issuance under the Plan. On March 17, 2016, the Board approved an amendment
to the Plan to increase the number of shares of Common Stock reserved for issuance under the Plan from 529,555 shares to 1,000,000
shares. On April 7, 2017, the Board of Directors approved an amendment to the Plan to further increase the number of shares of
Common Stock reserved for issuance under the Plan from 1,000,000 shares to 5,625,000 shares.
On
March 23, 2018, stockholders of the Company approved the two amendments to the Plan adopted by the Board as of April 7, 2017 and
February 15, 2018.
The
following table sets forth information as of March 31, 2018, with respect to securities authorized for issuance under the
Plan, which has been approved by Integrity’s stockholders, as well as securities authorized for issuance under certain compensation
arrangements that were not issued under the Plan and were not subject to approval by Integrity’s stockholders.
|
|
Number of securities to be issued upon exercise of
outstanding options, warrants and rights
|
|
|
Weighted-average exercise price of outstanding options, warrants and rights
|
|
|
Number of securities remaining available for future issuance under equity compensation
plans (excluding securities reflected in column (a))
|
|
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
Equity compensation issued under the Plan
|
|
|
6,058,955
|
|
|
$
|
5.28
|
|
|
|
941,045
|
(1)
|
Equity compensation not issued under the Plan (not subject to approval by security holders)
|
|
|
2,261,584
|
(2)
|
|
$
|
5.37
|
|
|
|
—
|
|
Total
|
|
|
8,320,539
|
|
|
$
|
5.31
|
|
|
|
941,045
|
|
|
(1)
|
As
of the date hereof, there are 7,000,000 shares of the Company’s Common Stock reserved for issuance under the Plan
.
|
|
|
|
|
(2)
|
Consists
of: (i) warrants to purchase 129,556 shares of Common Stock issuable to Andrew Garrett, Inc., as partial consideration
for its services as the placement agent for Integrity’s private placement of 1,295,545 shares of Common Stock completed
in July 2011, (ii) warrants to purchase 256,769 shares of Common Stock issued or issuable to Andrew Garrett, Inc., as partial
consideration for its services as placement agent for Integrity’s private placement of the Series A Units; (iii) warrants
to purchase 439,674 shares of Common Stock issued or issuable to Andrew Garrett, Inc., as partial consideration for its services
as placement agent for Integrity’s private placement of the Series B Units; (iv) warrants to purchase 844,605 shares
of Common Stock issued or issuable to Andrew Garrett, Inc., as partial consideration for its services as placement agent for
Integrity’s private placement of the Series C Units; (v) warrants to purchase 275,610 shares of Common Stock issued
or issuable to the placement agent for Integrity’s private placement of the Series D Units as partial consideration
for its services; (vi) warrants to purchase 244,572 shares of Common Stock issued pursuant to the anti-dilution provisions
of outstanding warrants held by Andrew Garrett, Inc.; (vii) options to purchase 17,656 shares of Common Stock issued to the
Company’s former investor relations provider, as partial consideration for their services; (viii) options to purchase
21,640 shares of Common Stock issued in consideration of regulatory services; and (ix) options to purchase 31,502 shares of
Common Stock issued in consideration of finder’s fee.
|
Warrants
As of June 7 , 2018,
the Company had warrants to purchase an aggregate of 14,886,585 shares of Common Stock, which included 2,666,290 Series B-1 Warrants
issued to investors, 2,666,290 Series B-2 Warrants issued to investors, 2,667,540 Series C-1 Warrants issued to investors,
2,667,540 Series C-2 Warrants issued to investors, 644,888 Series D-1 Warrants issued to investors, 644,888 Series D-2
Warrants issued to investors, 644,888 Series D-3 Warrants issued to investors, and 2,284,263 warrants issued to consultants as
described above.
Series
A Warrants
The
Series A Warrants had a five-year term commencing on March 13, 2013 and ending on March 31, 2018. Until the end of the term, the
Series A Warrants were exercisable at any time and from time to time at an exercise price of $6.96 per share. The Series A Warrants
contained adjustment provisions substantially similar to those to the adjustment provisions of the Series A Preferred Stock as
described above. In addition, the Series A Warrants provided for protection for a Buy-In on substantially the same terms as described
above with respect to the Series A Preferred Stock. No holder might exercise its Series A Warrants in excess of the Beneficial
Ownership Limitation.
As
a result of the initial issuance and sale of the Series B Units, the Company issued to the holders of Series A Warrants additional
256,589 Series A Warrants with an exercise price of $5.80 as anti-dilution warrants and reduced the exercise price of the outstanding
Series A Warrants to $5.80. Furthermore, as a result of the initial issuance and sale of the Series C Units, pursuant to the terms
of the warrants issued by the Company to the holders of Series A Warrants, the exercise price per share of the Series A Warrants
decreased from $5.80 per share to $4.50 per share and the number of shares of Common Stock issuable upon exercise of each of the
Series A Warrants, in the aggregate, increased such that the aggregate exercise price payable thereunder, after taking into account
the decrease in the exercise price, would be equal to the aggregate exercise price prior to such adjustment.
As
of the date hereof, all Series A Warrants have expired.
Series
B Warrants
The
Series B Warrants have a five-year term commencing on August 29, 2014 and ending on December 31 , 2019. Until the end of
the term, the Series B Warrants will be exercisable at any time and from time to time at an exercise price of $5.80 per share
(with respect to the Series B-1 Warrants) or $10.00 per share (with respect to the Series B-2 Warrants). The Series B Warrants
contain adjustment provisions substantially similar to those of the Series B Preferred Stock as described above, except that the
Series B Warrants shall not include dilution protection for issuances of securities at an effective price per share lower than
the conversion price of such Series B Warrants. In addition, the Series B Warrants provide for protection for a Buy-In on substantially
the same terms as described above with respect to the Series B Preferred Stock. No holder may exercise its Series B Warrants in
excess of the Beneficial Ownership Limitation.
As
a result of the initial issuance and sale of the Series C Units, pursuant to the terms of the warrants issued by the Company to
the holders of Series B Warrants, the exercise prices per share of the Series B-1 Warrants and Series B-2 Warrants decreased from
$5.80 per share and $10,00 per share to $4.50 per share and $7.75 per share, respectively, and the number of shares of Common
Stock issuable upon exercise of each of the Series B-1 Warrants and Series B-2 Warrants, in the aggregate, increased such that
the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, will be equal to
the aggregate exercise price prior to such adjustment.
Series
C Warrants
The
Series C Warrants have a five-year term commencing on their respective issuance dates. Until the end of the applicable term, each
Series C Warrant will be exercisable at any time and from time to time at an original exercise price of $4.50 per share (with
respect to the Series C-1 Warrants) or $7.75 per share (with respect to the Series C-2 Warrants). The Series C Warrants contain
adjustment provisions substantially similar to those to the adjustment provisions of the Series C Preferred Stock as described
above, except that the Series C Warrants do not include dilution protection for issuances of securities at an effective price
per share lower than the conversion price of such Series C Warrants. In addition, the Series C Warrants provide for protection
for a Buy-In on substantially the same terms as described above with respect to the Series C Preferred Stock. No holder may exercise
its Series C Warrants in excess of the Beneficial Ownership Limitation.
Series
D Warrants
The
Series D Warrants have a five-year term commencing on their respective issuance dates. Until the end of the applicable term, each
Series DWarrant will be exercisable at any time and from time to time at an original exercise price of
$4.50
per share (with respect to the Series D-1 Warrants), $5.75 (with respect to the Series D-2 Warrants) or $7.75 per share (with
respect to the Series D-3 Warrants)
. The Series DWarrants provide for protection for a Buy-In on substantially the same
terms as described above
under “Description of the rights attached to the Series A
Preferred Stock”.
No holder may exercise its Series DWarrants in excess of the Beneficial Ownership Limitation.
Limitations
on Resales by FINRA Members
Pursuant
to FINRA Rule 5110(g)(1), holders of shares who purchased shares of our Common Stock in the private placement during the 180 day
period prior to the filing of this Registration Statement who are affiliated with members of FINRA and who elect, pursuant to
the registration rights agreement, to include their shares for resale pursuant to the registration statement, are required to
refrain, during the period commencing on the effective date of the registration statement and ending on the date that is 180 days
after such effective date, from selling, transferring, assigning, pledging or hypothecating or otherwise entering into any hedging,
short sale, derivative, put or call transaction that would result in the effective economic disposition of such holder’s
shares.
Anti-Takeover
Effects of Delaware Law and Our Charter and Bylaws
Certificate
of Incorporation and Bylaws
Blank
Check Preferred Stock
. Our board of directors, without stockholder approval, has the authority under our certificate of incorporation
to issue preferred stock with rights superior to the rights of the holders of Common Stock. As a result, preferred stock could
be issued quickly and easily, could impair the rights of holders of Common Stock and could be issued with terms calculated to
delay or prevent a change of control or make removal of management more difficult.
Election
of Directors
. Our certificate of incorporation provides that a majority of directors then in office may fill any vacancy occurring
on the board of directors, even though less than a quorum may then be in office. These provisions may discourage a third-party
from voting to remove incumbent directors and simultaneously gaining control of the board of directors by filling the vacancies
created by that removal with its own nominees.
Stockholder
Action
. Our certificate of incorporation provides that stockholders may act at meetings of stockholders or by written consent
in lieu of a stockholders’ meeting.
Stockholder
Meetings
. Our bylaws provide that the only business that may be conducted at a special meeting of stockholders is such business
as was specified in the notice of the meeting. These provisions may discourage another person or entity from making a tender offer,
even if it acquired a majority of our outstanding voting stock, because the person or entity could only take action at a duly
called stockholders’ meeting relating to the business specified in the notice of meeting and not by written consent.
Requirements
for Advance Notification of Stockholder Nominations and Proposals
. Our bylaws provide that a stockholder seeking to bring
business before an annual meeting of stockholders, or to nominate candidates for election as directors at an annual meeting of
stockholders, must provide timely notice of this intention in writing. To be timely, a stockholder must deliver or mail the notice
and we must receive the notice at our principal executive offices not less than five days prior to the date our directors determine
for proposals to be received. The bylaws also include a similar requirement for making director nominations and specify requirements
as to the form and content of the stockholder’s notice. These provisions could delay stockholder actions that are favored
by the holders of a majority of our outstanding stock until the next stockholders’ meeting.
Delaware
Anti-Takeover Statute
We
are a Delaware corporation subject to Section 203 of the Delaware General Corporation Law (the “DGCL”). Under Section
203, some business combinations between a Delaware corporation whose stock generally is publicly-traded or held of record by more
than 2,000 stockholders and an interested stockholder are prohibited for a three-year period following the date that the stockholder
became an interested stockholder, unless:
|
●
|
the
corporation has elected in its certificate of incorporation not to be governed by Section 203;
|
|
|
|
|
●
|
the
board of directors of the corporation approved the transaction which resulted in the stockholder becoming an interested stockholder
before the stockholder became an interested stockholder;
|
|
|
|
|
●
|
upon
consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the commencement of the transaction, excluding voting
stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential
right to tender stock held by the plan in a tender or exchange offer; or
|
|
|
|
|
●
|
the
board of directors approves the business combination and holders of two-thirds of the voting stock which the interested stockholder
did not own authorize the business combination at a meeting.
|
We
have not made an election in our certificate of incorporation to opt out of Section 203. In addition to the above exceptions to
Section 203, the three-year prohibition does not apply to some business combinations proposed by an interested stockholder following
the announcement or notification of an extraordinary transaction involving the corporation and a person who was not an interested
stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the corporation’s
directors. For the purposes of Section 203, a business combination generally includes mergers or consolidations, transactions
involving the assets or stock of the corporation or its majority-owned subsidiaries and transactions which increase an interested
stockholder’s percentage ownership of stock. Also, an interested stockholder generally includes a stockholder who becomes
beneficial owner of 15% or more of a Delaware corporation’s voting stock, together with the affiliates or associates of
that stockholder.
Transfer
Agent and Registrar
American
Stock Transfer and Trust Company, LLC serves as transfer agent and registrar for our Common Stock.
PLAN
OF DISTRIBUTION
Each
selling stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time,
sell any or all of their securities covered hereby on the OTCQB or any other stock exchange, market or trading facility on which
the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder
may use any one or more of the following methods when selling securities:
|
●
|
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
|
|
●
|
block
trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the
block as principal to facilitate the transaction;
|
|
|
|
|
●
|
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account;
|
|
|
|
|
●
|
an
exchange distribution in accordance with the rules of the applicable exchange;
|
|
|
|
|
●
|
privately
negotiated transactions;
|
|
|
|
|
●
|
settlement
of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
|
|
|
|
|
●
|
in
transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities
at a stipulated price per security;
|
|
|
|
|
●
|
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
|
|
|
●
|
a
combination of any such methods of sale; or
|
|
|
|
|
●
|
any
other method permitted pursuant to applicable law.
|
The
selling stockholders may also sell securities under Rule 144 under the Securities Act, if available, rather than under this prospectus.
Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities,
from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an
agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a
principal transaction a markup or markdown in compliance with FINRA IM-2440.
In
connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of
hedging the positions they assume. The selling stockholders may also sell securities short and deliver these securities to close
out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one
or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered
by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).
The
selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters”
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement
or understanding, directly or indirectly, with any person to distribute the securities. In no event shall any broker-dealer receive
fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).
The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The
Company has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.
Because
selling stockholders may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject
to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered
by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than
under this prospectus. The selling stockholders have advised us that there is no underwriter or coordinating broker acting in
connection with the proposed sale of the resale securities by the selling stockholders.
We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling
stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without
the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act
or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under
the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed
brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered
hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the
registration or qualification requirement is available and is complied with.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined
in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of
purchases and sales of securities of the Common Stock by the selling stockholders or any other person. We will make copies of
this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus
to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).
LEGAL
MATTERS
The
legality of the securities offered by this prospectus has been passed upon by Robinson & Cole LLP, 1055 Washington Blvd, Stamford,
CT 06901.
EXPERTS
The audited consolidated
financial statements of Integrity Applications, Inc. incorporated by reference in this prospectus and elsewhere in the registration
statement have been so incorporated by reference in reliance upon the report of Fahn Kanne & Co. Grant Thornton Israel,
independent registered public accountants, upon the authority of said firm as experts in accounting and auditing.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the Common Stock. This prospectus,
which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement, some items of which are contained in exhibits to the registration statement as permitted by the rules and regulations
of the SEC. For further information with respect to us and our Common Stock, we refer you to the registration statement, including
the exhibits and the consolidated financial statements and notes incorporated by reference into the registration statement. Statements
contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a
contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document
that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in
all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete contents of
these contracts and documents.
We
also file annual, quarterly and current reports, proxy statements and other information with the SEC. Any document we file with
the SEC (including the registration statement of which this prospectus is a part) may be inspected without charge at the SEC’s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549, and copies of all or any part of any such document may be
obtained from the SEC upon the payment of fees prescribed by it. You may call the SEC at 1-800-SEC-0330 for more information on
the operation of the public reference facilities. The SEC maintains a website at http://www.sec.gov that contains reports, proxy
and information statements and other information regarding companies that file electronically with it.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
For
purposes of this prospectus, the SEC allows us to “incorporate by reference” certain information we have filed with
the SEC, which means that we are disclosing important information to you by referring you to other information we have filed with
the SEC. The information we incorporate by reference is considered part of this prospectus. We specifically are incorporating
by reference the following report filed with the SEC:
|
●
|
Current
Report on Form 8-K, filed with the SEC on December 28, 2017;
|
|
●
|
Current
Report on Form 8-K, filed with the SEC on March 7, 2018;
|
|
●
|
Current
Report on Form 8-K, filed with the SEC on March 23, 2018;
|
|
●
|
Annual
Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 30, 2018; and
|
|
●
|
Quarterly
Report on Form 10-Q for the period ended March 31, 2018, filed with the SEC on May 15, 2018.
|
These
reports and documents can be accessed free of charge on our website at
http://www.integrity-app.com
. We will provide without
charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy
of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other
than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus
incorporates. Please send written requests to:
Integrity
Applications, Inc.
19 Ha’Yahalomim St., Ashdod, Israel 7760049
972 (8) 675-7878
Attn: Chief Executive Officer
INTEGRITY
APPLICATIONS INC.
8,736,198
Shares of Common Stock
PROSPECTUS
June 7
, 2018
PART
II - INFORMATION NOT REQUIRED IN PROSPECTUS
Item
13. Other Expenses of Issuance and Distribution.
The
following table sets forth an estimate of the fees and expenses payable by us in connection with the registration of our securities
offered hereby. All of such fees and expenses, except for the SEC Registration Fee, are estimated:
SEC Registration and Filing Fee
|
|
$
|
4,894
|
|
Legal Fees and Expenses
|
|
$
|
50,000
|
|
Accounting Fees and Expenses
|
|
$
|
6,000
|
|
Printing Fees and Expenses
|
|
$
|
4,000
|
|
Miscellaneous
|
|
$
|
1,500
|
|
TOTAL
|
|
$
|
66,394
|
|
Item
14. Indemnification of Directors and Officers.
Section
145 of the DGCL empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other
than an action by or in the right of such corporation) by reason of the fact that such person is or was a director, officer, employee
or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent
of another corporation or enterprise. A corporation may, in advance of the final action of any civil, criminal, administrative
or investigative action, suit or proceeding, pay the expenses (including attorneys’ fees) incurred by any officer, director,
employee or agent in defending such action, provided that the director or officer undertakes to repay such amount if it shall
ultimately be determined that he or she is not entitled to be indemnified by the corporation. A corporation may indemnify such
person against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by such person in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
A
Delaware corporation may indemnify officers and directors in an action by or in the right of the corporation to procure a judgment
in its favor under the same conditions, except that no indemnification is permitted without judicial approval if the officer or
director is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in
the defense of any action referred to above, the corporation must indemnify him or her against the expenses (including attorneys’
fees) which he or she actually and reasonably incurred in connection therewith. The indemnification provided is not deemed to
be exclusive of any other rights to which an officer or director may be entitled under any corporation’s by-law, agreement,
vote or otherwise.
Our
bylaws provide that we will indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action
by or in the right of our company) by reason of the fact that he is or was a director, officer, employee or agent of ours, or
is or was serving at our request as a director, officer, employee, trustee or agent of one of our subsidiaries or another corporation,
partnership, joint venture, trust or other enterprise (all such persons being referred to hereinafter as an agent), against expenses
(including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or
her in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he or she reasonably believed
to be in or not opposed to our best interests, and with respect to any criminal action or proceeding, had no reasonable cause
to believe his or her conduct was unlawful.
Additionally,
our bylaws provide that we will indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action or suit by or in the right of our company to procure a judgment in our favor by reason of the fact
that he is or was an agent against expenses (including attorneys’ fees) actually and reasonably incurred by him or her in
connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably
believed to be in or not opposed to our best interests, except that no indemnification will be made in respect of any claim, issue
or matter as to which such person shall have been adjudged to be liable to us by a court of competent jurisdiction, after exhaustion
of all appeals therefrom, unless and only to the extent that the court in which such action or suit was brought shall determine
upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is
fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.
Our
certificate of incorporation provides that none of its directors shall be liable to us or our stockholders for monetary damages
for breach of fiduciary duty as a director, except for liability (a) for any breach of the director’s duty of loyalty to
us or our stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation
of law, (c) under Section 174 of the DGCL, or (d) for any transaction from which the director derived an improper personal benefit.
To the extent the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability
of one of our directors, in addition to the limitation on personal liability provided by our certificate of incorporation, shall
be limited to the fullest extent permitted by the amended DGCL.
We
have obtained and maintains insurance policies insuring our directors and officers and the directors and officers of our subsidiaries
against certain liabilities they may incur in their capacity as directors and officers. Under such policies, the insurer, on our
behalf, may also pay amounts for which we have granted indemnification to the directors or officers.
Additionally,
we have entered into indemnification agreements with all of our directors and officers to provide them with the maximum indemnification
allowed under our bylaws and applicable law, including indemnification for all judgments and expenses incurred as the result of
any lawsuit in which such person is named as a defendant by reason of being a director, officer or employee of our company, to
the extent indemnification is permitted by the laws of the State of Delaware.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling
us pursuant to the foregoing provisions, we understand that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.
Item
15. Recent Sales of Unregistered Securities
Offering
of Series A Unit
On
November 19, 2012, the Company completed the first closing of an offering (the “First Closing”), pursuant to which
the Company issued and sold an aggregate of 165,057 shares of Common Stock at a price of $7.00 per share to certain accredited
investors (the “First Closing Purchasers”). In March 2013, the offering was converted from an offering of Common Stock
to an offering of Series A Units (see Note 10 to the Company’s financial statements included in this Annual Report on Form
10-K for more details). On March 13, 2013, the Company entered into a series of Securities Purchase Agreements (“Series
A Purchase Agreements”) with certain accredited investors (the “Series A Unit Purchasers”) pursuant to which
the Company issued to the Series A Unit Purchasers an aggregate of 6,300 Series A Units, at a price of $1,000 per unit, each consisting
of (i) one share of Series A 5.0% Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred Stock”),
convertible into shares of Common Stock at an initial conversion price of $5.80 per share, and (ii) a warrant to purchase, at
an exercise price of $6.96 per share, up to 100% of the shares of Common Stock issuable upon conversion of such share of Series
A Preferred Stock. The issuance and sale of the Series A Units constituted the second and final closing of the offering.
As
a result of the conversion of the offering from an offering of Common Stock to an offering of Series A Units, the Company agreed
with Andrew Garrett, Inc., the placement agent for the offering (“AGI”), that, following the closing of the sale of
the Series A Units, the Company would exchange the shares of Common Stock acquired by each First Closing Purchaser in the First
Closing for such number of Series A Units equal to the aggregate purchase price paid by such First Closing Purchaser in the First
Closing, divided by $1,000, in each case subject to the execution by the First Closing Purchasers of a consent to such modification.
Pursuant to this agreement, on May 13, 2013, the Company cancelled 162,907 of the 165,057 shares of Common Stock issued to the
First Closing Purchasers and issued to such First Closing Purchasers an aggregate of 1,140.35 Series A Units. Such Series A Units
included Series A Preferred Stock convertible into an aggregate of 196,597 shares of Common Stock at a conversion price of $5.80
per share and Series A Warrants exercisable for 196,597 shares of Common Stock at an exercise price of $6.96 per share.
Offering
of Series B Units
Between
August and December 2014, the Company entered into a series of Securities Purchase Agreements (“Series B Purchase Agreement”)
with certain accredited investors (the “Series B Unit Purchasers”) pursuant to which the Company issued to the Series
B Unit Purchasers an aggregate of 8,500 Series B units (“Series B Units”), at a price of $1,000 per unit, each consisting
of (i) one share of our Series B 5.5% Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”),
convertible into shares of Common Stock, at an initial conversion price of $5.80 per share, (ii) a five year warrant to purchase,
at an exercise price of $5.80 per share, up to such number of shares of Common Stock issuable upon conversion of such share of
Series B Preferred Stock (each a “Series B-1 Warrant”) and (iii) a five year warrant to purchase, at an exercise price
of $10.00 per share, up to such number of shares of Common Stock issuable upon conversion of such share of Series B Preferred
Stock (each a “Series B-2 Warrant” and, together with the Series B-1 Warrants, collectively, the “Series B Warrants”).
The shares of Series B Preferred Stock included in the Series B Units are convertible into an aggregate of 1,465,578 shares of
Common Stock, and the Series B Warrants included in the Series B Units are exercisable for an aggregate of 2,931,156 shares of
Common Stock, in each case subject to adjustment in certain circumstances.
Offering
of Series C Units
Between
April 2016 and December of 2017, the Company received aggregate net proceeds of approximately $10.33 million (net of related cash
expenses) from the issuance and sale in a private placement transaction, at a price of $1,000 per unit, of 12,003.8 Series C units
(the “Series C Units”), each consisting of (i) one share of the Company’s Series C 5.5% Convertible Preferred
Stock, par value $0.001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock
and Series B Preferred Stock, the “Preferred Stock”), convertible into shares of Common Stock, at an initial conversion
price of $4.50 per share, (ii) a five year warrant to purchase, at an exercise price of $4.50 per share, up to such number of
shares of Common Stock issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-1 Warrant”)
and (iii) a five year warrant to purchase, at an exercise price of $7.75 per share, up to such number of shares of Common Stock
issuable upon conversion of such share of Series C Preferred Stock (each a “Series C-2 Warrant” and, together with
the Series C-1 Warrants, collectively, the “Series C Warrants”). The shares of Series C Preferred Stock included in
the Series C Units are convertible into an aggregate of 2,667,540 shares of Common Stock, and the Series C Warrants included
in the Series C Units are exercisable for an aggregate of 5,335,080 shares of Common Stock, in each case subject to adjustment
in certain circumstances.
Pursuant
to a placement agent agreement with AGI, at the initial closing of the sale of the Series C Units, the Company paid AGI, as a
commission, an amount equal to 6% of the aggregate sales price of the Series C Units, plus 4% of the aggregate sales price as
a management fee plus a non-accountable expense allowance equal to 3% of the aggregate sales price of the Series C Units. At the
end of the second, third, fourth, fifth, sixth and seventh closings of the sale of the Series C Units, the Company paid AGI, as
a commission, an amount equal to 10% of the aggregate sales price of the Series C Units sold in such closing, plus a non-accountable
expense allowance equal to 3% of the aggregate sales price of the Series C Units sold in such closing. In addition, pursuant to
the placement agent agreement, the Company is required to issue to AGI: (a) 5-year warrants to purchase up to 551,681 shares of
Common Stock at an exercise price of $4.50 per share and (b) 5-year warrants to purchase up to 288,924 shares of Common Stock
at an exercise price of $7.75 per share. The terms of such warrants will be substantially similar to the Series C Warrants except
that the warrants issued to AGI will also be exercisable on a cashless basis and will include full ratchet anti-dilution protection.
As
a result of the initial issuance and sale of the Series C Units, pursuant to the terms of the Series A Warrants, on April 8, 2016,
the exercise price per share of the Series A Warrants decreased from $5.80 per share to $4.50 per share and the number of shares
of Common Stock issuable upon exercise of each of the Series A Warrants, in the aggregate, increased such that the aggregate exercise
price payable thereunder, after taking into account the decrease in the exercise price, will be equal to the aggregate exercise
price prior to such adjustment. Also as a result of the initial issuance and sale of the Series C Units, pursuant to the terms
of the certificates of designations for the Series A Preferred Stock and Series B Preferred Stock, on April 8, 2016, the conversion
price per share of Series A Preferred Stock and Series B Preferred Stock decreased to $4.50 per share.
Based
on the terms of the purchase agreements relating to the issuance and sale of the Series A Units and the Series B Units, respectively,
so long as any initial purchaser of Series A Units or Series B Units, as applicable, holds any shares of Series A Preferred Stock
or Series B Preferred Stock, respectively, if (i) the Company sells any shares of Common Stock or other securities convertible
into, or rights to acquire, Common Stock and (ii) a purchaser then holding Series A or Series B Preferred Stock or Warrants reasonably
believes that any of the terms and conditions appurtenant to such issuance or sale are more favorable to the purchaser in such
subsequent sale of securities than are the terms and conditions granted to such purchaser, then the purchaser will be permitted
to require the Company to amend the terms of this transaction (only with respect to such purchaser) so as to match the terms of
the subsequent issuance (including, for the avoidance of doubt, any terms and provisions that are or may be less favorable to
such purchaser).
Pursuant
to the Series A Purchase Agreement and Series B Purchase Agreement, the Company was required to and did notify the holders of
the Series A Preferred Stock and Series B Preferred Stock of the closing of the sale of the Series C Units, and following receipt
thereof such holders of Series A Preferred Stock and Series B Preferred Stock were entitled, pursuant to the “most favored
nation” provisions contained in the Series A Purchase Agreement and Series B Purchase Agreement (as described above), to
elect to amend the terms of their purchase of Series A Units and Series B Units to match the terms of the Series C Units. The
Company was obligated to amend the terms of any Series A Units and Series B Units held by a Series A Purchaser or Series B Purchaser,
respectively, who timely made such election and tendered its Series A Units or Series B Units for exchange.
As
of December 31, 2015, the holders of approximately 6,931 Series A Units have elected, pursuant to the “most favored nation”
provision in the Series A Purchase Agreement, to amend the terms of their Series A Units to match the terms of the Series B Units.
Accordingly, the Company has exchanged 6,931 shares of Series A Preferred Stock into 6,931 shares of Series B Preferred Stock
and 1,440,880 Series A Warrants into 1,200,710 Series B-1 Warrants and 1,200,710 Series B-2 Warrants. Due to the differences in
the contractual terms of each of the financial instruments exchanged management determined that the exchange constitutes an extinguishment
of the existing instruments and an issuance of new financial instruments. As a result of the exchange elections, the Company recorded
during the year ended December 31, 2015 a non-cash loss on extinguishment of Series A Preferred Stock and Series A Warrants in
the amount of $1,284,354, resulting from the differences between the fair market value estimate of the new Series B Units less
the net book value of the exchanged Series A Preferred Stock and less the fair value of the exchanged Warrants with down-round
protection. During the year ended December 31, 2016, no holders of Series A Units elected to exercise their “most favored
nation” rights.
During
2016 and 2017, no holders of Series A Units or Series B Units have elected to amend the terms of their Series A or Series B Units,
as applicable, to match the terms of the Series C Units.
Offering
of Series D Units
From
December 1, 2017 to May 9, 2018, the Company conducted five closings of the private placement pursuant to a series of securities
purchase agreement (“Series D Purchase Agreement”) with certain accredited investors (the “Series D Unit Purchasers”)
and issued an aggregate of 644,888 units of the Company (collectively, the “Series D Units”), each consisting of (a)
one share of the Company’s Common Stock, (b) a five year warrant to purchase, at an exercise price of $4.50 per share, one
share of Common Stock (collectively, the “Series D-1 Warrants”), (c) a five year warrant to purchase, at an exercise
price of $5.75 per share, one share of Common Stock (collectively, the “Series D-2 Warrants”), and (d) a five year
warrant to purchase, at an exercise price of $7.75 per share, one share of Common Stock (collectively, the “Series D-3 Warrants”,
and together with the Series D-1 Warrants and Series D-2 Warrants, the “Series D Warrants”).
As
of the fifth closing, the Company received aggregate gross proceeds of $2,902,000 from the sale of the Series D Units pursuant
to the Series D Purchase Agreements.
Subject
to the beneficial ownership limitation described below, holders of the Series D Warrants will not be permitted to exercise their
Series D Warrants if such exercise would cause such holder to beneficially own more than 4.99% of the outstanding Common Stock
(subject to increase to 9.99%, at the option of the holder, upon no less than 61 days prior written notice to the Company).
In
connection with the sale of the Series D Units, the Company entered into a series of registration rights agreements with the Series
D Unit Purchasers (the “Series D Registration Rights Agreement”) pursuant to which, subject to certain exceptions,
the Company has agreed to file with the SEC, no later than 90 days after the final issuance of Series D Units, a registration
statement covering the resale of all of (a) the shares of Common Stock, (b) the shares of Common Stock issuable upon exercise
of the Series D Warrants in full; (c) any additional shares of Common Stock issuable in connection with any anti-dilution provisions
in the Series D Warrants; and (d) any securities issued or then issuable upon any stock split, dividend or other distribution,
recapitalization or similar event with respect to the foregoing. Subject to certain exceptions and limitations specified in the
Series D Registration Rights Agreement, the Company will be required to pay each holder monthly partial liquidated damages in
the amount of 2% of the aggregate purchase price paid by such holder pursuant to the Series D Purchase Agreement, if the Company
fails to timely file a registration statement; timely file a request for acceleration of a registration statement; timely respond
to SEC comments with respect to a registration statement; obtain the effectiveness of a registration statement within 120 days
from the filing thereof; or maintain the effectiveness of a registration statement for the periods required under the Series D
Registration Rights Agreement.
Pursuant
to a placement agent agreement with the placement agent for the Offering (the “Series D Placement Agent”), at the
closing of the sale of the Series D Units the Company paid the Series D Placement Agent, as a commission, a cash amount equal
to 7% of the aggregate sales price of the Series D Units, plus 3% of the aggregate sales price as a management fee plus a non-accountable
expense allowance equal to 3% of the aggregate sales price of the Series D Units. In addition, pursuant to the placement agent
agreement, the Company is required to issue to the Series D Placement Agent warrants to purchase up to such number of shares of
Common Stock equal to 10% of the aggregate shares of Common Stock sold in the offering plus warrants equal to 10% of the total
number of the Series D Warrants issued to the Series D Unit Purchasers in the offering (collectively, the “Placement Agent
Warrants”). The terms of the Placement Agent Warrants will be substantially similar to the Series D Warrants except that
the Placement Agent Warrants will also be exercisable on a cashless basis and will include full ratchet anti-dilution protection.
Issuance
of Securities to Advisor
During
February 2016, the Company entered into an advisory agreement with AGI, pursuant to which the Company retained AGI on a non-exclusive
basis to provide certain advisory services to the Company. As consideration for such services, the Company extended through December
31, 2019, the expiration date of 364,071 warrants issued to AGI and/or its designees in connection with the Company’s common
stock offering completed in 2010 and the Series A Unit offering completed in 2012. The advisory agreement had an initial term
of six months, subject to automatic renewal for additional 30 day terms unless terminated by either party with 30 days written
notice. In April 2016, the Company and AGI amended that advisory agreement to extend the term of the advisory agreement for an
additional six months. In consideration for such extension, the Company agreed to modify the terms of the 439,674 warrants issued
to AGI and/or its designees in connection with the Series B Unit offering to include full-ratchet anti- dilution protection. As
a result of the two agreements the Company recorded in its statement of operations for the year ended December 31, 2016, a one-time
charge in the amount of $211,077 representing the incremental fair market value adjustments in respect of the above modified warrants
issued to the placement agent. Such incremental fair market value adjustments represent the increase in the fair value of the
warrants resulting from the above modifications and were recorded against stockholders’ deficit. In addition, as a result
of the inclusion of anti-dilution protection, the Company classified $341,662, representing the fair market value as of April
2016 of the above 439,674 warrants issued to AGI out of stockholders’ deficit and presented them as warrants with down round
protection within long-term liabilities.
On
August 1, 2017, the Company entered into an advisory agreement with AGI, pursuant to which the Company retained AGI on a non-exclusive
basis to provide certain advisory services to the Company for a period of 9 months. As consideration for the advisory services,
the Company agreed to pay AGI $20,000 per month, payable in a cash payment of $10,000, and the balance in shares of the Company’s
Common Stock valued at $4.50 per share (2,223 shares per month). In addition, in recognition of the advisory services previously
provided by AGI prior to the advisory agreement, the Company also agreed to issue to AGI 8,889 shares of Common Stock.
Issuance
of Common Stock Pursuant to Consulting Agreements
On
March 20, 2017, we issued 13,334 shares of Common Stock, valued at $60,000, to Strand Strategy, a healthcare consulting firm (“Strand
Strategy”), as partial consideration for Strand Strategy’s services as an independent contractor on a temporary basis.
The founder and managing director of Strand Strategy, Angela Strand, is Vice Chairperson of the Board of Directors and a member
of the Audit Committee, and was then a member of the Compensation Committee.
Additionally,
on March 20, 2017, we issued 4,445 shares of Common Stock valued at $20,000 to Angela Strand as consideration for her services
as Vice Chairperson of the Board of Directors.
On
March 20, 2017, we issued 3,334 shares of Common Stock, valued at $15,000, to Leslie Seff, an independent member of the Board
of Directors, as consideration for the consulting services provided by Mr. Seff to the Company for the month of March, 2017.
The
shares of Common Stock issued to Strand Strategy, Angela Strand and Leslie Seff were issued pursuant to the exemption from registration
provided by Section 4(a)(2) of the Securities Act.
Issuance
of Stock Options to Employee
On
March 20, 2017, we issued a ten-year non-qualified stock option to John Graham, our Chief Executive Officer and Chairman of the
Board, for the purchase of 1,673,996 shares of Common Stock at an exercise price of $4.50 per share, vesting as follows: (i) 307,754
shares vest on the issuance date; (ii) 923,262 shares vest on the six-month anniversary of the issuance date; and (iii) 442,980
shares vest on the two-year anniversary of the issuance date.
Also
on March 20, 2017, we issued (i) a ten-year non-qualified stock option to John Graham for the purchase of 559,414 shares of Common
Stock at an exercise price of $5.41 per share, vesting in full on the two-year anniversary of the issuance date, and (ii) a ten-year
non-qualified stock option to John Graham for the purchase of 844,130 shares of Common Stock at an exercise price of $7.75 per
share, vesting in full on the two-year anniversary of the issuance date.
On
February 15, 2018, our Board approved the issuance of 767,500 stock options to 24 employees of the Company pursuant to
the terms of the Plan. The options will vest quarterly in 12 equal installments over a 3-year period.
Item
16. Exhibits
Exhibit
Number
|
|
Description
|
2.1
|
|
Merger Agreement and Plan of Reorganization, dated as of May 25, 2010, by and among Integrity Applications, Inc., Integrity Acquisition Ltd. and A.D. Integrity Applications Ltd. (1)
|
3.1
|
|
Certificate of Incorporation of Integrity Applications, Inc. (1)
|
3.2
|
|
Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (1)
|
3.3
|
|
Bylaws of Integrity Applications, Inc. (1)
|
3.4
|
|
Certificate of Designation of Preferences and Rights of Series A 5% Convertible Preferred Stock (2)
|
3.5
|
|
Certificate of Designation of Preferences and Rights of Series B 5.5% Convertible Preferred Stock (3)
|
3.6
|
|
Certificate of Designation of Preferences and Rights of Series C 5.5% Convertible Preferred Stock (8)
|
4.1
|
|
Specimen Certificate Evidencing Shares of Common Stock (1)
|
4.2
|
|
Form of Common Stock Purchase Warrant (1)
|
4.3
|
|
Form of Series A Securities Purchase Agreement (2)
|
4.4
|
|
Form of Series A Common Stock Purchase Warrant (2)
|
4.5
|
|
Form of Series A Registration Rights Agreement (2)
|
4.6
|
|
Form of Series B Securities Purchase Agreement (3)
|
4.7
|
|
Form of Series B-1 Common Stock Purchase Warrant (3)
|
4.8
|
|
Form of Series B-2 Common Stock Purchase Warrant (3)
|
4.9
|
|
Form of Series B Registration Rights Agreement (3)
|
4.10
|
|
Form of Series C Securities Purchase Agreement (8)
|
4.11
|
|
Form of Series C-1 Common Stock Purchase Warrant (8)
|
4.12
|
|
Form of Series C-2 Common Stock Purchase Warrant (8)
|
4.13
|
|
Form of Series C Registration Rights Agreement (8)
|
4.14
|
|
Form of Series D Securities Purchase Agreement (12)
|
4.15
|
|
Form of Series D-1 Common Stock Purchase Warrant (12)
|
4.16
|
|
Form of Series D-2 Common Stock Purchase Warrant (12)
|
4.17
|
|
Form of Series D-3 Common Stock Purchase Warrant (12)
|
4.18
|
|
Form of Series D Registration Rights Agreement (12)
|
5.1
|
|
Opinion of Robinson & Cole LLP (14)
|
10.1*
|
|
Integrity Applications, Inc. 2010 Incentive Compensation Plan (1)
|
10.2*
|
|
Amendment No. 1 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (13)
|
10.3*
|
|
Amendment No. 2 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (11)
|
10.4*
|
|
Amendment No. 3 to Integrity Applications, Inc. 2010 Incentive Compensation Plan (15)
|
10.5*
|
|
Form of Director and Officer Indemnification Agreement (1)
|
10.6*
|
|
Personal Employment Agreement, dated as of October 19, 2010, between A.D. Integrity Applications Ltd. and Avner Gal (1)
|
10.7*
|
|
Letter Agreement, effective as of April 7, 2017, among Integrity Applications, Inc., A.D. Integrity Applications Ltd., and Avner Gal (11)
|
10.8*
|
|
Amended and Restated Personal Employment Agreement, effective as of April 7, 2017, between A.D. Integrity Applications Ltd. and David Malka (11)
|
10.9
|
|
Irrevocable Undertaking of Indemnification, dated as of July 26, 2010, by and among Integrity Applications, Inc., Avner Gal, Zvi Cohen, Ilana Freger, David Malka and Alexander Raykhman (1)
|
10.10
|
|
Investment Agreement, dated February 18, 2003, between A.D. Integrity Applications Ltd., Avner Gal, Zvi Cohen, David Freger and David Malka and Yigal Dimri (1)
|
10.11*
|
|
Form of Stock Option Agreement (1)
|
10.12*
|
|
Form of Stock Option Agreement (ESOP) (1)
|
10.13
|
|
Letter of Approval, addressed to Integrity Applications Ltd. from the Ministry of Industry, Trade and Employment of the State of Israel (6)
|
10.14
|
|
Letter of Undertaking, addressed to the Ministry of Industry, Trade and Employment of the State of Israel – Office of the Chief Scientist from Integrity Applications Ltd. (4)
|
10.15
|
|
Investment Agreement, dated March 16, 2004, by and among A.D. Integrity Applications Ltd., Yitzhak Fisher, Asher Kugler and Nir Tarlovsky. (4)
|
10.16*
|
|
Personal Employment Agreement, dated as of October 22, 2013, between A.D. Integrity Applications Ltd. and Eran Hertz. (7)
|
10.17
|
|
Personal Employment Agreement, dated as of February 1, 2017, between A.D. Integrity Applications Ltd. and Sami Sassoun (9)
|
10.18
|
|
Amended and Restated Consulting Agreement, dated as of February 6, 2017, between Integrity Applications, Inc. and Strand Strategy (9)
|
10.19
|
|
Personal Employment Agreement, dated as of March 20, 2017, between Integrity Applications, Inc. and John Graham (9)
|
10.20*
|
|
First Amendment to Employment Agreement, effective as of April 7, 2017, between Integrity Applications, Inc. and John Graham (11)
|
10.21*
|
|
Employment Agreement, effective as of June 26, 2017, between Integrity Applications, Inc. and David Podwalski (5)
|
14.1
|
|
Code of Ethics (9)
|
21.1
|
|
Subsidiaries of Integrity Applications, Inc. (10)
|
23.1
|
|
Consent of Fahn Kanne & Co. Grant Thornton Israel **
|
23.2
|
|
Consent of Robinson & Cole LLP **
|
24.1
|
|
Power of Attorney (included on the signature page to this Registration Statement)
|
101.INS
|
|
XBRL
Instance Document (16)
|
101.SCH
|
|
XBRL
Schema Document (16)
|
101.CAL
|
|
XBRL
Calculation Linkbase Document (16)
|
101.DEF
|
|
XBRL
Taxonomy Extension Calculation Linkbase (16)
|
101.LAB
|
|
XBRL
Label Linkbase Document (16)
|
101.PRE
|
|
PRE
XBRL Presentation Linkbase Document (16)
|
(1)
|
Previously
filed as an exhibit to the Company’s Registration Statement on Form S-1, as filed with the SEC on August 22, 2011.
|
(2)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 18, 2013.
|
(3)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on September 5, 2014.
|
(4)
|
Previously
filed as an exhibit to Amendment No. 1 to the Company’s Registration Statement on Form S-1, as filed with the SEC on
October 7, 2011.
|
(5)
|
Previously
filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, as filed with
the SEC on August 18, 2017.
|
(6)
|
Previously
filed as an exhibit to Amendment No. 3 to the Company’s Registration Statement on Form S-1, as filed with the SEC on
November 10, 2011.
|
(7)
|
Previously
filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed
with the SEC on March 27, 2014.
|
(8)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 14, 2016.
|
(9)
|
Previously
filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed
with the SEC on March 31, 2017.
|
(10)
|
Previously
filed as an exhibit to the Company’s Registration Statement on Form S-1, as filed with the SEC on November 7, 2017.
|
(11)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on April 13, 2017
|
(12)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 7, 2018.
|
(13)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 23, 2016.
|
(14)
|
Previously
filed as an exhibit to Amendment No. 1 to the Company’s Registration Statement on Form S-1, as filed with the SEC on
December 8, 2017.
|
(15)
|
Previously
filed as an exhibit to the Company’s Current Report on Form 8-K, as filed with the SEC on March 23, 2018.
|
(16)
|
Previously
filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed
with the SEC on March 30, 2018. Pursuant to Rule 406T of Regulation S-T, the interactive files on Exhibit 101 hereto are deemed
not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act, are deemed
not filed for purposes of Section 18 of the Exchange Act, as amended, and otherwise are not subject to liability under those
sections.
|
*
|
Compensation
Plan or Arrangement or Management Contract.
|
**
|
Filed
herewith.
|
Item
17. Undertakings
(a)
The undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial
bona fide
offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant
to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule
430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus
that was part of the registration statement or made in any such document immediately prior to such date of first use.
(5)
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities, the registrant undertakes that in a primary offering of securities of the registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the registrant will be a seller to the
purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus or prospectus of the registrant relating to the offering required to be filed pursuant to Rule 424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the registrant or used or referred to by the
undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the registrant
or its securities provided by or on behalf of the registrant; and
(iv)
Any other communication that is an offer in the offering made by the registrant to the purchaser.
(b)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion
of the SEC such indemnification is against public policy expressed in the Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by
a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Tel Aviv, State of Israel on June 7 , 2018.
|
INTEGRITY
APPLICATIONS, INC.
|
|
(Registrant)
|
|
|
|
By:
|
/s/
John Graham
|
|
Name:
|
John
Graham
|
|
Title:
|
Chief
Executive Officer
|
POWER
OF ATTORNEY
Each
individual whose signature appears below constitutes and appoints each of John Graham and Sami Sassoun such person’s true
and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person and in such person’s
name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this
registration statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the SEC,
granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person,
hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them,
may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons
in the capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
John Graham
|
|
Chairman
of the Board and Chief Executive Officer
|
|
June 7 , 2018
|
John
Graham
|
|
(Principal
Executive Officer
|
|
|
|
|
|
|
|
/s/
Sami Sassoun
|
|
Chief
Financial Officer (Principal Financial
|
|
June 7, 2018
|
Sami
Sassoun
|
|
Officer
and Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/
Angela Strand
|
|
Vice
Chairperson
|
|
June
7
, 2018
|
Angela
Strand
|
|
|
|
|
|
|
|
|
|
/s/
Dr. Robert Fischell
|
|
Director
|
|
June
7
, 2018
|
Dr.
Robert Fischell
|
|
|
|
|
|
|
|
|
|
/s/
Leslie Seff
|
|
Director
|
|
June 7 , 2018
|
Leslie
Seff
|
|
|
|
|
|
|
|
|
|
/s/
Revan Schwartz
|
|
Director
|
|
June 7 , 2018
|
Revan
Schwartz
|
|
|
|
|
|
|
|
|
|
/s/
Michael Hauck
|
|
Director
|
|
June 7 , 2018
|
Michael
Hauck
|
|
|
|
|